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CHAPTER I 
 
INTRODUCTION 
 
Notch got its name from a mutant strain of Drosophila melanogaster with notches at the 
end of their wing blades in 1917.  In the mid-1980s, the group of Artananis-Tsakonas and 
Young cloned the Notch gene.  These discoveries opened a door to a widening 
understanding of the molecular mechanism of Notch signaling, as well as physiological and 
pathological processes that are controlled or influenced by Notch signaling.  Over the last 
two decades, Notch signaling has emerged as an important signaling pathway in the 
regulation of various oncogenic phenotypes in multiple types of human cancers, which 
makes Notch signaling an attractive target in various cancers.  The roles of Notch signaling 
in human cancers are quite divergent and context dependent.  Notch signaling has 
oncogenic effects in T-ALL, breast cancer, pancreatic cancer, ovarian cancer and lung 
cancer, while they have been found to be tumor suppressive in skin cancer.  In lung cancer, 
Notch3 is considered as an oncogene and contributes to maintenance of cancer stem cells.  
Targeting Notch3 signaling could thus represent a novel therapeutic approach for the 
treatment of lung cancer patients.  
 
Mechanisms of Notch signaling 
 
Molecules involved in Notch signaling  
Notch receptors are a class of single pass Type I transmembrane protein.  There are 4 
Notch receptors, known as Notch 1-4 in mammals, 1 Notch receptor in Drosophila, 
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whereas C.elegans have 2 Notch receptors with redundant functions (1).  The number and 
names of the components involved in Notch signaling differ among C.elegans, Drosophila 
and mammals (Table 1.1). The extracellular domains of Notch receptors contains 29-36 
tandem epidermal growth factor (EGF)-like repeats. Notch1 and Notch2 contain 36 EGF-
like repeats, Notch3 consists 34 EGF-like repeats, and Notch4 only has 29 EGF-like 
repeats.  Some of EGF-like repeats mediate ligand-receptor interaction. Trans activation, in 
which ligands presented by signaling sending cells activates Notch signaling in signaling 
receiving cells, is mediated by EGF-like repeat 11-12 of Drosophila Notch and human 
Notch1 (3, 4), On the other hand, cis inhibition, when ligand and receptors presented in the 
same cell inhibiting Notch signaling, is potentially mediated by repeats 24-29 identified in 
Drosophila Notch (5).  Most of the EGF-like repeats requires calcium for receptor-ligand 
interaction (6, 7).  The EGF repeats are followed by a unique negative regulatory region 
(NRR) consisting of three cysteine-rich Lin12-Notch repeats (LNR) and a 
heterodimerization domain (HD), which participates in preventing activation of receptors 
in the absence of ligand binding (8-10) (Fig 1.1).  Notch receptors are first synthesized in 
precursor form as 300-350 kD polypeptides.  During maturation, Notch polypeptides are 
cleaved by a furin-like convertase within an unstructured loop protruding from the HD 
subdomain, which is called S1 cleavage.  The cleaved Notch polypeptides, then hold 
together by a non-covalent bond between the N- and C- terminal halves of the HD domain 
to present at cell surface as a heterodimer composed of NECD (Notch extracellular 
domain) and NTMIC (Notch transmembrane and intracellular domain) (11-13).  The Notch 
intracellular domain consists of a RAM domain (RBPj κ associated module), which forms 
a high affinity binding module of 12-20 amino acids centered around a conserved WxP 
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motif (14), seven ANK repeates flanked by two NLS domain (nuclear localization 
sequence), TAD (transactivation domain), and a conserved PEST region (proline/glutamic 
acid/serine/threonine-rich motifs), which mediates protein degradation of Notch 
intracellular domain.  
 
Most Notch ligands are also Type I transmembrane proteins (Figure1.1).  Canonical Notch 
ligands fall into two classes, depending on whether they are homologous to the Drosophila 
prototypes Delta and Serrate.  There are three Delta-like proteins, named Delta-like1 
(DLL1), Delta-like 3 (DLL3) and Delta-like 4 (DLL4) and two homologues of Serrate, 
named Jagged1 (JAG1) and Jagged2 (JAG2) in mammals.  Both Delta and Serrate ligands 
consist of an N-terminal MNNL (Module at the N-terminus of Notch Ligand) domain, 
followed by a DSL domain (Delta-Serrate-LAG2) and a variable number of EGF-like 
repeats (both calcium binding and non-calcium binding) in their extracellular portion.  In 
some ligands, including all Serrate ligands and DLL1, the DSL domain is linked to two 
variant EGF like repeats, which are also referred to as the DOS domain (Delta and OSM-
11-like protein) (15).  Jagged family ligands are distinguished from Delta-like ligands by 
the presence of more EGF like repeats and an additional cysteine-rich domain homologous 
to the von Willebrand Factor C module linked to transmembrane region.  The DSL domain 
and first few EGF-like repeats of Delta and Serrate ligands are essential to mediate 
receptor-ligand interaction.  
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Table 1.1. Core components of the Notch pathway in worms, flies, and mammals 
Component&Funtion C. elegans Drosophila Mammals 
Receptors LIN-12, GLP-1 Notch Notch1-4 
Ligands    
DSL/DOS  Delta, Serrate DLL1, Jagged1 and 2 
DSL-only APX-1, LAG-2, 
ARG-2, DSL1-7 
 DLL3 and 4 
DOS Co-ligands DOS1-3,  
OSM7,11 
 DLK-1, DLK-2/EGFL9 
Non-canonical   DNER, MAGP-1 and 2, 
F3/Contactin1,  
NB-3/Contactin6 
 
Nuclear Effectors 
   
CSL DNA-binding transcription 
factor 
LAG-1 Su(H) RBPj κ/CBF-1 
Transcriptional Co-activator LAG-3 Mastermind MAML1-3 
Transcriptional Co-repressors  Hairless,  
SMRTR 
Mint/Sharp/SPEN,  
NCoR/SMRT, Kyot2 
Receptor Proteolysis    
Furin convertase(S1 cleavage) ? ? PC5/6, Furin 
Metalloprotease(S2 cleavage) SUP-17/Kuzbanian, 
ADM-4/TACE 
Kuzbanian, 
Kuzbanian-like, 
TACE 
ADAM10/Kuzbanian, 
ADAM17/TACE 
γ-secretase(S3/S4 cleavage) SEL-12. APH-1, 
APH-2, PEN-2 
Presenilin,  
Nicastrin,  
APH-1, PEN-2 
Presenilin1 and 2, 
Nicastrin,  
APH-1a-c, PEN-2 
Glycosyltransferase modifiers    
O-fucosyl-transferase OFUT-1 OFUT-1 POFUT-1 
O-glucosyl-transferase  RUMI RUMI 
Beta1,3-GlcNAc-transferase  Fringe Lunatic, Manic  
and Radical Fringe 
Endosomal Sorting/Membrane 
Trafficking Regulators 
   
Ring Finger E3 Ubiquitin ligase 
(Ligang endocytosis) 
Y47D3A.22 Mindbomb 1-2, 
Neuralized 
Mindbomb,  
Skeletrophin,  
Neuralized 1 and 2 
Ring Finger E3 ubiquitin ligase 
(recepor endocytosis) 
 Deltex Deltex 1-4 
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HECT domain E3 Ubiquitin  
ligase (receptor endocytosis) 
WWP-1 Nedd4, Su(Dx) Nedd4, Itch/AIP4 
Negative regulators  Numb Numb, Numb-like, ACBD3 
Neuralized Inhibitors  Bearded, Tom,  
M4 
 
Other endocytic modifiers  sanpodo  
NICD Degradation    
F-Box Ubiquitin ligase SEL-10 Archipelago Fbw-7/SEL-10 
Cononical Target bHLH 
Repressor Genes 
REF-1 E(spl) HES/ESR/HEY 
*adapted from Kopan and Ilagan, 2009(2). 
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Activation of Notch signaling is mediated by a sequence of proteolytic processes (Fig 1.2).  
Upon ligand binding, Notch receptors are cleaved by an ADAM metalloproteases at site 2, 
which is located around 12 amino acids before the TMA and deeply buried within the 
NRR.  It is still ambiguous what enzymes mediate S2 cleavage from different studies, such 
as on one hand, ADAM17/TACE is able to cleave Notch receptors in vitro (16), and on the 
other hand, TACE deficient mice do not have a Notch phenotype (17).  In contrast, 
Kuzbanian/ADAM10/Sup-17 function is required for Notch activity among C.elegans, 
Drosophila and mouse (18-21).  The S2 cleavage of Notch extracellular domain leads to a 
membrane-tethered intermediate, which is shed by a γ-secretase complex, a multi-
component member of a growing family of intramembrane cleaving proteases, within the 
TMD (22).  After S3 cleavage, released Notch intracellular domain (NICD) translocates 
into the nucleus where it binds to DNA-binding protein CSL (CBF-1/RBPj κ/Su(H)/Lag-1) 
via its RAM domain, and converts CSL from a transcriptional repressor into a 
transcriptional factor to initiate downstream target genes transcription via recruiting the 
coactivaor Mastermind/Lag-1 (14).  The typical Notch target genes are bHLH (basic helix-
loop-helix) transcriptional repressor proteins Hes (hairy and enhancer of split) and Hey ( 
hairy enhancer-of-split related with YRPW motif).  Besides interacting with CSL, full-
length Notch, membrane tethered Notch or NICD also can function in a CSL-independent 
manner by crosstalking with other signaling pathways. However, the mechanisms of CSL-
independent Notch signaling are not clear.  
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Figure1.1. Notch Receptors and Ligands.  Notch receptors are type I transmembrane proteins that 
composes of multiple EGF-like repeats in their extracellular domain.  Drosophila Notch has 36 EGF-like 
repeat, while human paralogs (hNotch 1-4) contains variable number of (36-29) EGF-like repeats.  C.elegans 
has 2 Notch receptors, which contains fewer EGF-like repeats.  EGF-like repeats are followed by the 
negative regulatory region (NRR) including three cysteine-rich Lin12-Notch repeats and a 
heterodimerization domain (HD), transmenbrane domain (TMD), a RAM domain (RBPj κ association 
module), nucleus localization sequences (NLS), a seven ankrin repeat domain (ANK), a transactivation 
domain (TAD) and a conserved proline/glutamic acid/serine/threonine-rich motifs (PEST).  Notch1 contains 
a strong TAD, and Notch2 is with a weak TAD, but no TAD is present in Notch3 and Notch4.  EGF-like 
repeat of 11 and 12 (red) are considered as a requirement for ligand interaction in dNotch and hNotch1, 2.  
dNotch EGF-like repeat 24-29 (green), also called Abruptex region mediates cis-inhibition of receptor and 
ligand interaction.  Notch ligands can be classified into two group based on their domain composition.  
DSerrate and hJagged1, 2 contains N-terminal , DSL domain (Delte-Serrate-LAG-2), DOS domain (Delta 
and OSM-11-like proteins), EGF-like repeats, C-rich domain (Cysteine-rich domain, also called vWF 
domain), and a transmembrane domain (TMD).  While dDelta and hDll1, 3, 4 has less EGF-like repeats and 
lack of C-rich domain, and hDll3, 4 also lack of DOS domain.  Both receptors and ligands can be cleaved by 
ADAM metalloproteases (S2) and γ-secretase complex (S3).  Modified from Kopan, 2009 (2).  
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Figure1.2. The core Notch signaling pathway and therapeutic strategies to interfere with Notch 
signaling.  Translated full-length Notch receptor proteins are glycoslated by the enzymes O-fucose and 
Rumi. and then the mature receptors are presented to the cell surface as a heterodimer after proteolytic 
cleavage by furin at site 1(S1).  In the glycosyltransferase Fringe expressing cells, the O-fucose is extended 
by Fringe to alter the specificity of Notch receptor to be activated by different ligands.  Upon the ligand 
binding in neighboring cell to generate mechanical force generated by ligand endocytosis exposes the S2 
cleavage, the receptors are cleaved by ADAM metalloproteases at site 2 (S2). Juxtamembrane Notch 
cleaved at S2 produces membrane-anchored Notch extracellular fragment, which is then recognized and 
cleaved by the γ-secretase complex at Notch transmembrane domain site 3 (S3) to released Notch 
intracellular domain (NICD).  NICD then translocates into nucleus where it converts DNA-binding protein 
CSL from a transcriptional repressor into a transcriptional factor by recruiting transcriptional coactivator 
Matermind (MAM) to initiate gene transcription.  In contrast, NICD can function in a CSL-independent 
manner by cross-talking with other signaling pathways.  Multiple strategies to therapeutically block Notch 
signaling are currently developed and tested in preclinical and clinical studies.  Blocking strategies are 
highlighted with a red box, and consist of Abs and receptor/ligand decoys to interfere receptor-ligand 
interaction, Abs to mask S2 cleavage of the receptors mediated by ADAM protease , GSIs to inhibition S3 
cleavage mediated by γ-secretase complex, and stapled peptides to prevent formation of NICD-MAML 
complex.  Modified from Kopan, 2009(2).  
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Knowledge of receptor-ligand interaction 
 
Domains mediating receptor-ligand interaction  
Notch receptors and ligands interaction were first identified using cell aggregation assay.  
Using this strategy, Rebay et al., showed that EGF-like repeats 11-12 of Drosophila Notch 
receptor is necessary and sufficient to promote aggregation of Notch receptor expressing 
cells with both Delta- and Serrate-presenting cells (23).  A series of evidence supports the 
conclusion that in mammals, the same region of Notch1 is also necessary for binding of 
Delta-like and Jagged ligands.  Knock-in mice bearing mutated Notch1 lacking EGF-like 
repeats 8-12 in place of wild-type receptors phenocopy Notch1 null phenotypes (24). The 
surface receptor expression levels of mutant Notch1 were not detectably altered, implying 
that EGF-like repeat 8-12 are required for Notch1 activity.  And biotinylated human 
Notch1 EGF-like repeats 11-13 are able to aggregate DLL1 expressing cells in vitro (3), 
indicating that EGF-like repeats 11-13 are sufficient to bind to DLL1 ligand.  Moreover, 
biochemical studies using purified proteins have demonstrated that EGF-like repeats 11-14 
of human Notch1 bind to a fragment of DLL1 containing the DSL domain and the first 
three EGF-like repeats.  This is a calcium dependent interaction with an estimated Kd of 
130uM as measured by equilibrium surface plasmon resonance (6).  The ligand binding 
studies of other Notch receptors have been very limited, however, it is widely assumed that 
the same region of mammalian Notches, 2, 3 and 4 is also responsible for ligand 
interaction.  This is supported by the finding that EGF-like repeats 1-15 of Notch2 binds to 
a soluble mouse Jagged1-Fc protein as determined by a solid phase-binding assay using 
protein fragments derived from mammalian expression systems (25).  Furthermore, 
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deletion of EGF-like repeats 10-11 of human Notch3 (which corresponds to EGF-like 
repeats 11-12 of Drosophila Notch and mammalian Notch1) prevents its binding to 
Jagged1 and reduces Jagged1 induced CBF-1 reporter activity (26).  
 
The structure of a fragment of human Notch1 containing EGF-like repeats 11-13 was 
solved both by solution NMR approach (3) and by X-ray crystallography (27).  In the X-
ray structure, three EGF-like repeats adopt an elongated conformation, with an interdomain 
orientation defined by the coordination of a calcium ion between two adjacent repeats and 
by the packing of a tyrosine residue from one repeat against an isoleucine residue from the 
next repeat.  Based on the structure of NMR, models for the entire ectodomain of Notch 
receptors have been proposed invoking rigidity at inter-repeat linkers, which contain 
consensus sequences for calcium coordination, and different degree of intrinsic flexibility 
at linkers lacking a predicted calcium-binding site.  The X-ray structure of a region of 
human Jagged1 including its DSL domain, and first 3 EGF-like repeats was also solved, in 
which the four-domain fragment is found in a rod-like conformation as well.  The 
combinatorial analysis of this structure using a multiple sequence alignment identified 
conserve residues and a surface patch on the DSL domain as a potential site for binding to 
Notch receptors.  Mutation of residues at this interface interferes with the formation of 
receptor-ligand complex, and causes loss-of-function to various degrees in transgenic flies 
(27).  Docking studies with the structure of Notch1 EGF-like repeats 11-13 to the structure 
of Jagged1 DSL domain and first 3 EGF-like repeats suggests that the contact interface 
between Notch1 and Jagged1 lies along an extended surface (27). However, the nature of 
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this interface remains unknown due to unavailability of the structure of their interacting 
complex.  
Glycosylation of receptors  
Notch receptors are large glycoproteins, in which many EGF-like repeats can be modified 
by two kinds of O-glycosylation, O-fucose and O-glucose (28).  O-fucose glycans 
modulate the binding affinity of Notch binding to DSL Notch ligands, while O-glucose 
glycans facilitate juxtamembrane cleavage of Notch to promote intramembrane cleavage 
and activation of Notch signaling (29). Loss of OFUT1, a gene encoding O-
fucosyltransferase 1 protein, phenocopies Notch loss-of-function in Drosophila and mice, 
indicating that O-fucose modification is required for production of functional Notch 
receptors (30).  However, later studies demonstrated that non-fucosylated Notch receptors 
can still go to the cell surface, interact with ligands and activate signaling, and the 
phenotype of OFUT1 loss is mainly due to lack of its activity of ER chaperone, which is 
not dependent on its fucosylation function (31).  This suggests that fucosylation during 
Notch signaling is only required for Fringe-dependent glycosyltransferase activity to 
extend O-fucose, but not O-fucosyltranferase activity of Ofut.  The Fringe gene was 
identified via the screen in Drosophila for novel genes that regulate Notch signaling (32).  
Later on, Fringe was shown to be required for Notch signaling at the wing margin and at 
other tissue boundaries in Drosophila (33, 34).  In the ligand binding regions of Drosophila 
Notch receptor, this process can affect ligand specificity such that Fringe-mediated adding 
of a single N-acetylglucosamine on EGF like repeat 12 of Drosophila Notch enhances 
binding to Delta and suppresses binding to Serrate in vivo and in vitro (35).  Mammalian 
homologues of Fringe, named Lunatic, Manic, and Radical Fringe, were identified with 
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conserved functions in Drosophila (36).  Disrupting LFNG in mice result in defective 
somitogenesis leading to pronunced skeletal aberrations (37, 38).  The study demonstrated 
that Notch1 in mammals carries two unusual glycans, one began with fucose linked to 
Serine or Threonine located between the second and the third cysteine of an EGF like 
repeat in the consensus C2X4-5S/TC3, and the other began with glucose linked to Serine and 
Threonine between the first and the second cysteine of an EGF like repeat with the 
consensus C1XSXPC2 (39, 40). 
 
Endocytosis of receptors and ligands 
Endocytosis of Notch receptors and ligands has been shown to be essential for the 
activation of Notch signaling in both signal-sending and signal-receiving cells.  Early 
studies revealed the presence of Delta in intracellular vesicles in Drosophila embryos and 
imaginal discs (41), implying a endocytotic process of Delta ligand.  Moreover, in vivo 
structure-function analysis of specific point mutant alleles of Delta ligand demonstrated 
that certain EGF-like repeats and certain intracellular lysine residues are indispensable for 
its endocytosis and proper signaling (42).  Work from many laboratories conducted in 
different model organisms indicates that two distinct RING-containing E3 ligase families, 
Mind bomb (Mib) 1 and 2, and Neuralized (Neur1 and 2 in mammals), directly mediate 
DSL ligand endocytosis (43-46).  In mice, neur1 and neur2 are dispensable for normal 
development.  However, mice defective in neur1 and neur2 or mib2 do not have Notch-null 
phenotype (47).  The single gene disruption of Mib1 recapitulates the pleiotropic Notch 
mutant phenotype in mouse embryo (48, 49).  Ubiquitinated DSL ligands are potentially 
recognized by an ubiquitin binding protein Epsin.  Loss of function of Epsin in signal 
sending cells shows Notch loss-of-function phenotype in flies and mice, indicating that 
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espin mediated trafficking of ubiquitinated DSL ligands is important for activation of 
Notch signaling.  
 
Endocytosis of DSL ligands is necessary for Notch signaling activation through two 
potential mechanisms, one is the “ligand activation” model, in which ligands undergo 
endocytosis and subsequent trafficking back to the surface, following modifications or 
some changes in the cell, which makes Delta a more effective ligand to send signals.  The 
“ligand activation” hypothesis has been proposed to contain clustering of ligands, 
trafficking into lipid microdomain, proteolytic cleavage, and other posttranscriptional 
modifications (45, 50, 51).  However, the exact mechanism of this “ligand activation” 
model is unclear.  The other one is the “ pulling force” theory, in which endocytosis of 
ligands facilitates S2 cleavage and removal of Notch extracellular domain. In support of 
this theory, structural studies have elucidated that the S2 cleavage site of Notch receptors is 
buried deep within the heterodimerization domain and protected by three LNR domains, 
suggesting that a physical pulling force is required to expose this site for accessibility of 
the ADAM protease (52-54).  In addition, most secreted forms of DSL ligands act in a 
dominant-negative fashion to prevent ligand-mediated activation of Notch (55, 56).  
However, when soluble ligands are crossed-linked, immobilized, or clustered, they can 
activate Notch signaling in cultured cells (57, 58).  This evidence supports the theory that 
tension and force generated from the interaction between the receptors and ligands is 
necessary for Notch activation.   
Receptor endocytosis 
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Although NICD is polyubiquitinated and degraded in a proteasome-dependent manner in 
the nucleus, a substantial amount of intact Notch is present in endosomes (59).  Intact 
Notch receptors are constitutively endocytosed and recycled to the cell surface (60) or 
degraded in the lysosome (61).  Studies from multiple groups indicate that endocytosis of 
Notch receptors could control their availability for ligand binding and for S3 cleavage.  
Production of NICD may occur on lysosomal membranes bypassing the requirement for 
ligand interaction as well as S2 cleavage (62).  Disruption of lysosomal degradation of 
Notch receptor leads to accumulation of Notch receptor in endosomes and ectopic 
activation of Notch signaling in a ligand-independent manner (63-65).  Several components 
in the pathway of lyosomal degradation of Notch have been reported to be associated with 
tumor progression, indicating that ligand-independent constitutive activation of Notch 
signaling in endosomes is important in certain cancers (66).   
Notch signaling in development 
 
A short history of Notch 
Homozygous mutations of Notch result in lethal phenotypes via neurogenic aberrations, 
where cells intended to differentiate into epidermis, switch fate and give rise to neural 
tissue (70, 71).  Moreover, Notch is involved in many other developmental steps in 
Drosophila, such as bristle formation (72), and maintenance of muscle founder cells (73).  
The studies of the nematode Caenorhabditis elegans increased our knowledge of Notch 
signaling, in which Notch signaling plays important roles in specifying cell fate decisions 
as well. Unlike Drosophila, C. elegans has two Notch homologues, LIN-12 and GLP-1.  
Both can substitute for each other when expressed in the appropriate tissue (1). In contrast, 
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LIN12 is important for gonad development in later stage of growth (74), whereas GLP-1 
regulates blastomere specification in the early C.elegans embryo (75).  
 
 
Ablations of Notch components in genetically engineered mice 
The function of the mammalian Notch signaling has been investigated using mice with 
genetically engineered gene knockouts of Notch components.  These studies prove the 
importance of Notch signaling in the development of mammals.  
 
Notch1: Notch1 null mice are embryonic lethal, and embryos die before embryonic day 
11.5. Lack of Notch1 causes a delayed and disorganized somitogenesis in the first half of 
gestation and enhanced neurogenesis by regulation of neural stem cell differentiation.  
Increased cell death is also observed, but is not considered to be the main cause of 
developmental defects (76-78).  Further study of knock-in mice with a single point 
mutation at intramembranous processing site of Notch1, V1744G recapitulates the Notch1 
null pheynotypes, suggesting that intramembranous processing of Notch1 is indispensable 
for embryonic viability and early development (79). 
 
Notch2: By replacing ankyrin repeats of Notch2 receptor with a beta-galactosidase, a 
mutant Notch2 mouse was created.  Notch2 mutated mice die before E11.5, suggesting an 
indispensable function of ankyrin repeats in Notch2. In contrast to Notch1 mutant, Notch2 
mutant mice did not show disorganized somitogenesis, while increased cell death is also 
observed (80).  Using a hypomorphic allele rather than a real null allele of Notch2, 
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McCright et al. demonstrated a perinatal lethality due to dysfuntion of kidney, and defects 
of heart and eye vasculature (81).  
 
Notch3: Notch3 deficient mice are viable and fertile.  There is no apparenten redundant 
with the Notch1 gene during early embryogenesis (82).  Later study elucidated that Notch3-
/- adult mice show dysfunctional arteries in mice due to dysregulation of arterial 
differentiation and immaturation of vascular smooth muscle cells (vSMC) (83). 
 
Notch4: Notch4 null mice are also viable and fertile.  However, embryos homozygous for 
mutations of both Notch4 and Notch1 genes displayed a more severe phenotype than 
Notch1 homozygous mutant embryo with severe defects in angiogenic vascular remodeling 
(84). 
 
Jagged1: Jagged1 disrupted mice die prior to E11.5 from hemorrhage early during 
embryogenesis, displaying defects in remodeling of embryonic and yolk sac vasculature.  
Heterozygous Jagged1+/-mice display an eye phenotype similar to that in Alagille’s 
syndrome, but do not exhibit other characteristics of the disease (85).  Moreover, double 
heterozygote mutants Jagged1+/- Notch2+/- exhibit more severe phenotypes than the single 
mutants (81). 
 
Jagged2: Mice with DSL-domain deletion mutant of Jagged2 die at birth with severe 
craniofacial and limb malformations.  The mutant homozygotes exhibit cleft palate and 
fusion of the tongue with the palatal shelves, and digit fusion of fore-and hindlimbs (86). 
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DLL1: DLL1 null mice die around day 12 of embryonic development, exhibiting severe 
segmentation defects and loss of the ability to maintain the integrity of the somites (87), 
which is similar to that with Notch1 deficiency. 
 
DLL3: DLL3 knockout mice are viable but have a shortened body and short tail.  Gene 
targeting of DLL3 results in severe axial skeletal defects with highly disorganized 
vertebrae, costal defects, which are similar to the phenotypes of spondylocostal dysplasis in 
humans, and delayed and irregular somite formation (88).  
 
DLL4: Homozygous deletion of DLL4 is lethal before E9.5 and only small portion of 
heterozygous mice are viable.  The incompletely penetrant haploinsufficiency depends on 
the genetic background of mice.  DLL4+/- embryos show defects in vascular structures and 
reduction of the caliber of the dorsal aortae.  DLL4 ligand alone is required in a dosage-
sensitive manner for normal arterial patterning in development, suggesting that DLL4 may 
be a suitable target for intervention in arterial angiogenesis (89). 
 
RBPj κ: RBPj κ null mutant mice showed embryonic lethality before 10.5 days of 
gestation and exhibited severe growth retardation as early as 8.5 days of gestation. 
Developmental defects include incomplete turning of the body axis, microencephaly, 
abnormal placental development, anterior neuropore opening and deficient somitogenesis 
(90).    
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Notch signaling in mammlian lung development 
Lung development in the fetus origdinates from a primitive foregut endodermal bud 
surrounded by mesenchyme to become a highly branched tracheobronchial tree with bunch 
of specialized cell types, including ciliated and goblet cells in the proximal airway, Clara 
cells in the mid-sized and smaller airway, interspersed neuroendocrine and basal cells, and 
type I and II alveolar cells, plus endothelial cells, smooth muscle, neurons, chondrocytes 
and fibroblasts (91).  Quantitative expression analyses from the developing mouse lung 
elucidate an increased expression of Notch1-4, DLL1 and Jagged1 mRNA from E11.5 into 
adulthood (92, 93).  Notch1 is expressed in the distal lung endoderm as early as E11.5 and 
persists through fetal development, but is not expressed at high levels in fetal lung 
mesenchyme surrounding the primitive epithelium (92, 94).  Both Notch2 and Notch3 are 
expressed in lung mesenchyme.  Notch2 does not appear to be expressed in epithelial cells, 
whereas Notch3 can be detected in epithelial cells.  Notch4 expression is endothelial 
specific.  None of the four Notch receptors is found to be expressed in neuroendocrine cells 
(94).  Expression of Notch ligands can be identified in the mesenchymal and 
neuroendocrine cells.  Jagged1 is expressed in lung mesenchyme and prominently in lung 
vessels, while Jagged2 expression appears to be limited to the most peripheral lung 
mesenchyme at E13 (94).  DLL4 expression in the lung is confined to endothelial cells, 
potentially to interact with Notch4 (95).  In the lung, DLL1 mRNA expression increases in 
abundance from E12 to E18 (92), and is strikingly limited to neuroendocrine cells, first 
confirmed at E14.5 (94, 96).  Notch target gene Hes1 mRNA has been detected in mouse 
lung of early pseudoglandular stage at E12, then its expression progressively increases until 
birth and also remains detectable in adult lung.  Hes1 protein expresses in non-endocrine 
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airway epithelial cells, which express Notch1 and Notch3 as well.  Moreover, most Hes1 
expressing cells in the distal airway epithelium are destined to become Clara cells, 
suggesting that Notch signaling activity appears to predetermin the Clara cell lineage in the 
lung. Another Notch target gene Hes5 is not detectable in whole fetal lung (92).  HeyL is 
expressed in lung vasculature (97), Hey1 mRNA is dominantly expressed in adult lung, and 
Hey2 expression is much lower than Hey1 (98). 
 
A growing body of evidences elucidates the importance of Notch signaling in the 
development of respiratory systems. A target of Notch signaling, Hes1-deficient mice show 
hyperplasia of pulmonary neuroendocrine cells (PNECs) and a decreased number of Clara 
cells, indicating the precursors of Clara and ciliated cells are separated from PNEC 
precursors through lateral inhibition feedback loop mediated by Notch signaling (92, 99).  
Forced expression of a constitutively activated form of Notch1 receptor (N1ICD) in lung 
epithelial cells promoted mucous metaplasia and significantly reduced the number of 
ciliated cells (100).  Conditional deletion of OFUT1, a glycosyltransferase required for 
Notch signaling, or RBPj κ, an essential DNA binding partner of all Notch receptors, in the 
endoderm promoted ciliated cell expansion and caused absence of secretory Clara cells 
(101).  By preventing γ-secretase cleavage of Notch receptors, Tsao et al. demonstrated 
that disruption of Notch signaling remarkably expands the population of distal progenitors, 
altering morphogenetic boundaries and preventing formation of proximal structures (102).  
By deletion of RBPj κ in lung mesenchymal and mesothelial cells, Kopan’s group has 
demonstrated that RBPj κ is required for the recruitment and specification of arterial 
vascular smooth muscle cells (vSMC) and for regulating mesothelial epithelial-
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mesenchymal transition (EMT). vThey also conclude that primary roles for canonical 
Notch signaling in lung development are in selection of Clara cell fate and in vSMC 
recruitment (103).  Forced expression of Notch3 intracellular domain (N3ICD) in 
peripheral epithelium resulted in perinatal lethality with phenotypes of altered lung 
morphology and delayed lung development.  In N3ICD transgenic mice, metaplasia of 
undifferentiated cells in the terminal airways was observed, and the majority of the 
epithelial cells are undifferentiated, with some maturation of type II pneumocytes but no 
type I alveolar cells (104).  These data strongly suggest the importance of Notch signaling 
in lung development.    
The Notch signaling in human cancers 
In the last two decades, evidence has accumulated on the deregulation of Notch receptors, 
ligands, modulators and downstream targets in an extensive number of solid tumors and 
subsets of hematopoietic malignancy.  Notch signaling can have opposing roles in human 
tumorigenesis dependent of the cancer types.  Even in the same type of cancer, the role of 
Notch signaling is complicated and highly dependent on the spatial and temporal context of 
Notch activation as well as other signaling pathways in the cells (Table 1.2).  
 
Notch genes as oncogenes  
Notch signaling plays an oncogenic role in various human cancers (Table 1.2).  Here we 
mainly emphasized on Notch signaling in T-cell acute lymphoblastic leukemia (T-ALL) 
and solid tumors including breast cancer, pancreatic cancer, ovarian cancer and colorectal 
cancer.  The oncogenic role of Notch signaling in lung cancer will be discussed separately.  
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T-ALL 
The oncogenic role of Notch was first identified in human T-ALL, in which a t(7;9)(q34; 
q34.3) chromosomal translocation has been identified in a subset of these leukemias.  The 
gene at the chromosome 7 locus fused to the T-cell-receptor- β (TCR β) promoter/enhancer 
is very similar to Drosophila Notch so as to get its name TAN1 (translocation-associated 
Notch homologue), which later became known as human Notch1.  This translocation 
results in constitutive expression of active form of Notch1, N1ICD (105, 106).  Indeed, 
Notch1 signaling drives hematopoietic progenitor cells into the T-cell lineage (107), and 
mice reconstituted with hematopoietic progenitor cells expressing TAN1 proteins develop 
T-cell leukemia (108).  In contrast, loss of Notch1 in bone marrow progenitor cells showed 
a cell autonomous blockage in T cell development at an early stage (109).  Subsequently, 
Weng et al identified activating Notch1 mutations in 56% of T-ALL patients.  Sequencing 
of T-ALL cell lines and patient samples revealed that the majority of Notch1 mutations are 
located in two regions, the HD, which causes ligand-independent activation of signaling, 
and PEST domain, which results in prevention of NICD from proteosome degradation 
(110, 111).  Notch1 has been found can cooperate with c-Myc (112), E2A-PBX1 (113) and 
Ikaros (114) to induce T-ALL.  Consistently, forced expression of the Notch ligand DLL4 
also results in the development of T-cell leukemia/lymphoma (115, 116).  Notch signaling 
not only plays important roles for initiation of T-ALL, but also is required for maintenance 
of T-ALL that continued growth and survival of Notch1-transformed lymphoid cell lines 
require nuclear access and transcriptional coactivator recruitment by Notch1 (117).  In 
addition to Notch1, other Notch isoforms can also be oncogenic in T-ALL. Rohn et al. 
showed that recombinant feline leukaemis virus (FeLV) provirus isolated from FeLV-
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induced lymphomas in cats contained active Notch2 sequence, suggesting a correlation 
between Notch2 and leukaemogenesis (118).  Dysregulation of Notch3 signaling has been 
also proposed to be important in T-ALL due to the fact that forced expression of N3ICD in 
T cells results in multi-organ infiltration of T lymphoblasts and death at 10-14 weeks of 
age, and Notch3 has been shown to be highly expressed by T-ALL cells and reduced level 
of Notch3 was found to correlate with disease remission, indicating that Notch3 may be 
able to induce T-cell leukemia similar to Notch1 (119, 120).  Furthermore, Masiero et al. 
showed that Notch3 promotes survival of T-ALL cells through regulating MKP-1 levels 
(121).  In addition to the mutation of Notch1 in T-ALL, around 20% of T-ALL patients 
harbor inactivating mutations of an E3 ubiquitin ligase FBW7 (F-box and WD repeat 
domain containing 7), which could potentially function as a tumor suppressor by 
upregulating the expression of NICD (122, 123).  
 
Breast cancer 
The first evidence describing function of Notch signaling in solid tumor came from the 
observation that integration of the mouse mammary virus (MMTV) into the Notch4 locus 
results in a truncated Notch4 mRNA named int3 representing a gain-of-function mutation, 
and results in the formation of mammary tumors (124-128).  This phenomenon was 
confirmed by studies of transgenic mice with activated form of Notch4 under control of 
MMTV long term repeat or the whey acidic protein (WAP) demonstrating that 100% of 
female mice developed mammary tumors (129, 130).  Besides Notch4, similar gain-of-
function Notch1 truncations were also found by MMTV integration, which further 
accelerated MMTV-Nue induced mammary tumors (131).  MMTV-N1ICD transgenic 
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female mice developed lactation-dependent papillary tumor by their third pregnancy, which 
were non-invasive and regressed upon gland involution, but progressed to invasive 
adenocarcinomas in subsequent pregnancies.  In addition, microarray analysis of N1ICD 
and c-myc induced tumors reveals a high profile similarity, further suggesting that c-myc is 
a direct target of Notch1 in mammary tumors (132).  Notch signaling in mouse mammary 
tumorigenesis also showed relevance to human breast cancer development.  Activated 
forms of Notch1 and Notch4 have been identified in several human breast cancer cell line 
(133, 134).  Notch3 has been shown to play an important role in the proliferation of ErbB2-
negative breast cancer cell lines (135). Further, high levels of Jagged1 and Notch1 
expression correlate with poor survival and they are independent prognostic markers in 
human breast cancer (136, 137).  In addition, increased accumulation of N1ICD and Hes1 
in ductal carcinoma in situ (DCIS) compared with normal breast tissue can predict 
reduction of recurrence time 5 years after surgery (138).  Interestingly, Notch2 appears to 
antagonize signals induced by other three Notch receptors in breast cancer cells (139).  
Consistently, high level of Notch2 expression in breast tumors correlated to higher chance 
of survival, whereas high level of Notch1 expression seems to be associated with a poorer 
outcome (140).  In primary breast cancer, Weijzen et al. showed increased expression of 
Notch1 in four breast cancer tumors overexpressing H-Ras, which revealed that Notch1 is a 
downstream target of oncogene H-Ras and implied that Notch1 is essential for H-Ras 
transformed breast tumor (141).  This scenario is further supported by the study that in the 
majority of double transgenic mice expressing both v-Ha-ras under control of MMTV 
promoter and Deltex1, a negative regulator of Notch signaling, palpable mammary tumors 
were not detectable (142).  Additionally, another Notch negative regulator Numb has been 
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identified to be lost in approximately 50% of human breast cancer (143).  In estrogen 
receptor (ER)-negative breast cancer cells, activation of Notch signaling leads to direct 
transcriptional up-regulation of the apoptosis inhibitor and cell cycle regulator survivin to 
enhance cell proliferation, and treatment with a γ-secretase inhibitor (GSI) induced 
apoptosis and inhibited local and metastatic mammary tumor growth in mice (144).  In 
contrast, in ER positive breast cancer, Rizzo et al. demonstrated that estrodiol could inhibit 
Notch activity, and Notch inhibition fostered the effects of tamoxifen (145).  Taken 
together, these studies strongly indicated the oncogenic role of Notch signaling in breast 
cancer.  
 
Pancreatic cancer 
Recently, there is increasing evidence to link Notch directly to pancreatic cancer. Various 
Notch receptors, ligands and downstream target genes have been shown to be expressed in 
pancreatic intraepithelial neoplasia (PanIN) as well as in pancreatic ductal adenocarcinoma 
(PDAC) tissue of mice and human (146, 147).  Plentz et al. analyzed the responsiveness to 
a GSI (MRK003) in more than 400 human cancer cell lines, and found that remarkably 
50% of 26 PDAC cell lines tested were sensitive to the inhibitor, suggesting that Notch 
signaling is essential in PDAC (148).  In many genetically engineered mouse models for 
PDAC, expression of Notch1 and its downstream effector Hes1 are increased in PanIN and 
fully developed PDACs (149, 150).  Simultaneous expression of activated form of Notch 
receptor with an oncogenic form of KRAS in either pancreatic progenitors or mature acinar 
cells leads to developing of PanIN lesions earlier than expression of either genes alone, 
suggesting that Notch and KRAS synergize to initiate pancreatic tumorigenesis (149).  
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Ovarian cancer 
Notch3 amplification was identified in around 19% of human ovarian cancer patients, and 
inactivation of Notch3 by both GSI and Notch3-specific siRNA suppressed cell 
proliferation and induced apoptosis in the cell lines with Notch3 amplification (151).  
Recently, a comprehensive and integrated genomic analyses of 489 ovarian tumors 
revealed that Notch signaling pathway is highly activated in ovarian cancer patients, in 
which Notch signling was altered in around 22% of ovarian cancer samples, further 
suggesting importance of Notch signaling in human ovarian cancer (152).  Moreover, 
Notch3 protein expression was significantly associated with advanced stage, lymph node, 
and distant metastasis of ovarian cancers (153).  In addition, Notch3 expression is 
associated with recurrent postchemotherapy high-grade serous carcinoma (HGSC) and 
knockdown of Notch3 in the ovarian cancer cell line OVCAR3, which expressed abundant 
Notch3, made it resensitized to chemo-agents carboplatin (154). Jagged1 has been 
identified as the primary Notch3 ligand in ovarian cancer cells and Jagged1/Notch3 
interaction constitutes a juxtacrine loop promoting proliferation and dissemination of 
ovarian cancer cells within the intraperitoneal cavity (155).  Besides Notch3 amplification, 
an activated form of Notch1 is also frequently expressed in human ovarian specimens as 
well as ovarian cancer cell lines, and depletion of Notch1 results in growth inhibition of 
ovarian cancer cells (156).  Consistently, transfection of the activated form of Notch1 leads 
to a proliferative and colony formation advantage of ovarian cancer cells (157).  Overall, 
these data suggest that Notch1, Notch3 and Jagged1 are oncogenic in ovarian cancer. 
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Colon cancer 
The coordination of Wnt and Notch signaling pathway is essential for regulation of colonic 
progenitor cell division and differentiation (158), which suggests that these may also play 
an important role in intestinal tumorigenesis.  Indeed, Fre et al. had demonstrated that 
Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the 
intestine (159).  Moreover, it has been shown that Notch ligand Jagged1 is transcriptionally 
regulated by Wnt/β-catanin pathway in colorectal cancer cells, and expression of N1ICD 
partially reverts the effects of blocking Wnt/β-catanin pathway in tumors implanted 
subcutaneously in nude mice.  Crossing APC (Min/+) with Jagged1 hemizygous mice is 
sufficient to remarkably reduce the size of the polyps arising in the APC mutant 
background, implying that Jagged1 mediated Notch signaling is an essential modulator of 
tumorigenesis induced by nuclear β-catenin (160).  In addition, Notch signaling has been 
shown to suppress transcription of Kruppel-like factor (KLF4), which could inhibit cell 
proliferation, in colon cancer cells and treatment of APC (Min/+) mice with GSIs resulted 
in a 50% reduction in the number of intestinal adenomas, and increase of Klf4 expression 
(161).  In human colorectal cancer, the vast majority of 130 colorectal cancer tissues 
expressed Notch downstream effector Hes1 mRNA (162), and somatic mutations of 
FBXW7 gene were found frequently in human colorectal cancer as well (163).  Most 
recently, Guilmeau et al. also demonstrated that in human small intestinal and colonic 
epithelium, Jagged1 expression was restricted to enteroendocrine cells or was undetectable, 
respectively, but was elevated in about 50% of human colon tumors (164).  In short, these 
studies support the notion that many of colorectal tumors, like the APC (Min/+) derived 
tumor, may respond to anti-Notch or anti-Jagged1 therapy.  
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Table 1.2. Multiple roles of Notch signaling in solid tumors 
Tumor Type Oncogenic Tumor  
suppressive 
Tumor 
 progression 
Tumor  
maintenance 
Drug 
resistance 
Lung √ √ √   
Breast √ √ √ √ √ 
Colorectal √  √   
Cervical √  √  √ 
Pancreatic √  √  √ 
Liver  √ √  √ 
Medulloblastoma   √ √  
Glioblastoma  √ √ √ √ 
Prosate  √ √   
Melanoma   √ √  
Head and neck     √ 
Oral SCC √ √    
Skin  √    
Adopted from Ranganathan et al., Nature Review Cancer, 2011. 
 
 
 
 
 
 
  28 
Notch genes as tumor suppressors 
Studies on skin cancers have provided evidences that Notch signaling can also be a tumor 
suppressor.  Notch1-deficient mice develop spontaneous basal-cell-carcinoma-like tumors 
over time (165).  Additionally, in the same study the authors had shown that Notch1 
deficiency in the skin facilitates chemical-induced carcinogenesis. To determine what 
mechanism underlies the tumor suppressive property of Notch1 in skin, Nicolas et al. 
demonstrated that the absence of Notch1 in skin results in a downregulation of Waf1, 
which leads to increased sensitivity to chemical-induced carcinogenesis.  Furthermore, 
absence of Notch1 in the mouse epidermis leads to aberrant expression of a Sonic 
Hedgehog downstream effector Gli2, which plays important roles in the regulation of 
basal-cell carcinoma.  Also they found that in the skin of Notch1-deficient mice, Wnt 
pathway is re-activated, which is also associated with basal-cell carcinomas (165).  
Consistent with mice data, reduced expression level of Notch1, Notch2 and Jagged1 were 
found in human basal-cell carcinoma (166).  
 
In prostate cancer cells, overexpression of a constitutive activated form of Notch1 inhibits 
proliferation of various prostate cancer cells (167).  And ectopic activation of Notch 
inhibits cell proliferation concomitantly with an induction of PTEN level, indicating that 
Notch positively regulates expression of PTEN (168).  In liver cancer, Notch1/Jagged1 
were frequently low expressed in hepatocellular carcinoma and correlated with the high 
expression of β-catenin suggesting that downregulation of Notch1/Jagged1 signaling may 
sustain tumor progression (169).  
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Notch ligand DLL4 has emerged as an attractive target for tumor angiogenesis.  However, 
chronic inhibition of DLL4 by a DLL4 antibody resulted in pathological activation of 
endothelial cells, disrupts normal organ homeostasis and induces vascular neoplasmas 
(170), which not only arises the safety concern of chronic DLL4 blockade, but also 
implicates that DLL4-Notch signaling may have tumor suppressive function in vascular 
neoplasmas.  
 
In a recent study, Aifantis’s group deleted the Nicastrin (Ncstn) gene, which is a member of 
the γ-secretase complex and one of the few non-redundant members of the pathway in 
haematopoitic cells, resulted in the development of a myeloproliferative/ myelodysplastic 
process, reminiscent of human chronic myelomonocytic leukaemia (CMML).  Moreover, 
triple deletion of Notch1, Notch2 and Notch3 phenocopied the Ncstn-deficient phenotypes, 
suggesting that Notch signaling also can play tumor-suppressive roles within the 
hematopoietic system.  Consistently, they identified novel somatic inactivating Notch 
pathway mutations, including NCSTN, APH1, MAML and Notch2, in a subset of patient 
with CMML, which further confirmed the tumor suppressive role of Notch signaling in 
CMML (171).  
 
Notch in tumor progression 
 
Notch signaling in cancer stem cell (CSC) 
Many cancers seem to contain a small population of pluripotent tumor initiating cells, also 
called cancer stem cells (CSCs) (172).  The cancer stem cell hypothesis states that CSCs 
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possess some of the biological properties of normal stem cells, such as indefinite self-
replication, asymmetric cell division, and resistance to cytotoxic agents.  Signaling 
pathways essential for embryonic development and cell fate decision are considered to be 
important in maintenance of CSCs.  Notch signaling has been well studied for its roles in 
CSCs in breast cancer, medulloblastoma, glioma, and lung cancer.  In breast ductal 
carcinoma in situ (DCIS), the ability to form mammospheres is significantly reduced by 
GSIs or a Notch4 neutralizing antibody, suggesting that Notch4 signaling is important in 
maintenance of CSCs of DCIS (138).  In mammospheres of human breast cancers, Sansone 
et al. demonstrated that autocrine IL-6 signaling maintains CSCs is through induction of 
Notch3 signaling to promote a hypoxia-resistant phenotype (173).  Indeed, p66Shc-Notch3 
pathway has been reported to be an essential factor to maintain the hypoxia-resistant 
phenotype of human breast cancer mammospheres (174).  In medulloblastoma and 
glioblastoma, GSIs selectively deplete CD133-high cells, which is commonly used as a 
marker of CSCs (175, 176).  Moreover, Wang et al. showed that inhibition of Notch 
pathway with GSIs renders the glioma stem cells sensitive to radiation by enhancement of 
radiation-induced cell death and impairment of clonogenic survival of glioma CSCs but not 
non-stem glioma cells, which was further confirmed by abrogation of Notch1 or Notch2 
receptors (177).  In pancreatic cancer, activation of Notch signaling promotes epithelial-
mesenchymal transition (EMT), which is consistent with CSCs phenotype and contributes 
to drug resistance (178, 179).  In lung cancer, Sullivan et al. used Aldehyde dehydrogenase 
(ALDH) activity as an indicator to select stem cells of lung adenocarcinoma, and further 
demonstrated that inhibition of Notch signaling via a GSI or Notch3 shRNA significantly 
decreased percentage of ALDH-positive lung cancer stem cells, implicating importance of 
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Notch signaling, especially Notch3 in the maintenance of lung CSCs (180).  And Yang et 
al. using mouse adenocarcinoma cells from KRAS and TP53 mutant mice, demonstrated 
that CD133-positive cells have higher Notch receptors and ligands expression compared 
with CD133-negative cells, indicating the importance of Notch signaling in the 
maintenance of stemness of lung adenocarcinoma (181).  By using neutralizing antibody 
against human DLL4 to treat mouse xenograft tumors, which does not cross react with 
mouse DLL4, Hoey et al. identified that inhibition of DLL4 in tumor cells substantially 
reduced colon cancer stem cell frequency (182).  These data suggest that therapeutic 
targeting Notch signaling could be used in clinic to target CSCs, so as to reverse chemo- or 
radio-resistance of many kinds of cancers.  
 
Notch in EMT and metastasis 
The processes of Epithelial-Mesenchymal Transition (EMT) is a unique process by which 
epithelial cells undergo remarkable morphologic changes characterized by a transition from 
epithelial cobblestone phenotype to elongated mesenchymal phenotype leading to 
increased motility and invasion (183).  The same signaling pathways govern the processes 
of EMT in development as well as tumor metastasis (184).  A hallmark of EMT from an in 
situ to an invasive carcinoma is loss of expression of the adhesion molecule E-cadherin, the 
expression of which is inversely correlated with cancer grade and patient survival (185, 
186). Zinc finger transcriptional repressors Snail and Slug bind to E boxes located 
proximal to the transcription start site of the E-cadherin gene to suppress transcription of 
E-cadherin (187).  During development, mice with a targeted mutation in the Notch1 
receptor or Rbpj κ effector exhibits severely attenuated cardiac snail expression, abnormal 
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maintenance of intercellular endocardial adhesion complex, and abortive endocardial EMT 
in vivo and in vitro.  Consistently, overexpression of N1ICD in immortalized porcine aortic 
endothelial cells induces both EMT and oncogenic transformation, and leads to induction 
of snail and repression of VE-cadherin.  In the study, N1ICD activation of the Snail 
promoter is dependent of Rbpj κ, but the snail promoter itself lacks Rbpj κ binding sites, 
suggesting that Notch regulates Snail promoter activation may be indirect (188).   
 
In human cancers, Notch signaling drives EMT by upregulation of Snail, Slug and ZEB as 
well as interaction with TGF β signaling. Lendahl’s group had demonstrated that Notch 
signaling is required to convert the hypoxic stimulus into EMT, increased motility, and 
invasiveness by upregulation of Snail (189).  Moreover, it had been reported that another 
EMT inducer Slug is a downstream target gene of Notch as well and is upregulated in 
Jagged1 and Notch1 positive human breast cancers (190).  Pancreatic cancer cells that are 
gencitabine-resistant (GR) acquired an EMT phenotype as evidenced by elongated 
fibroblast morphology with downregulation of E-cadherin, and upregulation of ZEB1 (191, 
192).  Notch2 and its ligand Jagged-1 are remarkably upregulated in GR cells, and 
attenuation of Notch signaling by siRNA led to partial reversal of the EMT phenotype 
associated with decreased expression of vimentin, ZEB1, Slug and Snail, suggesting a role 
of Notch signaling in the acquisition of EMT in pancreatic cancer (178).  TGF-β signaling 
is involved in the promotion of EMT by extensive communication with other signaling 
pathways, including Notch.  TGF-β-induced EMT was attenuated by silencing Hey1, 
Jagged1, or treatment with GSIs, suggesting the roles of Hey1, Jagged1/Notch in mediating 
TGF-β signaling-induced EMT (193).  
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Metastasic disease is the major cause of cancer-associated death. The roles of Notch 
signaling in the regulation of cancer invasion and metastasis have also been documented. 
In 154 resected human prostate cancers, high Jagged1 expression is associated with 
increases in metastases and tumor recurrence, with the pro-metastatic property of Jagged1 
thought to be mediated by the induction of EMT (194).  In osteosarcoma, osteosarcoma 
cell lines with the ability to metastasize have higher levels of Notch 1, Notch 2, DLL1 and 
Hes1 compared to normal human osteoblasts and non-metastatic osteosarcoma cell lines.  
When invasive osteosarcoma cells are treated with GSIs, invasiveness is abrogated.  In a 
novel orthotopic murine xenograft model of osteosarcoma pulmonary metastasis, blockade 
of Hes1 expression and Notch signaling eliminated spread of disease from the tibial 
primary tumor (195).  Recently, Sonoshita et al. demonstrate that in their Colon26 
transplantation model, Notch receptors are expressed on cancer cells, whereas the ligands 
are found on stromal cells.  The activation of Notch signaling is mainly found in cancer 
cells in the vicinity of blood vessels in primary tumors, while in metastatic lesions, 
activated Notch signaling are either in micrometastasis or in the outer rim of large 
metastasis next to stromal cells, suggesting that Notch activation by tumor-stroma 
interaction is critical for cancer cell intravasation.  Inhibition of Notch signaling by GSIs 
repressed tumor invasion driven by loss of Aes/Grg5, suggesting that Aes/Grg5 
suppressing colon cancer metastasis is mainly by preventing Notch signaling and Notch 
mediated local invasion and intravasation (196).  Their results suggest that inhibition of 
Notch signaling can be a promising strategy for prevention and treatment of colon cancer 
metastasis.  Tumor-derived Jagged1 had been shown to promote osteolytic bone metastasis 
of breast cancer by engaging Notch signaling in bone cells, in which Jagged1 enhances 
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tumor growth by stimulation of IL-6 release from osteoblasts and directly activates 
osteoclast differentiation.  Indeed, GSIs treatment reduces Jagged1-mediated bone 
metastasis by interfering with the Notch signaling in stromal bone cells, providing a 
rationale for targeting Notch signaling for breast cancer bone metastasis (197). 
 
Notch in tumor angiogenesis 
Components of the Notch signaling pathway have been identified in endothelial cells in 
vitro and in vivo during embryonic development and tumor angiogenesis (198).  Of the 
Notch receptors, endothelial cells express Notch1 and Notch4; among the DSL ligands, 
endothelial cells express DLL1, DLL4, Jagged1 and Jagged2 (199-201).  Other key 
signaling components, including Rpbj κ (202), Hey1, Hey2 (203), Maml (204) are 
expressed in endothelial cells.  Functional studies using gene knockout in mice, 
mutagenesis and knockdown in zebrafish, and biochemical analysis in cultured endothelial 
cells have shown that Notch signaling plays a fundamental and crucial role during tumor 
angiogenesis, which suggests that Notch signaling could be an attractive target for tumor 
angiogenesis.   
 
In endothelial cells, Notch signaling plays a central role in the cell specification, 
proliferation, cell motility and cell adhesion. Mosaic analysis of endothelial cells deficient 
in Notch signaling in mice and zebrafish illustrated that Notch is required cell 
autonomously for stalk cell specification by actively suppressing the tip cell phenotype 
(205).  In mice, mosaic endothelial Cre recombination of a floxed Notch1 allele showed 
that the majority of Notch-null endothelial cells adopt tip cell properties.  Conversely, 
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ectopic activation of Notch signaling in the mouse retina by injection of the Jagged1 
peptide leads to reduced tip cell formation and filopodia extension (206).  Studies in 
several mouse tumor models supports the hypothesis that tip-stalk specification regulated 
by Notch signaling controls the branching frequency of tumor blood vessels as well.  
Transplantable tumors in DLL4 heterozygous hosts show significantly increased sprouting 
angiogenesis.  Furthermore, inhibition of Notch signaling by GSIs, DLL4 or Notch1 
blocking antibodies results in similar phenotypes. Analysis of tumor growth reveals that the 
increased vascularization upon inactivation of DLL4/Notch signaling paradoxically causes 
reduced tumor growth due to unproductive angiogenesis (207).  Similarly, increased 
endothelial Notch signaling triggered by DLL4 expressing tumor cells resulted in reduced 
vascular branching and density, but enhanced vessel diameter, perfusion, and hence 
promoted tumor growth (208, 209).  Overall, these studies support the concept that Notch 
coordinated the balance of tip and stalk cell numbers, which is required for effective 
vascular patterning and function in angiogenesis.  However, the exact mechanism for 
Notch suppresses tip cell formation is not fully understood.  
 
Notch in drug resistance 
Cancer cells usually develop resistance to chemotherapeutic and targeted therapeutic 
agents mainly by activation of survival signaling or by inhibition of apoptosis.  Notch 
signaling is a major regulator of cell survival and has been shown to be very important in 
drug resistance of multiple cancers.  For example, in colorectal cancer, Notch signaling and 
PI3K-AKT signaling are activated by the treatment with the chemotherapeutic agent 
oxaliplatin, and inhibition of Notch signaling by GSIs resensitizes cells to oxaliplatin 
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(210), and combination of GSI and cisplatin elicits a striking induction of cell death (211).  
Furthermore, blockade of Notch signaling by GSIs also enhance taxane/ taxol-induced 
mitotic arrest and apoptosis of colon cancer cells both in vitro and in vivo, indicating that 
GSIs could be used in combination with these chemotherapeutics to overcome resistance 
colon cancers (212).  Upregulation of Notch1 was found in cisplatin-resistant HNSCC 
patients and cisplatin resistance of HNSCC was reduced upon inhibition of Notch signaling 
by GSIs (213).  In addition, Notch3 was upregulated and contributed to doxorubicin 
resistance in human hepatocellular carcinoma (HCC) via regulation of p53 expression and 
DNA damage machinery, implying that inhibition of Notch3 signaling in combination with 
chemotherapy could conceivably provide a novel approach for HCC (214).  In 
Trastuzumab, a HER2 neutralizing antibody, resistant HER2-positive breast cancer, Notch 
activity is upregulated when cells are treated with trastuzumab and treatment with a 
combination of trastuzumab and a GSI further induced apoptosis in these cells (215).   In 
addition, treatment with tamoxifen in estrogen receptor (ER)-positive breast cancer cells 
activated Notch pathway so as to activate survival signaling pathway, in which Notch-1 
increased the transcription of ERα -responsive genes in the presence or absence of estrogen 
via a novel chromatin crosstalk mechanism, suggesting that combined inhibition of Notch 
and estrogen signaling has synergistic effects in ERα -positive breast cancer models (216).  
 
Notch signaling in lung cancer 
Lung cancer is the leading cause of cancer-related deaths in the United State.  The five-
year survival rate for patient with lung cancer remains low-15%-and has not changed 
significantly during the past 30 years (217).  Lung cancer can be classified as non-small 
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cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC representing 
the majority of lung cancers. Although lung cancer is strongly associated with tobacco 
exposure, there is an increasing NSCLC morbidity in patients who have never smoked. In 
the past two decades there has been a growing body of evidence underscoring the 
importance of developmental pathways in tumorigenesis, such as Notch, Wnt and 
Hedgehog.  Two Notch paralogs have been implicated in lung cancer tumorigenesis, 
Notch1 and Notch3. The role for Notch1 in NSCLC has been controversial.  Forced 
expression of constitutively activated Notch1 inhibited growth of the lung adenocarcinoma 
cell line A549 in culture and suppressed tumor growth in an in vivo xenograft model (218).  
However, under hypoxia condition, Notch1 provides a critical survival signal to NSCLC 
cells.  Moreover, inhibition of Notch1 signaling in NSCLC cells either through genetic 
downregulation or using a GSI resulted in apoptosis only under hypoxia condition (219).  
Notch1 activating mutations has been found in 10% of NSCLC patients.  These mutations 
correlated with a worse prognosis in patients with wild-type p53.  Moreover, 
downregulation of Numb, a negative regulator of Notch signaling was detected in 
approximately 30% of NSCLC.  Primary cells from patients with either Notch1 mutation or 
low expression of Numb are more sensitive to GSIs (220). A recent study conducted by 
Bocchetta’s group demonstrated that Notch1 signaling in hypoxic NSCLC 
microenvironment appears to promote cancer cell survival by dual mechanisms: inhibition 
of PTEN expression and positive regulation of IGF-1 and its receptor, IGF-1R (221).  The 
connection between Notch1 signaling and hypoxia has been independently shown in A549 
cells by Chen et al, in which they also demonstrated that Notch1 signaling upregulates of 
survivin expression in lung cancer synergistically with HIF-1 alpha (222).  These data 
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suggest that Notch1 appears to be an attractive target in hypoxic tumor regions, which are 
thought to promote resistance to standard chemotherapy. In addition, a recently study has 
linked Notch1 and EGF signaling in NSCLC, in which the authors demonstrated a novel 
molecular circuitry in NSCLC where ADAM17 up-regulates EGFR expression through the 
activation of Notch1, and that proliferation, survival and colony formation of Notch1 
deficient NSCLC cells were insensitive to EGF stimulation.  Indeed, there is a significant 
correlation between Notch1 and EGFR overexpression in NSCLC specimens, but not in 
normal lung (223).  Given their functions in the survival of NSCLC, both ADAM17 and 
Notch1 constitute promising targets for the treatment of NSCLC.  
 
Notch3 has been considered as an oncogene in NSCLC as well. In an early study from our 
group, a chromosomal translocation t(15;19) was initially identified in an aggressive lung 
cancer metastatic to mediastinum and bone arising in a 34-year-old woman without a 
history of smoking or a family history of cancer. The cell line isolated from this patient, 
HCC2429 harbors this translocation and causes high expression of full-length Notch3 
mRNA. Using Northern blot hybridization, our group also identified seven out of 44 
NSCLC cell lines expressed the Notch3 mRNA (224).  Furthermore, 
immunohistochemistry analysis showed that 80 out of 207 resected lung cancers expressed 
Notch3.  The function of Notch3 in NSCLC has been demonstrated by expression of a 
dominant negative form of the Notch3 receptor lacking the intracellular portion of the 
protein in NSCLC HCC2429 and H460, which caused reduced growth and increase growth 
factor dependency of these two cell lines (225).  The oncogenic role of Notch3 in NSCLC 
is further demonstrated by the treatment of a GSI, MRK003 in NSCLC, in which Konishi 
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et al. demonstrated that treatment with the MRK003 in NSCLC cell lines HCC2429 and 
H460 resulted in induction of apoptosis and decrease of colonies in soft agar.  In vivo 
treatment of MRK003 in xenograft mouse model generated with HCC2429 and H460 cell 
lines significantly suppressed tumor growth, while the effect was very limited with A549 
cells.  Genetic inhibition of Notch3 in HCC2429 cell by siRNA converts the cell to be GSI-
insensitive, indicating that Notch3 but not Notch1 is the right target of GSI in the inhibition 
of NSCLC tumor growth (226).  EGFR signaling pathway plays a very pivotal role in 
NSCLC progression.  The link between Notch3 and EGFR has been proposed as well, 
which emphasizes importance of Notch3 in NSCLC.  Firstly, expression of Notch3 in 
NSCLC tumors was significantly correlated to the expression of EGFR (225).  Secondly, 
abrogation of Notch3 in HCC2429 cells resulted in an increase of proapoptotic, BH3-only 
polypeptide Bim, which is a well-known mediator of gefitinib toxicity in NSCLC with 
activating mutations of the EGFR (227).  Treatment of MRK003 along with erlotinib in 
xenograft mouse model generated with H460 cells remarkably reduced tumor sizes and 
increased Bim expression compared with either agent alone(228).  
 
Notch ligands Jagged1 and Jagged2 play roles in lung cancer progression as well.  Kurie 
and colleagues have shown that Jagged1 and Jagged2 have distinct biological functions in 
lung cancer, in which depletion of Jagged1 but not Jagged2 induced apoptosis of HCC827 
cells harboring an EGFR mutation, whereas depletion of Jagged2 but not Jagged1 
enhanced the ability of HCC827 cells to chemoattract THP-1 human monocytes, 
suggesting the novel role of Jagged2 in the promotion of antitumor immunity in lung 
cancer (229).  Subsequently, the same group demonstrated that Jagged2 but not Jagged1 
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promoted EMT process and metastasis of mouse lung adenocarcinoma cells through 
suppression of miR-200 expression (181).  
 
In contrast, Notch signaling seems to function as a tumor suppressor in SCLC.  In primary 
SCLC, mammalian achaete scute homologue 1 (Mash1) protein is highly expressed.  
Mash1 transcription is suppressed by Notch target gene Hes1.  During lung development, 
Notch1 and Hes1 are highly expressed in non-neuroendocrine airway epithelial cells, 
whereas Mash1 expression is restricted to pulmonary neuroendocrine cells, implicating that 
Notch signaling seems to control pulmonary epithelial cell fate by upregulation of Hes1, 
whereas suppresses the neuroendocrine cell fate by repressing Mash1 (92, 230).  
Intriguingly, activated form of Notch1 and Notch2 cause cell cycle arrest in series of SCLC 
cell lines by upregulation of WAF, KIP1 and negatively regulating Mash1(231, 232).  
 
CBF-1 independency of Notch signaling in cancer  
CBF-1 dependent canonical Notch signaling plays an important role in diverse cellular 
processes and various human diseases, including cancer.  Studies conducted on Drosophila 
mutants provided some clues for existence of CBF-1-independent non-canonical Notch 
signaling, because the Su(H) mutants examined do not exhibit the same phenotypes as 
Notch mutants (233, 234).  In CBF-1 independent non-canonical Notch signaling, cleaved 
NICD could interact with components of other signaling pathways then activates 
downstream signaling.  CBF-1-independent non-canonical Notch signaling has also been 
demonstrated to be involved in the regulation and maintenance of various cancers.  In a 
breast cancer mouse model, MMTV-Notch4/Int3 transgenic mice develops mammary 
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tumors independent of CBF-1 activity as mice with targeted deletion of Rbpj κ (eg. CBF-1) 
in Notch4/Int3 overexpressing background also developed mammary tumors at a frequency 
similar to Notch4/Int3 transgenic mice, suggesting that Notch4-induced mammary tumor 
development is independent of CBF-1 activity (235).  In human breast cancer, KLF4-
induced cellular transformation requires Notch1. However, inhibition of canonical Notch 
signaling by blocking either CBF-1 or MAML1 did not suppress cellular transformation 
mediated by KLF4, implying that KLF4 contributes to breast tumor progression by 
activating synthesis of Notch1 and promoting Notch signaling through a CBF-1 
independent non-canonical Notch signaling (236).  In RK3E cells, a baby rat kidney cell 
line immortalized by Adenovirus early antigen 1A (E1A), Notch1 receptor lacking the 
CBF-1 interacting RAM domain is able to translocate into the nucleus and induces 
neoplastic transformation (237, 238).  In HPV-driven human cervical cancer, Jagged1 is 
preferentially upregulated in human cervical tumors and its expression correlates with the 
rapid induction of PI3K-mediated EMT.  However, expression of dominant negative CBF-
1 failed to abrogate EMT-driven motility and PI3K-mediated phosphorylation of Akt in 
HaCaT-Jagged1 cell, suggesting that Jagged1-Notch-PI3K oncogenic functions can be 
independent of CBF-1 transcriptional activity (239).  Furthermore, Perumalsamy et al. have 
elucidated that CBF-1-independent non-canonical Notch signaling is involved in the 
inhibition of apoptosis in mammalian cells and cancerous cells via the activation of mTOR-
Akt kinase through membrane-tethered N1ICD (240).  In addition, the NICD has been 
shown to activate the expression of YY1 target gene c-myc in cancer cells through directly 
interaction with YY1 transcription factor on c-myc promoter region independent of CBF-1 
(241).  One of the major Notch target genes, Hes1, can be activated by other signaling 
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pathways as well such as Sonic Hedgehog, independent of Notch in various cancers (242, 
243). Stockhausen et al. have demonstrated that the rapid activation of Hes1 in 
neuroblastoma cells through TGF α-mediated Ras/MAPK pathway is independent of Notch 
receptor cleavage (244) providing the indication that Notch/CBF-1-independent activation 
of Hes1 may be also involved in the activation or maintenance of cancers.   
 
Roles of DSL ligands independent of Notch activation 
Although the primary role of DSL ligands is to activate Notch signaling, DSL ligands can 
also function independent of Notch activation.  Previous studies indicate that DSL ligands 
are able to undergo proteolytic cleavage and initiate signaling events in the ligand-
expressing cells.  For example, forced expression of Jagged1 can transform rat kidney 
epithelial cells through its intact PDZ-ligand motif. This independent of Notch activation as 
PDZ-domain of Jagged1 did not affect the ability of JAGGED1 to initiate Notch signaling 
in neighboring cells, suggesting the existence of bidirectional Notch-DSL signaling (245).  
Moreover, DSL ligands undergo processing that is similar to the processing of Notch 
receptors using the same proteolytic machinery to release of the ICD, indicating the 
biological functions of DLL ICD (246, 247).  In addition, Jagged1 ICD (J1ICD) has been 
shown to activate AP1-mediated transcription, whereas NICD has an antagonistic effect on 
the AP1-mediated activation produced by J1ICD (246).  Consistently, the ICD of the DLL1 
ligand is able to induce growth arrest and senescence through the induction of p21 
expression, which can be overcome by the NICD as well (248).  Although, this in vitro 
evidences supports the existence of reverse signaling of Notch ligands, the physiological 
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relevance of reverse signaling of DSL ligands and its role in tumorigenesis is still not 
determined.  
 
Therapeutic agents targeting Notch signaling  
Based on the many effects of Notch signaling exhibited in multiple human cancers this 
pathway represents an attractive target for potential therapeutic benefit, which may result in 
suppression of cell proliferation, induction of cell death, depletion of CSCs, inhibition of 
cell proliferation, induction of cell death, depletion of CSCs, inhibition of tumor 
angiogenesis, and induction of differentiation.  There are multiple strategies that have been 
considered to target Notch signaling:  1). Neutralizing antibodies (Abs) or receptor/ligand 
decoys against individual Notch receptor and ligands to interfere with receptor-ligand 
interaction;  2). Receptors specific blocking Abs targeting NRR region to mask S2 
cleavage site thereby blocking ADAM-protease-mediated cleavage of receptors;  3). 
Various γ-secretase inhibitors (GSIs) with different selectivity and efficacy preventing S3 
cleavage of receptors by γ-secretase complex;  4). Stapled peptides interfering with the 
formation of NICD-MAML transcriptional complex.  These strategies to target Notch 
signaling are currently being tested in preclinical studies as well as in clinical trials (Table 
1.3).  
 
Receptor/Ligand neutralizing antibodies/decoys 
The use of neutralizing Abs or decoys for Notch ligands DLL4 has been shown to be 
effective in blocking tumor angiogenesis.  The expression of DLL4 is restricted to 
endothelial cells during development, and knockout of a single allele of DLL4 results in an 
embryonic lethal phenotype due to defect in vasculogenesis.  DLL4 upregulation is also 
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found in tumor vasculature (249).  Studies targeting DLL4 ligands by a soluble DLL4-Fc 
or a DLL4 neutralizing antibody show substantial reduction of tumor growth in xenograft 
models (209, 250, 251).  The mechanism of DLL4 antitumor effect appears to be the 
promotion of non-productive angiogenesis by increased sprouting of endothelial tip cells 
(206).  Therefore, inhibition of DLL4 in suppression of tumor angiogenesis leading to 
hyperproliferation of non-functional tumor vessels to inhibit tumor growth is in a manner 
distinct from traditional anti-angiogenesis therapies (207).  In addition to its function on 
tumor angiogenesis, inhibition of DLL4 can also reduce colon cancer tumor growth via 
depletion of CSCs by using DLL4 blocking antibody against human DLL4, which does not 
cross react with mouse DLL4 (182).  So far, both the feasibility and efficacy of DLL4 Abs 
or decoys in the treatment of cancer have yet to be demonstrated in clinical trials.  
Recently, Yan’s group at Genentech reported that chronic inhibition of DLL4 results in 
severe disruption of normal tissue homeostasis and leads to vascular neoplasma in multiple 
organs, which has raised a significant safety concern for using DLL4 Abs to treat human 
cancers (170).  Besides inhibition of DLL4, Kitajewski’s group had demonstrated that 
ectopic expression of soluble Notch1 receptor (Notch1 decoy) could reduce signaling 
stimulated by the binding of three distinct Notch ligands to Notch1 and inhibit 
morphogenesis of endothelial cells overexpressing Notch4.  In their study, Notch1 decoy 
did not affect tumor cell growth in vitro, instead, it inhibited tumor angiogenesis in an in 
vivo xenograft model (252).  In addition, expression of dominant negative form of Notch3 
in lung cancer cell line remarkably reduced colonies in soft agarose (225).  These studies 
suggest the feasibility of blocking receptor-ligand binding for targeting Notch signaling in 
cancers.  
  45 
Receptors antibodies masking S2 cleavage 
Proteolytic resistance of Notch prior to ligand binding depends on the structural integrity of 
the NRR in the receptor.  The crystal structure of Notch1 NRR in its autoinhibited 
conformation provides evidence that antibodies masking NRR might stabilize the “off” 
conformation of the receptor even in the presence of  ligands activation (54).  Li et al. had 
generated antibodies against whole extracellular domain of Notch3 and found out that the 
strongest inhibitory Abs are specific for the extracellular NRR but not to the ligand binding 
domain of Notch3 receptor.  Those inhibitory antibodies can revert phenotypes conveyed to 
293T cells by Notch3 signaling, such as increased cellular proliferation, survival, and 
motility (253).  However, they did not test for anti-tumor activity of those antibodies.  
Nevertheless, their study provides evidence that targeting NRR of Notch receptors may 
represent a viable strategy to block ligand-induced Notch signaling.  Recently, Siebel’s 
group at Genentech developed blocking antibodies against Notch1 and Notch2 NRR by 
screening a phage display library.  Those antibodies can cross-react with human and mouse 
sequences.  They have demonstrated that selective blockade of Notch1 inhibits tumor 
growth in pre-clinical models through inhibition of cancer cell growth in T-ALL and 
deregulation of angiogenesis in solid tumors.  Inhibition of Notch1 plus Notch2 causes 
severe intestinal toxicity as is observed with GSIs treatment, while inhibition of either 
receptor alone reduces or avoids this effect, demonstrating that inhibition of individual 
Notch receptors may have advantages over pan-Notch inhibitor, such as GSIs (254).  In 
contrast, Aste-Amezaga et al. developed Notch1 antibodies against either ligand binding 
regions (LBD) or NRR derived from cell-based and solid-phase screening of a phage 
display library.  They observed that both classes of antibodies are specific for Notch1, bind 
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Notch1 on the surface of human tumor cell lines, and inhibit ligand-induced expression of 
Notch target genes in cell lines expressing wild-type Notch1 receptors, while antibodies 
against NRR are more potent than those against LBD.  On the other hand, antibodies 
against NRR appear to be much less effective in inhibiting Notch1 activation in T-ALL 
cells than GSIs (255).  Ultimately, it is difficult to make conclusions about the relative 
efficacies of these approaches, as their anti-tumor effects have not been tested in vivo.  
 
Gamma secretase inhibitors 
One of the emerging strategies for inhibiting Notch signaling is to suppress the S3 
proteolytic cleavage of Notch receptors mediated by γ-secretase complex. γ-secretase is a 
large intramembrane aspartylprotease complex composed of a catalytic subunit (presenilin-
1, presenilin-2) and accessory subunits (Pen-2, Aph1 and nicastrin).  Originally, GSIs were 
developed to treat or prevent Alzheimer’s disease to prevent release of the amyloid β-
peptide, the precursor of amyloid plaques found in the brain of Alzheimer’s disease (256).  
Since GSIs are also able to prevent activation of Notch signaling, several GSIs have been 
tested for antitumor activity. An early GSI, IL-X (cbz-IL-CHO) was shown to have 
antineoplastic activity in Ras-transformed fibroblasts. Furthermore, tripeptide GSI (z-Leu-
leu-Nle-CHO) was reported to suppress tumor growth in Kaposi sarcoma both in vitro and 
in vivo (257).  Another GSI, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT) has been demonstrated to reduce growth of medulloblastoma cells and 
xenograft tumors (243) as well as induce G0-G1 cell cycle arrest and apoptosis in a T-ALL 
animal models (258).  Furthermore, treatment of a tripeptide GSI, MRK003 in a Notch3 
dependent NSCLC cell line leads to suppression of cell proliferation and induction of 
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apoptosis both in vitro and in vivo (226).  These exciting results strongly indicate a 
potential clinical application of GSIs in the treatment of human cancers. Currently, several 
GSIs produced by different pharmaceutical companies have launched preclinical study or 
clinical trails for T-ALL and solid tumors (Table 1.3).  For example, the compound MK-
0752 from Merck & Co., Inc is currently under a phase I clinical trial for the treatment of 
T-ALL and advanced breast cancer (Clinical Trial ID: NCT00106145);  Roche’s GSI 
RO4929097 is in phase I/II clinical trail as a single agent in treating young patients with 
relapsed or refractory solid tumors, CNS tumors, lymphoma, and T-cell leukemia (Clinical 
Trail ID: NCT01088763);  Moreover, combination of RO4929097 and Gemcitabine 
Hydrochloride is in phase I clinical trail with advanced solid tumor as well (Clinical Trail 
ID: NCT01145456).  However, the major challenges of using GSIs in the cancer treatment 
is its side effects, especially toxicity in the gastrointestinal tract by induction of goblet cell 
differentiation, which probably results from chronic blockade of both Notch1 and Notch2 
processing in the intestine (259, 260).  The toxicity and lack ofspecificity of GSIs in the 
inhibition of Notch signaling may limit its clinical application.  Firstly, pan-Notch 
signaling pathway is known to be essential in cellular physiology in normal tissue, 
including intestine (261), hematopoiesis (262) and maintenance of arterial smooth muscle 
(263), suggesting the possibility that inhibition of γ-secretase may cause dysfunction of 
multiple organs.  Secondly, there are many substrates of γ-secretase in addition to Notch 
receptors and ligands, such as ErbB4 (264) and CD44 (265).  Thirdly, GSIs may target 
other proteases other than γ-secretase, which participate in various physiological 
conditions, so GSIs may have other side effects in vivo.  However, it may be possible to 
overcome the toxicity of GSIs. One approach could be to decrease the dose of GSIs in hope 
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that partially inhibition of γ-secretase activity could sufficiently suppress Notch signaling 
in cancer cells without significantly impairing its function in normal tissue;  Alternatively, 
intermittent dosing of GSIs with 3 consecutive days followed by a rest period of 4 days 
could help to decrease the gut toxicity (266);  Also, combination with other agents might 
increase the efficacy of GSIs while decreasing its toxicity (266, 267).  
 
Stapled peptides interfering NICD/MAML interaction  
A dominant negative fragment of MAML1 has been reported to antagonize canonical 
Notch signaling thereby suppress cell proliferation when expressed in T-ALL cell lines 
(117, 268).  Based on this notion, Moellering et al. have reported the design of synthetic, 
cell-permeable, stabilized alpha-helical hydrocarbon stapled peptide SAHM1 that target a 
critical protein-protein interface in the Notch transactivation complex.  Direct antagonism 
of the Notch transcriptional program by SAHM1 results in a Notch-specific anti-
proliferative effects in vitro and in a mouse model of Notch1-drived T-ALL while 
exhibiting less severe gut toxicity than GSIs (269). 
 
Overall, there are many approaches to target Notch signaling in cancer. And the anti-tumor 
activities of existing anti-Notch agents are under investigation in cancer cell lines and pre- 
clinical mouse models, which would be applied to anti-tumor therapies and benefit cancer 
patients later.  
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Table 1.3. Notch-targeting agents 
Agents Mechanism Targets Companies/ 
institutes 
Development 
phase 
GSIs Inhibition of S3 
cleavage by γ-
secretase 
All 4 Notch 
receptors,  
Notch ligands and  
multiple other γ-
secretase substrates 
  
MK0752   Merck Phase I 
RO4929097   Roche Phase I/II 
PF-03084014   Pfizer Phase I 
LY450139   Eli Lilly Phase I 
BMS-unknown   Bristol-Myers 
Squibb 
Phase I 
GSM Inhibition of S3 
cleavage by γ-
secretase 
Selective for specific 
γ-secretase substrates 
Myriad Failed 
Notch mAbs Interference 
with ligand-
induced Notch 
activation 
Specific for 
individual  
Notch receptors 
  
Notch1 mAb  Against NRR 
masking S2 cleavage 
Roche/Genentech 
Merck 
Preclinical 
Notch2 mAb  Against NRR 
masking S2 cleavage 
Roche/Genentech Preclinical 
Notch3 mAb  Receptor-ligand 
interaction/ Against 
NRR masking S2 
cleavage 
Aveo 
Tanox 
Preclinical 
Ligand mAbs Interference 
with ligand-
receptor 
interaction 
Specific for 
individual Notch 
ligands 
 Preclinical 
DLL4 
mAb/decoy 
 Block DLL4 receptor 
binding  
Roche/Genentech 
Regeneron 
Preclinical 
Transcription 
complex 
inhibitors  
Interference 
Notch induced 
gene 
transcription 
All four Notch 
receptors, potentially 
other nuclear 
transcriptional factors 
  
MAML-stapled 
peptide 
Interference 
with Notch 
interaction with 
MAML1 
All four Notch 
receptors, potentially 
other nuclear 
transcriptional factors 
using coactivator 
MAML1 
Harvard 
University 
Preclinical 
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clinical mouse models, which would be applied to anti-tumor therapies and benefit cancer 
patients later.  
 
Summary 
Notch signaling is pivotal in embryonic development, as knockout of several Notch 
components resulted in embryonic lethal phenotypes.  During the last decade, a growing 
body of literature demonstrates that Notch signaling also plays pleiotropic roles in human 
cancer by promotion of cellular proliferation, suppression of apoptosis, induction of EMT, 
facilitation of tumor angiogenesis, maintenance of cancer stem cells and prevention of cell 
differentiation, which makes Notch signaling an attractive target in the development of 
cancer therapies.  Our group first linked Notch3 to lung cancer tumorigenesis. Inhibition of 
Notch3 signaling by RNA interference or by treatment with a GSI in lung cancer cell lines 
suppressed tumor progression in vitro and in vivo xenograft tumor model. There are four 
key strategies to target Notch signaling: mAbs, receptors/ligands decoys to interfere 
receptor-ligand interaction; mAbs to mask S2 cleavage site; GSIs to block S3 cleavage; and 
stapled peptides to prevent formation of Notch-CBF-1-MAML complex.  Due to the lack 
of specificity and severe side effects of GSI, reagents that specifically inhibit Notch3 
signaling may be more efficacious for the treatment of lung cancer.  Therefore, the goal of 
this thesis is to develop agents to specifically target Notch3 signaling in lung cancer. 
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CHAPTER II 
 
TARGETING SPECIFIC REGIONS OF THE NOTCH3 LIGAND-BINDING DOMAIN 
INDUCES APOPTOSIS AND INHIBITS TUMOR GROWTH IN LUNG CANCER 
 
The work presented in this chapter is published with the same title in the Cancer Research, 
Jan 2010 [70]. 
 
Abstract 
Like many signaling pathways in development, the Notch receptor pathway plays an 
important role in cancer pathobiology when it is dysregulated.  Potential ligand-binding 
sites within the epidermal growth factor (EGF)-like repeats of Notch1 have been identified, 
but the ligand-binding domains in Notch3, which is implicated in lung cancer, are not 
known.  In screening a library of 155 peptides representing all 34 EGF-like repeats in 
Notch3, we discovered two distinct ligand-binding regions involving the 7-10 and 21-22 
repeats that are distinct from the putative ligand-binding domain of Notch1.  In cell-based 
assays, peptides from these regions induced apoptosis and reduced expression of the 
Notch3-dependent gene Hey1.  They also bound directly to the Notch ligand Jagged1, 
suggesting that their mechanism of action involves disrupting interactions between Notch3 
and Jagged1.  Recombinant Fc fusion peptides engineered for in vivo testing showed that 
the Notch3 peptides defined could trigger apoptosis and suppress tumor growth in tumor 
xenograft assays.  These findings rationalize a mechanistic approach to lung cancer 
treatment based on Notch3 receptor-targeted therapeutic development. 
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Introduction 
Notch3 is a type I transmembrane receptor belonging to a family of proteins essential for 
cellular differentiation and embryonic development.  In mammals, there are four Notch 
receptors (Notch1-Notch4) and two families of ligands, Jagged (Jagged1 and Jagged2) and 
Delta-like (DLL1, DLL3, and DLL4).  Binding of the ligand to the extracellular domain 
(ECD) of the Notch receptor triggers two successive proteolytic cleavages and untethers 
the Notch intracellular domain (ICD) from the cytoplasmic membrane.  The Notch ICD is 
then translocated to the nucleus, binds to the transcription factor CSL, and induces 
expression of target genes.  These genes include the hairy-enhancer of split (Hes) and hairy 
and enhancer-of-split related with YRPW motif (Hey) families.  
 
Activation of the Notch pathway depends on the interaction of the ECD between the ligand 
and the receptor with subsequent release of the activated ICD.  Notch3 is a large protein 
containing 2,321 amino acids with a predicted molecular mass of 243.66 kDa.  The Notch3 
ECD, a region containing the ligand recognition site, is estimated to be 210 kDa.  
Identifying the part within the large ECD important for receptor-ligand interaction will 
help to better understand the biology of Notch3 signaling and therapeutic design.  Using 
deletion mutants and point mutations of Drosophila Notch and mammalian Notch1, the 
identified ligand-binding site seems to involve epidermal growth factor (EGF)-like repeats 
11–12 (4, 6).  However, given the functional diversity and the variation in tissue 
distribution among the different Notch family members, we hypothesized that the 
targetable ligand recognition sites on Notch3 receptor differ from those of other family 
members.  
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Notch3 is overexpressed in ∼40% of resected non–small cell lung cancers, and its 
suppression results in loss of the malignant phenotype both in vitro and in vivo (225, 226).  
In both development and cancer, Notch has been shown to cross-talk with oncogenic 
pathways such as the EGF receptor/ras/ mitogen-activated protein kinase pathway (131, 
141, 225, 270).  Thus, targeting this pathway represents a rational strategy in the treatment 
of patients with lung cancer.  One approach currently being explored in clinical trials is 
blocking the essential proteolytic processing of Notch receptors with γ-secretase inhibitors. 
The efficacy of this class of compounds needs exploring, but the relative lack of target 
specificity suggests that new more specific strategies targeting this pathway should be 
pursued.  
 
In this study, we identify the domains within Notch3 ECD important for ligand recognition 
and binding.  Using a high throughput system and a Notch3 peptide library, we discovered 
two previously unknown regions; EGF-like repeats 7-10 and 21-22, important for Notch3 
activation.  In addition, we showed that interfering peptides and recombinant proteins 
mimicking these regions can abrogate Notch3 activation, induce apoptosis, and inhibit 
tumor growth in vivo.  The findings of the present study not only give novel insights into 
Notch3 signaling but also establish a foundation on which targeted therapy can be 
developed. 
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Materials and Methods 
 
Peptide library.  The peptide library consisted of 155 synthetic peptides.  Their sequences 
were 5 to 15 amino acids in length and spanned nearly the entire Notch3 ECD.  Each 
peptide represented a unique extracellular site on the ECD, with peptide 1 representing the 
NH2 terminus and peptide 155 representing the COOH terminus of the last EGF-like 
repeat.  They were synthesized by SynPep and diluted in deionized H2O to bring the 
concentration to ∼10 mg/mL of peptide in 1× PBS.  The peptides were biotinylated using 
E-Z Link Biotin BMCC (Thermo Fisher Scientific, Inc.) in PBS at a molar ratio of 
approximately 1 to 2 moles of biotin per mole of synthetic peptide for immunofluorescence 
staining and pull-down assays. 
 
Cell culture and inhibitor.  The Notch3-expressing lung cancer cell line HCC2429 was 
established as previously described (224).  HEK293T and HeLa cells were obtained from 
the American Type Culture Collection and maintained in DMEM with 10% FCS.  
MRK003 was provided by Merck, Inc. & Co., and its formulation was described previously 
(271).  
 
Apoptosis screen of peptide library.  Both HCC2429 and HeLa cells were seeded onto 384-
well plates at 3,000 in 50 µL per well.  Twenty-five microliters of Annexin V-Alexa Fluor 
680 (Invitrogen, Inc.), diluted 1:2,200 in RPMI 1640 and 10 µL of peptide (diluted to 0.1 
mg/mL in RPMI 1640), were added.  After an overnight incubation, the treated cells were 
analyzed with a FMAT 8100 HTS System fluorescent plate reader (Applied Biosystems).  
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Each peptide was assayed in quadruplicate.  
 
Notch3 deletion mutants.  With the Notch3 ECD as template, inverse PCR was used to 
generate deletions of Notch3 EGF-like repeats 7-10 and EGF 21-22.  The ECD containing 
the deletions was confirmed by DNA sequencing, cloned into pcDNA4, and religated to 
Notch3 intracellular fragment to generate full-length Notch3 deletion mutants. 
 
In vitro pull-down assay.  HEK293T cells were transfected with hemagglutinin (HA)-
tagged Jagged1 (provided by Dr. Artavanis-Tsakonas, Harvard Medical School, Boston, 
MA) using Lipofectamine 2000.  The cells were lysed in NP40 buffer [10 mmol/L Tris-
HCl (pH 7.5), 150 mmol/L NaCl, 1% NP40 plus 50 mmol/L protease inhibitors].  One 
microgram of biotin-labeled peptides and streptavidin-conjugated magnetic beads 
(Promega) was used to pull down HA-tagged Jagged1.  The resulting proteins were 
resolved on SDS-PAGE and detected with an anti-HA antibody.  For the Fc fusion protein 
binding assay, 5 µg of Fc fusion protein and protein A agarose beads (Sigma-Aldrich, Inc.) 
were used. 
 
Immunofluorescent staining assay.  HCC2429 and HEK293T cells were plated on glass 
chamber slides.  After 24 h, the cells were rinsed twice in PBS and fixed in 4% 
paraformaldehyde and treated with 1 mL of biotin-labeled peptides and 0.5 µg/mL of Alexa 
Fluor 488–labeled streptavidin (Invitrogen).  TO-PRO3 (Invitrogen) was used for nucleus 
staining.  The cells were then examined under confocal fluorescence microscopy. 
 
  56 
Antibodies.  Notch3 and HA-targeted Jagged1 were detected using a rabbit Notch3 
antibody (Orbigen, Inc.) and an anti-HA monoclonal antibody (HA-7; Sigma-Aldrich), 
respectively, at 1:1,000 dilution.  The goat anti-human IgGhorseradish peroxidase antibody 
(Santa Cruz Biotechnology, Inc.) and the mouse anti–β-tubulin monoclonal antibody 
(AA2; Millipore) at 1:5,000 dilution were used to detect human Fc fusion protein and β-
tubulin, respectively. Fc fusion protein expression.  The peptide DNA sequences were 
cloned into the NH2 terminus of pFUSE-hIgG1-Fc2 and pFUSE-mIgG1-Fc2 vectors 
(Invivogen).  These vectors produce secreted fusion protein in mammalian cells.  The 
plasmids were then transiently expressed in HEK293E, and the proteins were purified from 
culture medium with a protein A/G column (GE Healthcare Life Sciences).  The eluted Fc 
fusion proteins were equilibrated with PBS buffer using a HiTrap desalting column (GE 
Healthcare Life Sciences). 
 
Real-time PCR.  Total RNA was extracted from HCC2429 or HeLa cells 24 h after peptide 
treatment or transfection with deletion mutants using the Qiagen RNase Mini kit.  RNA 
was reverse transcribed with the SuperScript II First-Strand Synthesis kit (Invitrogen) and 
quantitated using the iQ5 Multicolor Real-Time PCR detection system (Bio-Rad) and 
QuantiTect SYBR Green reverse transcription-PCR (RT-PCR) kit (Qiagen).  Annealing 
temperature for PCR was 58°C with the following primers: glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), 5′-TGCACCACCAACTGCTTAGC-3′ (sense) and 5′-
GGCATGGACTGTGGTCATGAG-3′ (antisense);  Hey1, 5′-
AGATGACCGTGGATCACCTG-3′ (sense) and 5′-TGTTGAGAGCGAAACCAGTC-3′ 
(antisense); and Hes1, 5′-AGAAGGCGGACATTCTGGA-3′ (sense) and 5′-
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GAGTGCGCACCTCGGTATTA-3′ (antisense).  The threshold cycle value (Ct) was 
determined with iCycler Optical system interface software.  Mean Ct of Hey1 or Hes1 was 
calculated from triplicate measurements and normalized with the mean Ct of the gene 
GAPDH as internal control. 
 
Apoptosis assay.  HCC2429 cells were treated with peptides or Fc fusion proteins for 24 h 
and maintained in serum-free RPMI 1640.  Percent apoptosis was determined using the 
Annexin V-FITC Apoptosis Detection kit (Calbiochem) and a FACSCalibur Flow 
Cytometer (Beckman Coulter, Inc.). 
 
In vivo tumorigenicity.  HCC2429 cells (1 × 106) suspended in 50% Matrigel (BD 
Biosciences) were injected s.c. into hind limbs of athymic 4- to 6-wk-old female nude mice 
(nu+/nu+).  When the tumors were palpable, the mice were treated with Fc control or with 
a single loading dose of recombinant protein at 15 mg/kg followed by dose of 10 mg/kg 
every 3 d.  The tumor size was measured every 3 d with a caliper. Tumor volume was 
calculated with the formula: volume = (length) (width)2/2. 
 
Statistical analyses.  The size of implanted tumors at different time intervals after treatment 
was compared with that of control treated with mouse Fc.  Unless specifically stated, 
statistical inference in comparative experiments both in vivo and in vitro was obtained 
using Wilcoxon rank-sum tests.  For all statistical comparisons, the differences were 
considered significant at P < 0.05. 
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Results 
 
Peptide library screening identifies potential ligand binding sites 
Notch receptors differ in the number of tandem EGF-like repeats in the ECD.  Notch3 
contains 34 EGF-like repeats, whereas Notch1 possesses 36.  In contrast to Notch1, the 
ligand-binding site for Notch3 is not as well characterized.  Therefore, to identify Notch3-
binding sites, we created a peptide library consisting of 155 short peptides sequences, 5 to 
15 amino acids in length, spanning the entire 34 EGF-like repeats within the Notch3 ECD.  
Because inhibition of Notch3 induces apoptosis in tumor cells, the conjugated carrier 
peptides were then screened for the ability to induce apoptosis.  Of the 155 peptides, we 
identified 15 peptides with reproducible apoptosis-promoting activities in both HCC2429 
and HeLa cells (Table 2.1).  The effect on apoptosis by these peptides was dose dependent 
(Fig. 2.1A and B).  Interestingly, the locations of these peptides mapped to two discrete 
regions, EGF-like repeats 7-10 and 21-22 (Fig. 2.1C). The amino acid sequences from 
Notch3 repeats 7-10 are most similar to Notch1 EGF-like repeats 8-11 with 79% identity 
(data not shown).  When we compared the Notch3 sequence with that from putative Notch1 
ligand-binding sites, the EGF-like repeats 11-12, only 40% identity was observed, 
suggesting that the Notch3-binding domain differs from that of Notch1.  An example of the 
alignment between Notch3 EGF-like repeat 7 and Notch 1 EGF-like repeat 11 is shown in 
Fig. 2.1D.  The highly conserved class II EGF-like repeat is observed in all Notch 
receptors, and its secondary structure contains a core with a β-pleated sheet, three disulfide 
bonds, and a series of loops (10).  At this time, only the structure of the class II EGF-like 
domain from human Notch1 is known. Because Notch3 also contains class II EGF-like 
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repeats, we mapped the Notch3 peptides with proapoptotic-promoting activity to the class 
II consensus sequence (PDB ID: 2VJ3).  Interestingly, the peptide sequences mapped to the 
loop regions of the EGF-like repeats, suggesting that the loop regions are responsible for 
ligand interaction.  Molecular visualizations of the relative positions of N17 and N132 
peptides within an EGF-like repeat are shown in Fig. 2.1E (blue).   
Notch3 peptides bind to Jagged1 and inhibit Hey1 transcription 
To determine whether the apoptosis induced by the peptides is Notch dependent, we 
examined the ability of the peptides to bind to Jagged1 and to alter transcription of Notch-
dependent genes.  Using biotin-labeled Notch3 peptides, we found that the labeled peptides 
bind to Jagged1- expressing HCC2429 but not HEK293T, which does not express 
endogenous Jagged1 (Fig. 2.2A).  Of the 15 peptides identified, 6 were found to both 
induce apoptosis and bind to Jagged1.  This interaction was subsequently confirmed with 
the in vitro pull-down studies (Fig. 2.2B).  The peptides also inhibited Hey1 transcription 
with varying potency (Fig. 2.2C).  Interestingly, Hes1 transcription was not altered (data 
not shown).  These findings were consistent with our earlier observation that Notch3 
preferentially regulates Hey1 and not Hes1 in our lung cancer models (4).  The ability of 
the peptides to induce apoptosis confirmed the findings from the fluorescent screening 
assay (Fig. 2.2D).  Of the 15 peptides identified by FMAT 8100 HTS screen, six induced 
apoptosis and bound to Jagged1.      
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Peptide ID Peptide sequences Effects on apoptosis EGF-like 
repeats 
N16 CFNTLGGHS + 7 
N17 CVCVNGWTGES ++ 7 
N22 CVNTQGSFL + 10 
N52 CTCHGGYTGPS + 21 
N65 CREAAAQIGVRLEQL + 21 
N70 CIDLVARYL + 29 
N102 CATAV ++ 8 
N103 CFHGAT ++ 8 
N105 CVSNP + 9 
N117 CTFGV + 16 
N130 CDQDIND + 21 
N132 CLNGGS ++ 22 
              
Table 2.1. List of peptides, their location, and effect on apoptosis in HCC2429 
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Figure 2.1. Screening of peptides.  A. Result from a representative experiment performed on the FMAT 
8100 HTS fluorescent plate reader and assayed with Annexin V–Alexa Fluor 680 showing that Notch3  
peptides N132, N105, N103, and N102 induced apoptosis.  Fifteen of the total 155 peptides induced 
apoptosis in HCC2429 cells. Top, each peptide was assayed in quadruplicate; bottom, a dose response was 
noted in which signal intensity was correlated with peptide concentration.  B. The peptides with 
proapoptotic activity mapped to two distinct regions, EGF-like repeats 7–10 and 21–22, within the ECD.  Z  
axis is fluorescence intensity, as a measure of apoptosis.  X and Y axes show the location of individual wells 
on the plate.  C. Blue background, alignment of Notch3 EGF-like repeat 7 and Notch1 EGF-like repeat 11 
showing 40% identity. Conserved substitution (*) was observed in five residues within these repeats.  D. 
Cartoon and surface representations of an EGF-like domain reconstructed using PyMOL molecular 
visualization software. Location of N17 (top) and N132 (bottom) sequences based on class II EGF domain 
consensus sequence is colored in blue, illustrating the putative surface involved in ligand binding.  
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Notch3 Fc fusion proteins bind to Jagged1 and inhibit Notch3 activation  
A major limitation to using peptides for in vivo applications is their short biological half-
life in the bloodstream.  To overcome this limitation, we used Notch3 Fc fusion proteins, in 
which recombinant protein is fused to the Fc domain of human IgG. Fc-N17, Fc-N16,N17, 
and Fc-N132 Fc fusion proteins reduced activated Notch3 to differing degrees.  Fc-N132 
had a greater effect than either Fc- N16 or Fc-N130, suggesting that the inhibiting activity 
may be related to the sequences themselves and not the length.  A similar effect was 
observed when conditioned media containing secreted Fc fusion protein were used (Fig. 
2.3A).  Interestingly, although not all Fc fusion constructs affected Notch3 activation, they 
all retained the ability to bind to Jagged1 (Fig. 2.3B).  Notch3 Fc fusion proteins induce 
apoptosis and inhibit tumor growth in vivo.  Treatment with purified Fc-N16,N17 and Fc-
N132 proteins resulted in inhibition of Notch3 activation to levels resemble those obtained 
with MRK003 (Fig. 2.4A).  This observation confirmed our early peptide data (Fig. 2.2D). 
To determine the effect of Notch3 Fc fusion proteins in vivo, we used a HCC2429 human 
lung cancer xenograft model.  We observed a statistically significant reduction of tumor 
volume with Fc-N16,N17 and Fc-N132 treatment compared with Fc control after 12 days 
of treatment.  After 16 days, the average tumor volumes with Fc-N16, N17 (0.256 cm3) and 
Fc-N132 (0.256 cm3) treatment showed a 2-fold reduction compared with Fc control (0.612 
cm3; Fig. 2.4B and C). 
 
Deletion of putative ligand-binding sites abrogated Notch3 activation in vitro 
To determine whether EGF-like repeats 7–10 and 21–22 are necessary for signaling, we 
created constructs N3Δ7-10, N3Δ21-22 and N3Δ7-10, Δ21-22, similar to the full-length  
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Figure 2.2. Notch3 peptides bound to Jagged1 and inhibited transcription of Notch3-dependent 
gene Hey1. A. Fluorescent-labeled Notch3 peptides N16, N17, N102, N103, and N132 (green) bind to 
HCC2429 cells expressing Jagged1 but not to HEK293T cells that do not express endogenous Jagged1.  
B. Notch3 peptides inhibited signaling through binding to Jagged1.  Immunoprecipitation experiment 
showing that Jagged1 binds to Notch3 peptides but not to control peptide (C). No, no input.  C. 
Treatment of lung cancer cell line HCC2429 with Notch3 peptides reduced transcription of Notch3-
dependent gene Hey1 determined by real-time RT-PCR. Note that the N17 peptide exhibited both the 
highest apoptotic activity and greatest reduction in Hey1 transcription.  D. All Notch3 peptides can 
induce apoptosis in Notch3-expressing HCC2429 cancer cells.  Cells treated with a γ-secretase inhibitor 
MRK003 were used as positive control. *, P < 0.05.   
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Figure 2.3. Notch3 Fc fusion proteins bind to Jagged1 and inhibit Notch3 activation. A. Transfection 
of Notch3 Fc fusion expression plasmids Fc-N16, Fc-N16,N17, and Fc-N132 into HCC2429 
downregulated expression of Notch3 ICD.  Conditioned media from transfected HEK293T also reduced 
activated Notch3 in HCC2429.  Similar to the previous transfection experiment, Fc-N16, Fc-N16,N17, and 
Fc-N132 can reduce Notch3 ICD level but not Fc-N16 or Fc-N130.  B. Consistent with the peptide data, 
the immunoprecipitation experiment shows that Fc fusion proteins bound to Jagged1 but not to Fc control.   
Figure 2.4. Notch3 Fc fusion proteins induced apoptosis and inhibited tumor growth in vivo. A. 
Purified Fc fusion proteins Fc-N16,N17 and Fc-N132 inhibited Notch3 activation compared with control. 
B. When HCC2429 xenografts were treated with Fc fusion proteins Fc-N16,N17 and Fc-N132, tumor 
growth was significantly reduced.  C. Tumors resected from mice treated with Fc-N132, Fc-N16,N17, Fc 
control, and PBS. The tumors from Fc fusion protein–treated animals were significantly smaller than 
those treated with Fc control and PBS. *, P < 0.05.   
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Figure 2.5. Deletions of EGF-like repeats 7–10 and 21–22 reduce Notch3 activity in vitro.  A. Diagrams 
of full-length receptors and mutants with deletions of EGF-like repeats 7–10, 21–22, or both.  B. 
Cotransfection of Jagged1 and full-length Notch3 into HeLa cells resulted in induction of activated Notch3 
(ICD).  In contrast, activated Notch3 was absent in cells transfected with Jagged1 and mutants N3Δ7-10 and 
N3Δ21-22.  Full-length Notch3 induced transcription of Hes1 (C) and Hey1 (D) in HeLa cells in the presence 
of Jagged1.  Deletions of EGF-like repeats 7–10, 21–22, or both resulted in decreased level of Hes1 
transcription compared with full-length Notch3. *, P < 0.05.   
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receptor but lacking EGF-like domains 7–10, 21–22, or both (Fig. 2.5A).  Similar strategies 
were used in Drosophila to better understand domain functions of Drosophila Notch (11).  
Unlike the native full-length receptor, both N3Δ7-10 and N3Δ21-22 constructs were unable 
to activate Notch3 cleavage in the presence of Jagged1 (Fig. 2.5B).  As in many biological 
systems, modulation of Notch3-dependent genes is context dependent.  In contrast to early 
findings that Notch3 regulates only Hey1 in lung cancer cell lines, in HeLa cells, 
transcription of both Hes1 and Hey1 was reduced when Notch3 with deletions of EGF-like 
domains 7-10, 21-22, or both was used (Fig. 2.5C and D), supporting the hypothesis that 
these regions are important for Notch activation. 
 
Discussion 
Information about the binding site for Notch receptors has been mostly gleaned from 
studies using Notch deletion mutants in Drosophila.  Of the 36 EGF-like repeats in 
Drosophila Notch, repeats 11-12 are sufficient and necessary for interaction with both 
Delta and Serrate (12). Similar observations have been made for mammalian Notch1, in 
which the loss of calcium binding EGF-like repeats 11, 12, and 13 has been shown to 
abrogate receptor function (6). 
 
However, there are differences in structure, tissue distribution, and activation of 
downstream target genes among the Notch receptors (272).  Unlike Notch1, Notch3 
contains 34 instead of 36 EGF-like repeats.  Notch3 also differs from Notch1 and Notch2 
by its lack of a transactivation domain.  Structural and functional differences, therefore, can 
implicate different ligand recognition sites among the four mammalian Notch receptors.  In 
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this study, using a Notch3 peptide library, we discovered two regions within the Notch3 
ECD important for ligand binding.  Unlike EGF-like repeats 11-13 in Notch1, our findings 
suggest that the binding site on Notch3 involves EGF-like repeats 7-10, with the strongest 
functional activity in EGF-like repeats 7-8.  This observation differs from that of Joutel and 
colleagues (273), in which the mutation C428S located on EGF-like repeat 11 abrogated 
ligand binding.  It is possible that this mutation results in a conformational change in the 
receptor that prevents ligand binding without being within the ligand-interacting surface of 
the receptor. 
 
The present data show two potential ligand-binding sites, EGF-like repeats 7-10 and 21-22, 
within the ECD of Notch3.  Either site seemed sufficient for receptor activation.  Because 
similar studies have not been carried out for Notch1, it is not known whether Notch3 is the 
only mammalian Notch receptor with two functional domains.  In Drosophila, deletion of 
Notch EGF-like repeats 24-26, a part of the genetically defined Abruptex region, results in 
reduced signaling by the ligand Serrate but not the ligand Delta (274).  This observation 
suggests that all mammalian Notch receptors may possess two ligand domains and that the 
second binding site is important for regulating ligand specificity.  Further studies are 
needed to test this hypothesis. 
 
The expression of Notch3 in adult mammals is limited to the vascular system.  Embryonic 
deletion of Notch3 in mice results in vascular smooth vessel defects, suggesting that 
targeting this pathway in cancer will result in antiangiogenic effects (83).  Given the role of 
Notch signaling in maintaining stem cells, it is possible that inhibiting Notch3 could also 
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have gut toxicity as observed with γ-secretase inhibitors (259).  Unlike Notch1 in T-cell 
acute lymphoblastic leukemia, oncogenic mutation has not been associated with Notch3 
(110, 275).  By contrast, the dysregulation of the Notch3 pathway in cancer has mostly 
been associated with overexpression and gene amplification (151, 225).  Thus, interfering 
with ligand-receptor interaction using peptides and recombinant protein constitutes 
promising strategies targeting this pathway.  
 
Although the effects of the peptides and recombinant proteins may not be specific to 
Notch3, because other Notch receptors use similar ligands, the strategies used in the 
present study can potentially be developed for clinical use.  Furthermore, the identified 
functional sites within the receptor could also serve as targets for therapeutic antibodies or 
chemical peptidomimetic screening and production.  Our study, therefore, provides not 
only insights into the mechanism of Notch3 signaling in lung cancer but also uncovers 
specific receptor regions whose targeting results in antitumor activity and may serve as the 
basis for designing specific anticancer therapeutics targeting this pathway. 
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CHAPTER III 
 
GENERATION OF NOTCH3 NEUTRALIZING ANTIBODIES AGAINST ITS LIGAND 
BINDING REGIONS 
 
Abstract 
The Notch receptors are essential for both normal development and tumorigenesis in many 
human cancers.  Notch3 is expressed in 40% of all lung cancers. Inhibiting this pathway 
results in reduced tumor growth in lung in vitro as well as in vivo.  Thus, this pathway 
represents a potentially important target for therapeutic development.  Here we report the 
early results of a strategy to inhibiting Notch3 signaling through the development of 
Notch3 monoclonal antibodies.  Using a Notch3 peptide library, we discovered two regions 
of the extracellular domain, believed to be the binding regions for the Notch3 ligand, 
Jagged1.  The recombinant proteins representing these two regions, respectively, were used 
as antigens to immunize mice.  We demonstrated that antisera from these mice immunized 
with portions of the receptor extracellular domain could inhibit Notch3 activation.  Further 
developments of hybridoma clones were screened with ELISA, immunoprecipitation and 
their ability to inhibit Notch3 cleavage. 12 hybridoma clones were selected, and 4 out of 12 
antibodies with IgG1 or IgM isotypes were found to specifically inhibit Notch3 activation 
but not Notch1.  Further testing is on going to validate these findings as well as to 
determine affinity and anti-tumor activity of these antibodies.  Development of monoclonal 
antibody to specifically inhibit Notch3 ligand binding regions could serve as a strategy for 
the development of future therapeutics for patients with lung cancer. 
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Introduction 
Notch signaling is a conserved developmental pathway that regulates embryonic 
development and cellular homeostasis as well as multiple human diseases including cancer 
(2, 276, 277).  Activating mutations of Notch1 have been found in 50% of T-ALL patients 
(110) that makes Notch1 as a very attractive target for the treatment of Notch1-drived T-
ALL.  Moreover, Notch ligand DLL4 is emerging as a critical regulator of tumor 
angiogenesis, and anti-DLL4 mAbs and decoys are effective in the inhibition of tumor 
angiogenesis and tumor initiating cells (182, 209, 250).  In lung cancer, Notch3 is 
overexpressed in 40% of resected lung tumors, and inhibition of Notch3 by either siRNA 
or a γ-Secretase inhibitor in HCC2429 cell induced apoptosis and suppressed tumor growth 
in vivo xenograft tumor models (225, 226).   
 
Activation of Notch signaling is mediated by receptor-ligand interaction. Then receptor get 
sequential cleavages by ADAM protease and γ-secretase complex to release its intracellular 
domain, which translocates into nucleus to convert transcriptional repressor CSL to be a 
transcription factor to initiate gene transcription by recruiting transcriptional coactivators, 
such as Mastermind-like protein and p300 (2, 276). There are four strategies to block 
Notch signaling,  1). using mAbs or decoys of receptor/ligand to interfere receptor-ligand 
interaction;  2), using mAbs making S2 cleavage site to prevent S2 cleavage;  3). γ-
secretase inhibitor to block S3 cleavage;  4). stapled peptides or small molecule inhibitors 
to prevent formation of NICD-CBF-1-MAML complex.  Nowadays, pan-Notch inhibitors 
GSIs, would work to target Notch3 driven cancers.  However, the unspecificity and gut 
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toxicity limit applications of GSIs in clinic (259, 278, 279).  Therefore, development of 
specific inhibitors targeting Notch3 signaling is needed for the treatment of lung cancer.  
 
Owing to their exquisite specificity, antibodies have been in the spotlights as potential 
therapy for human cancer (280).  Anti-cancer mAbs typically have a combination of 
mechanisms in directing cytotoxic effects to a tumor cell.  Most interact with components 
of the immune system through antibody-dependent cellular cytotoxicity (ADCC) and or 
complement-dependent cytotoxicity (CDC), and many alter signal transduction within the 
tumor cell or act to eliminate a critical cell-surface antigen (281).  Monoclonal antibodies 
generally have been correctly viewed as being less toxic than cytotoxic chemotherapy 
agents for cancer treatment (281).  Notch3 monoclonal antibodies raised against whole the 
extracellular domain of Notch3 including ligand binding regions and NRR of Notch3 have 
been reported (253).  However, the antitumor effects of these antibodies have not been 
determined.  Previously we have identified that Notch3 EGF-like repeats 7-10 and 21-22 
are important for receptor-ligand interaction.  Given the advantages of monoclonal 
antibodies in the treatment of cancer, no existing mutations of Notch3 in lung cancer, and 
overexpression of both Notch3 and ligand Jagged1 in lung cancer, generating monoclonal 
antibodies against ligand binding regions of Notch3 receptor will be a prominent strategy 
to target Notch3 in lung cancer.  
 
In this chapter, we reported that we have generated monoclonal antibodies against Notch3 
ligand binding regions, which are EGF-like repeat 7-10 and EGF-like repeat 21-22 in its 
extracellular domain.  These antibodies are able to bind to Notch3 expressing cells, 
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immunoprecipitate full-length Notch3 receptor, and suppressed production of activated 
form of Notch3 receptor in HCC2429 cells.  
 
Materials and Methods 
 
Production of Antigen.  cDNAs encoding (i) the EGF-like repeat 7-10 and (ii) the EGF-like 
repeat 21-22 of Notch3 was ligated in-frame into pSV282 vector provided by Center for 
Structural biology at Vanderbilt University.  The pSV282-EGFL7-10 and pSV282-
EGFL21-22 were transformed into E. coli BL21 (DE3) for expression of recombinant 
protein.  Bacterial expressed proteins were purified by Amylose resin (NEB) following 
manufactory introduction.  
 
Immunization and Fusion.  Four A/J (or BALB/c) mice were immunized with the antigen 
described above.  For primary injections, 50 µg of purified antigen were emulsified in 50% 
phosphate-buffered saline (PBS), 50% Freund’s complete adjuvant and injected 
subcutaneously into the nape of the neck (50%) and intramuscularly to the gluteal muscles 
(50%).  In subsequent booster injections, Freund’s incomplete adjuvant was substituted for 
Freund’s complete adjuvant.  Fourteen days after each booster injection, serum was 
collected from each mouse and assayed for reactivity with the antigen by enzyme-linked 
immunoadsorbent assay (ELISA), other assays.  The mouse with the highest level of 
reactivity was chosen for final boosting by intraperitoneal injection of the antigen diluted in 
PBS.  Fours days after the final immunization, spleen cells were harvested and electro-
fused/fused by standard methods with SP2/0 myeloma cells.  The products of the fusion 
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were plated for under selection for fourteen days in semi-solid media (Stemcell 
Technologies).  Resulting colonies were picked and distributed individually into 96-well 
plates.  Hybridomas producing antigen-specific antibodies were initially identified by 
ELISA, and subsequently verified by other assays.  Clones producing antibodies with the 
desired properties were subcloned to ensure monoclonality and cryopreserved.  Selected 
clones were scaled up and inoculated into one-liter bioreactors (Wilson Wolf 
Manufacturing Corporation) and grown for 3-4 weeks.  mAbs were subsequently purified 
from the supernatant by affinity chromatography on Protein-G sepharose (GE Life 
Sciences).  Purified MAbs were isotyped and subsequently quantified by SDS-PAGE 
electrophoresis followed by infrared coomassie staining. 
 
ELISA assay.  Flat-bottomed 96-well microtiter plates were coated with the desired antigen 
at 10 µg/ml in Carbonate-Bicarbonate buffer pH 9.6 (15mM Na2CO3, 30mM NaHCO3, 
.001% Thimerosal) and incubated for 4 h at 37°C or overnight at 4°C.  Coated plates were 
then washed and blocked with PBST (PBS + 0.1% Tween-20) utilizing an ELx405 Select 
(Bio-Tek, Winooski, VT).  One hundred microliters per well of supernatant or 
appropriately diluted sera were added and the plates were incubated at 37°C for 1 h before 
washing three times with PBST.  Peroxidase-conjugated goat anti-mouse IgG Fc fragment 
specific secondary antibody (Jackson Immunoresearch labs) diluted 1:5000 in PBST/1% 
BSA was added to the wells and incubated 1 h at 37°C.  Plates were washed three times in 
PBST and bound antibodies were detected utilizing the colorimetric substrate 2,2'-azino-
bis(3-ethylbenzthiazoline-6-sulphonic acid) (Sigma, St Louis, MO) and hydrogen peroxide.  
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The reaction was allowed to develop for 30 minutes at room temperature and the optical 
density was determined at 405nM using a Powerwave HT-340 (Bio-Tek, Winooski, VT). 
 
Immunoprecipitation assay.  HEK293T cells were transfected with Myc-tagged full-length 
Notch3 using Lipofectamine 2000.  The cells were lysed in NP40 buffer [10 mmol/L Tris-
HCl (pH 7.5), 150 mmol/L NaCl, 1% NP40 plus 50 mmol/L protease inhibitors].  One 
microgram of individual antibodies was used to pull down myc-tagged full-length.  The 
resulting proteins were resolved on SDS-PAGE and detected with an anti-myc antibody 
(Sigma-Aldrich, Inc.).  
 
Immunofluorecent staining.  HCC2429 and H1171 cells were plated on glass chamber 
slides.   After 24 h, the cells were rinsed twice in PBS and fixed in 4% paraformaldehyde 
and stained with individual antibodies and Alexa Fluor 594-labeled anti-mouse IgG or IgM 
(Invitrogen). TO-PRO3 (Invitrogen) was used for nucleus staining.  The cells were then 
examined under confocal fluorescence microscopy. 
 
Western blotting.  HCC2429 cells (1.5× 105) were plated in a 6-well plate 24 hours before 
the treatment, and were treated with 1 microliter of sera or various dosing of purified 
antibodies in complete RPMI 1640 medium. 24 hours after treatment, cells were lysed with 
RIPA buffer (50mM Tris, 150 mM NaCl, 0.1 % SDS, 0.5 % Na.Deoxycholate, 1% NP40), 
then were applied for SDS-PAGE and immunobloted with anti-Notch3 antibody (Cell 
Signaling Technology), anti-tubulin antibody (AA2; Millipore) and anti-actin antibody 
(Sigma-Aldrich, Inc.).  
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Result 
 
Antisera from immunized mice are able to bind to full-length Notch3 and inhibit N3ICD 
production 
Recombinant MPB-tagged proteins containing the sequences of Notch3 EGF-like repeat 7-
10 and 21-22 were expressed and purified from in E. coli to immunize A/J and BALB/c 
mice. The antisera were screened for binding and activity using immunoblotting (IB) and 
cell-based functional assay.  For the mice immunized with EGF-like repeat 7-10, the 
specific antibodies were detected from the antisera of AJ/R mice, while for the mice 
immunized with EGF-like repeat 21-22, the specific antibodies were detected from the 
antisera of AJ/O, AJ/L, AJ/R, Balb/R and Balb/RL mice.  When treated HCC2429 cells 
with pre-and post-immunized antisera of, the activated form of Notch3 (N3ICD) was 
significantly decreased in AJ/O mouse with antigen of EGF-like repeat 7-10, AJ/RL, 
Balb/O mice with antigen of EGF-like repeat 21-22 (Fig 3.1).  Thus, AJ/O, AJ/R, and 
Balb/O mice were for fusion to make hybridomas.  
 
Monoclonal antibodies are able to bind to Notch3 and inhibit N3ICD production  
The resulting hybridomas were first screened with ELISA using purified EGF-like repeat 
7-10-GST and EGF-like repeat 21-22-GST.  About 50 parental hybridoma were further 
tested for abilities of Notch3 binding and inhibition.  We picked these parental hybridomas: 
7G7, 1B1, 2E6, 5F5, 1D9, 3C7 for subcloning based on their performance on ELISA score, 
Notch3 binding (immunobloting), immunoprecipitation, and cell-based functional assay.  
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The mAbs from subcloned hybridomas were screened by ELISA.  We picked 2 clones with 
high ELISA scores from each parental hybridoma for further study.  We first ran a cell-
based functional assay by treating HCC2429 cells with increasing dose of mAbs, and found 
that 4 (7G7B12, 1B1F1, 2E6C3, 2E6D12 ) out of 12 mAbs are able to inhibit production of 
N3ICD (Fig 3.2). mAbs 7G7B12, 1B1F1, 1B1F6, 2E6C2, 2E6D12, 5F5C4, 1D9E4 and 
3C7A10 are able to immunoprecipitate full-length Notch3 from the cell lysate of 
HEK293T overexpression myc-tagged Notch3 (Fig 3.3A).  mAbs from 3C7A10, 3C7F1, 
1D9A7, 1D9E4, 7G7A11, 7G7B12, 5F5C4, 5F5C6, 2E6D12 are able to bind to HCC2429 
cell in which Notch3 expression level is very high, but not H1171 cell which expressed 
Notch1 receptor instead of Notch3 clones.  MAbs 7G7B12 and 1B1F1 inhibit N3ICD 
production in a dosage dependent manner.  Treatment with 1B1F1 mAb does not affect 
production of N1ICD, whereas higher dosage of 7G7B12 mAb inhibits production of 
N1ICD as well (Fig 3.3C).  However, these mAbs fail to recognize full-length Notch3 
protein by immunoblotting, which may due to these mAbs only recognize natural Notch3 
protein but not denatured form.  We also checked the isotypes of these antibodies.  In fact, 
1B1F1 is an IgM antibody; 2E6D12 is a mixture of IgM, IgG2a and IgG2b. 7G7B12 shared 
the same isotype IgG1 with 7G7A11 for that the parental 7G7 is a pure IgG1 antibody 
(Table 3.1 and 3.2).  1B1F1 is hybrodoma fusions from the mice immunized with EGF-like 
repeat 7-10, while 7G7B12 mAbs are that with EGF-like 21-22 antigen. 
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Figure 3.1. A representative screen for Notch3 binding and inhibition of mice antisera. A. 
Polyclonal antibodies from immunized mice can detect full-length Notch3 (N3FL).  B. HCC2429 cells 
were treated with sera ( 1 µl) for 24 hours, then analyzed for activated Notch3 (N3ICD), and Tubulin as 
an internal control.   
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Figure 3.2. 4 out 12 purified mAbs are able to inhibit production of 
Notch3 ICD. Western blotting showing that mAbs 7G7B12, 1B1F1, 
2E6C2 and 2E6D12 are able to inhibit production of N3ICD in a dose 
dependent manner when treat to HCC2429 cell.  
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Figure 3.3. mAbs are able to immunoprecipitate Notch3, bind to Notch3 expressing cells and 
inhibit N3ICD production. A. A representative experiment demonstrating the ability of many mAbs 
from hybridoma subclones to immunoprecipitate Notch3 in HEK 293 transfected with full-length, 
myc-tagged Notch3.  B. Using immunofluorescence, mAbs bind to Notch3-expressing lung cancer 
cell line HCC2429 but not in H1171, which expresses only Notch1.  C. A representative western 
blotting experiment demonstrating that some mAbs are able to specifically inhibit Notch3 signaling 
but not Notch1 (1B1F1) and with higher dose, 7G7B12 can also inhibit Notch1 activation. 
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 2E6D12 5F5C6 7G7A11 1B1F1 
IgG 4.165 4.209 4.221 3.635 
IgM 4.292 0.052 0.088 4.02 
IgG1 0.05 0.045 4.345 0.055 
IgG2a 2.524 0.249 0.06 0.054 
IgG2b 2.777 4.234 0.233 0.046 
IgG3 0.041 0.041 0.044 0.043 
Kappa 4.287 4.07 3.942 4.077 
Lamda 0.044 0.122 0.082 0.049 
 
 
 
 
 
 
 
 
 
Parental pools Antigen (EGF-like repeats) Isotypes 
3C7 7-10 IgG2a 
1B1 7-10 N/A 
2E6 21-22 N/A 
5F5 21-22 IgG1 
1D9 21-22 IgG2b 
7G7 21-22 IgG1 
Table 3.2 Immunoglobin isotypes of candidate hybridomas clones  
Table 3.1 Immunoglobin isotypes of parental hybridoma 
pools 
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Discussion 
In this chapter, we have generated monoclonal antibodies against Notch3 EGF-like repeat 
7-10 and 21-22, respectively.  Antisera from immunized mice are able to bind to full-length 
Notch3 protein and inhibit production of N3ICD when treated to HCC2429 cells.  AJ/O, 
AJ/R and Balb/O mice were selected to generate hybridomas fusions.  Parental hybridomas 
pool were screened by ELISA for antigen binding, immunoblotting, immunoprecipitation 
and cell-based functional assay.  Pool of 7G7, 3C7, 1B1, 2E6, 5F5, 1D6 were selected for 
subcloning process.  mAbs 1B1F1 with IgM isotype, 7G7B12 with IgG1 isotype and 
2E6D12 with mixed isotypes (both IgM, IgG2a and IgG2b) are able to bind to natural 
Notch3 protein and suppress production of N3ICD in a dose dependent manner.  Our study 
provides a rationale that antibodies against Notch3 putative ligand binding region, 
especially the one differs from that of Notch1 EGF-like repeat 21-22, are able to 
specifically targeting Notch3 signaling.  
 
We tried to study anti-tumor activity of 7G7B12 and 1B1F1 antibodies purified from large-
scale bioreactor production.  However, the mAbs purified from large-scale production 
failed to inhibit production of N3ICD when treated to HCC2429 cells as the mAbs purified 
from small-scale production shown by figure 3.2C.  We have not found out the reason why 
these mAbs lost their capacity of anti-Notch3 when produced in a large-scale bioreactor.  
We have went back to culture the same batch of hybridomas in a small-scale culture flask, 
and the mAbs from the same batch of cells but cultured in flasks are able to inhibit N3ICD 
production.  Moreover, we have purified some of mAbs from the large-scale culture 
medium using a small purification column and found that these mAbs are not able to 
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inhibit production of N3ICD either, suggesting that either the hybridomas themselves or 
purification processes is not the cause for lost of function of mAbs.  It is possible that our 
monoclonal antibody core may have a technical problem in the process of antibody 
production. However, it is also possible that the mAbs affects growth, expansion and 
antibody production of hybridomas in the bioreactor as inhibition of Notch signaling could 
induce apoptosis of myeloma cells used to make hybridoma fusions. Currently, we have 
collaborated with a biotech company to further develop these antibodies, and test their anti-
tumor properties by proliferation assay, soft agarose colony formation assay, apopotosis 
assay and in vivo xenograft tumor model.  
 
One of the candidate antibodies, 1B1F1, is an IgM isotype, which can be purified by 
Protein L column.  IgM monoclonal antibodies have been underrepresented in human 
therapeutic development due to production difficulties and other manufacturing constraints.  
In our study, we found that the yield of IgM antibody is much lower than that of IgG 
isotype, around 2 folds less.  However, it is still possible to use IgMs mAbs as performed 
successfully by CMC Biopharmaceuticals of Copenhagen to produce a therapeutic 
antibody MORAb-028 to target advanced melanoma and other cancers including NSCLC.  
In addition, a recent paper showed that monoclonal IgM antibodies against PIM-1 protein 
could suppress tumor growth (282).  Therefore, we are further developing and testing the 
anti-tumor ability of 7G7B12 IgG1 antibody as well as 1B1F1 IgM antibody.  If IgM 
antibody would be very effective in the inhibition of Notch3 signaling and tumor 
progression, we would either try to use IgM antibody for further development to preclinical 
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trial or clone the Fab region of IgM to mammalian expressing vectors, such as pIgG, to 
make IgG.  
 
We have not tested the specificity of the mAbs to other Notch receptors or mouse Notch 
receptors.  As the Figure 3.3 C shown, 7G7B12 mAb suppressed activated forms of both 
Notch3 and Notch1 receptors, suggesting that 7G7B12 mAb may cross-react with Notch1 
as well.  However, it is possible that Notch3 regulates production or expression of N1ICD. 
In fact, in HCC2429 cell, inhibition of Notch3 by siRNA, a GSI or Notch3 peptides, results 
in decrease expression of Notch3 itself, Notch1 and Notch ligand Jagged1 measured by 
immunoblotting. Therefore, it is possible that 7G7B12 mAb inhibits Notch3 initially, and 
then Jagged1 and Notch1 receptor are further attenuated by suppressed Notch3 signaling.  
Indeed, cell-autonomous role for Notch has been established in endothelial cells during 
EMT and valve development (188, 283), whereas during Drosophila development, the 
involvement non-cell autonomous effects of Notch signaling is a very important aspect, in 
which Notch signaling between two populations of cells results in segregation of those 
cells (277).  It is also possible that high dosage of mAbs causes its unspecific binding to 
Notch1. The identity between Notch3 EGF-like repeats of human and that of mouse are 
very high.  Thus, it is highly possible that these mAbs can cross-react with mouse Notch3. 
In fact, human mAbs cross-reacting to mouse Notch3 actually mimic the action of 
antibody-based therapy in human that anti-Notch3 agents suppress both tumor cells and 
tumor microenvironment, such as endothelial cells and pericytes.  Further studies are 
needed to investigate the specificity of these mAbs against Notch3.  
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Some mAbs are able to immunoprecipitate full-length Notch3 and bind to Notch3 
expressing cells, but are not able to inhibit production of N3ICD.  Those mAbs can be 
further developed to use in immunoprecipitation, immunofluorecent, or flow cytometry 
assays for studying Notch3 signaling.  
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CHAPTER IV 
 
JAGGED1 PARADOXICALLY REGULATES LUNG CANCER GROWTH AND 
MIGRATION THROUGH A CBF-1-INDEPENDENT MECHANISM 
 
Abstract 
Many lines of evidence suggest that deregulation of the Notch pathway plays an important 
role in oncogenesis.  Although evidence for Notch receptors in cancer is clear, the role of 
tumor cell expression of the Notch ligands is less well established.  We show that Jagged1 
and Notch3, but not Notch1, are overexpressed in NSCLC samples compared with normal 
lung tissue.  Abrogation of Jagged1 in lung cancer cell lines attenuates lung cancer growth 
both in vitro and in vivo.  Further, our data suggest that Jagged1 activates AKT signaling 
via cross talk with EGF and/or IGF signaling.  Paradoxically, abrogation of Jagged1 in 
lung cancer cell lines promotes cell migration through upregulation of the integrin β1 
protein level, which then promotes focal adhesion and activates FAK-SRC signaling 
cascades. We also show that inhibition of CBF-1-dependent Notch signaling by DNMAML 
protein does not recapitulate the phenotype of Jagged1 knockdown in lung cancer tumor 
growth and migration, suggesting that Jagged1 promotes tumor growth and suppresses 
migration in lung cancer primarily through a CBF-1-independent mechanism.  Overall, 
these findings suggest that Jagged1 plays paradoxical roles in lung cancer progression 
through activation of AKT and suppression of integrin β1 protein expression, suggesting 
that the combination of Jagged1 and Integrin β1 inhibitors may be a reasonable new 
therapeutic approach for lung cancer.   
  86 
 
Introduction 
Notch signaling is an evolutionary conserved signaling pathway involved in the regulation 
of embryonic development and cellular homeostasis (2, 276).  There are four Notch 
receptors, Notch 1-4, and five canonical ligands (Jagged1, 2, Delta-like 1, 3, 4) in 
mammals.  Canonical Notch signaling takes place between two juxtaposed cells in normal 
development. Notch signaling can be classified into two different pathways, CBF-1-
dependent and –independent.  Signal regulated CBF-1-dependent Notch signaling is 
activated upon ligand-receptor binding, inducing Notch receptor sequential cleavages to 
release the Notch intracellular domain (NICD) from the membrane. NICD then translocates 
into the nucleus to convert the CBF-1 transcriptional repressor complex into a 
transcriptional activator complex to initiate gene transcription by recruiting transcriptional 
coactivators, including mastermind (MAML) (2).  In reported CBF-1-independent Notch 
signaling, NICD interacts with components of other signaling pathways, such as EGFR, 
Wnt, BMP, NFkB, to activate downstream targets (284).  The detailed mechanisms for 
CBF-1-independent Notch signaling remain unclear.  
 
Our group has identified Notch3 as an oncogene contributing to lung cancer progression. 
Inhibition of Notch3 signaling by a γ-secretase inhibitor or decoy receptor peptides 
suppress the growth of lung cancer cell lines both in vitro and in vivo (224-226, 285). 
Importantly, inhibition of Notch3 by shRNA results in a significant decrease of the 
aldehyde dehydrogenase-positive stem cell-like population in lung cancer cell lines, 
suggesting a role for Notch3 in lung cancer stem cells (286).  Published work has also 
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suggested the importance of Notch1 lung cancer progression.  Activating mutations of 
NOTCH1 and loss of a negative regulator of Notch signaling, Numb are present in 
NSCLC, and inhibition of Notch1 signaling in primary cells harboring NOTCH1 activating 
mutations suppressed NSCLC progression (220).  Regarding the role of Notch ligands in 
lung cancer, Jagged1 has been shown to suppress apoptosis in the EGFR mutant lung 
cancer cell line HCC827 (229).  The role(s) of Notch ligands in lung cancer cell lines with 
different genetic backgrounds, such as KRAS mutations found in 20-30% of NSCLC, is 
unknown (287).  In addition to interactions with mutant oncoproteins in cancer cells, 
cancers often express high levels of both ligands and receptors, in contrast to juxtaposed 
cells during normal development, adding to the complexity of Notch signaling in cancer. 
Additionally, besides regulating tumor proliferation and apoptosis, Notch signaling has 
been linked to epithelial-mesenchymal transition and metastasis in human cancers (190, 
196, 288, 289).  However, it is not known if Jagged1-mediated Notch signaling plays roles 
in lung cancer invasion.   
 
A growing body of evidence also indicates the existence of non-canonical Notch signaling 
in tumorigenesis.  For example, loss of Rbpj κ (i.e., CBF-1) in Notch (N)4ICD transgenic 
mice does not attenuate N4ICD-induced mammary tumor development, suggesting that 
Notch4 induced breast cancer progression is through a CBF-1-independent mechanism 
(235). Although the involvement of the Notch pathway in lung cancer progression is clear, 
it has not been established whether canonical, CBF-1-independent, or both drive 
progression of lung cancer. 
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In this study, we identified that elevated expression levels of Jagged1 and Notch3, but not 
Notch1, are associated with advanced stages of NSCLC tumors, and that knocking down 
Jagged1 suppresses lung cancer cell growth both in vitro and in vivo through activation of 
the AKT signaling pathway via cross talk with EGF signaling and/or IGF signaling.  
Surprisingly, abrogation of Jagged1 increases lung cancer cell migration via increased 
protein expression of integrin β1, which in turn activates the FAK-SRC signaling cascade 
to promote cell migration.  Intriguingly, these processes of lung cancer cell growth and 
migration are not mainly CBF-1-dependent canonical Notch signaling, as expression of 
dominant-negative Mastermind does not recapitulate the phenotypes observed with 
knockdown of Jagged1.  
 
Materials and Methods  
 
Antibodies  Antibodies against Jagged1, Notch1, DLL1, DLL3, DLL4, Jagged2, 
Phospho-FAK, total-FAK, phospho-Src, total-Src, phospho-Erk, total-Erk, phospho-
Akt, total-Akt for Western Blot analysis are purchased from Cell Signaling Technology, 
Danvers, MA.  Antibodies against Integrin β1 for both Western Blot analysis and 
functional blocking are purchased from Millipore, Billerica, MA.  An antibody against 
β-actin is from Sigma-Aldrich, Inc. IHC staining for Notch1 was done using 
monoclonal antibody (1:100, Cell Signaling Technology, #3608); Notch3 using 
polyclonal antibody (1:100, Abcam, ab60087-100); and Jagged1 using monoclonal 
antibody (1:100, R&D, AF1277).  FITC-conjugated Phalloidin for F-actin, Phospho-
FAK (Tyr925) antibody (Cell Signaling Technology, Danvers, MA) and Alexa594-
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conjugated goat anti-Rabbit and TOTO-3 (Invitrogen, Carlsbad, CA) are used in 
immunofluorecent staining.  
 
Tissue microarray and IHC evaluation.  Tissue microarrays were obtained from the Lung 
Cancer Specialized Program of Research Excellence (SPORE) Tissue Core at Vanderbilt 
University and analyzed by immunohistochemistry for Notch1, Notch3 and Jagged1.  For 
evaluation, the localized membrane expression was scored with slight modifications to 
Ariol SL-50 platform based on the percentage of the cells with positive 
immunohistochemical staining.  Staining indices were classified as follow: 0-Negative; 1-
weak; 2-moderate; 3-strong.  The correlation between expression levels and stages was 
analyzed using Chi square test.  
 
Quantitative Real-time PCR.  Total RNA was extracted using Qiagen RNase Mini kit. 
RNA was reverse transcribed with SuperScript II First-Strand Synthesis kit (Invitrogen).  
Annealing temperature for PCR was 58°C with the following primers: Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), 5′ TGCACCACCAACTGCTTAGC-3′ (sense) and 
5′-GGCATGGACTGTGGTCATGAG-3′ (antisense); Hey1, 5′-AGATGACCGTGGAT 
CACCTG-3′ (sense) and 5′-TGTTGAGAGCGAAACCAGTC-3′ (antisense); and ITGB, 
5’-GTTACACGGCTGCTGGTGTT-3’ (sense) and 5’-CTACTGCTGACTTAGGGATC-
3’(antisense). The threshold cycle value (Ct) was determined with iCycler Optical system 
interface software. Primers for Mean Ct was calculated from triplicate measurements and 
normalized with the mean Ct of GAPDH as internal control.  
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Stable expression of Jagged1 short hairpin RNA and DNMAML in lung cancer cell lines.  
Lung cancer cell lines were obtained from American Type Culture Collection and 
maintained in RPMI-1640 (Invitrogen) with 10% FBS (hyclone). The lenti-viral based 
short hairpin RNA plasmid constructs against human JAG1 and corresponding empty 
vector were purchased (Sigma-Aldrich, Inc).  Plasminds were co-transfected into 
HEK293FT with lenti-virus packaging vectors using FuGENE 6 (Roche). The filtered viral 
supernatant was resuspended in 3µg/mL polybrene (Sigma-Aldrich, Inc) and added to 
culture medium of NSCLC lines.  After 6 hours, media was replaced with complete 
medium. After 48 hours, 1µg/ml puromycin (Invivogen) was added to the medium for 
selection and transfectants were passed serially for 2 weeks to generate Jag1 knockdown 
(KD) stable cell lines. The migR1-GFP control constructs and migR1-DNMAML-GFP 
constructs were kindly provided by Dr. Warren Pear (University of Pennsylvania, 
Philadelphia, PA).  Plasmids were transfected into GP2-293 Packaging cell line using 
FuGENE 6 (Roche).  After 24 hours, medium was replaced with RPMI 1640 containing 
10% FBS.  After 72 hours, infected cells were sorted for GFP positivity by flow cytometry. 
 
Rat Jagged1 stable expression in Jag1 KD lung cancer cell line.  The full-length Rat 
Jagged1 was subcloned from pBOS-SN3T, which was kindly provided by Dr. Geraldine 
Weinmaster (University of California, Los Angeles, CA) into pCDNA3.1 vectors with 
G418 selection marker.  pCDNA3.1 control vector and pCDNA3.1-rJag1 were transfected 
into Calu-6 non-target control shRNA cells and Calu-6 Jag1 KD cells.  After 72 hours, 
transfected cells are selected with 500mg/ml G418 for 2 weeks to obtain stably expressing 
rJag1. 
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Luciferase assay.  NSCLC cells were seeded on 24-well plates (1x105 cells/well) one day 
before co-transfecting with 400ng 12XCBF-1-reporter construct, 1ug NICD1 plasmid, and 
25ng TK-Renilla construct as an internal control.  After 24 hours after transfection, 
luciferase activity was measured with Dual-Luciferase Reporter Assay System (Promega) 
according to the manufacturer’s protocol. 
 
MTT cell proliferation assay.  NSCLCs (2x104/well) were plated in triplicate in complete 
medium on 12-well plates for 1-3 days as indicated.  Cells were incubated with 550ul 
(0.5mg/ml) MTT into complete medium for 4 hours, then 500ul of SDS-HCl (0.01M HCl, 
10% SDS) is added to each well. Cell proliferation was quantified using High-throughput 
microplate reader at 560nm.  
 
Soft agar colony formation assay.  Cells were suspended in 0.4% soft agarose in RMPI 
1640 supplemented with 10% FBS and plated in triplicate over a layer of 0.6% soft agarose 
in 6-well plates. After 2 weeks, colonies were stained with 0.05% crystal violet and 
counted. 
 
Cell migration assay.  Transwell plates (Corning) were used as instructed by 
manufacturers. Briefly, cells were cultured in serum-free medium for 24 hours, then 1x105 
cells were plated in triplicate in serum-free OPTIMEN medium in upper chamber, and 
complete medium placed in bottom wells for 24 hours.  The migrating cells were fixed in 
10% formalin solution, and stained by 0.05% crystal violet.  Three microscopic fields 
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(20X) were photographed and counted per chamber, and results were expressed as mean ± 
SD of results from replicate wells.  For Integrin β1 blocking experiment, 10ug/ml Integrin 
β1 blocking antibody was added into complete medium placed in bottom wells.  
 
Wound healing assay.  H358 cells with non-target shRNA and Jagged1 shRNA were 
cultured in a 6-well plate.  24 hours later, at 90% confluence, a single wound was generated 
in the center of the cell monolayer by gentle removal of the attached cells with a sterile 
plastic pipette tip.  The debris was removed by washing with medium.  After 24 and 48 
hours, migrated cells were visualized and photographed using an inverted microscope.  
Each experiment was performed three times independently. 
 
Immunofluorescent staining.  4-well Glass Chamber Slides (Thermo Scientific Inc, Nunc, 
NY) were coated with 400ul (10ug/ml) overnight at 4°C and rinsed one time with PBS. 
5x103 cells were cultured on Fibronectin coated chamber slides overnight, washed one 
time with PBS, then fixed in 4% paraformaldehyde for 30 minutes.  Following fixation, 
cells were blocked by 2% BSA then stained with primary antibodies (see Supplementary 
Materials) overnight at 4°C, followed by secondary antibody. Images were recorded by 
confocal microscopy.  
 
In vivo tumorigenesis.  Athymic 4- to 6-week-old nude mice (Jackson Laboratory) were 
used for the xenograft experiments. 1x106 cells from Calu-6 and H358 cell lines with 
either non-target shRNA, Jag1 shRNA, migR1 or DNMAML were diluted into 200ul of 
1:1 PBS-Matrigel solution (BD Biosciences).  Control and experimental cells were 
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subcutaneously injected into left or right flank of nude mice respectively.  When the tumors 
were palpable, tumor volume was measured every 3 days using a caliper and calculated 
with the formula: volume = (length) 2 × (width) 2/2. All experimental procedures were 
performed with approval from the Vanderbilt Institutional Animal Care and Use 
Committee. 
  
Statistical Analysis.  Unless specifically stated, statistical inference in comparative 
experiments both in vivo and in vitro was performed using the two-tailed Welch’s t test. 
For all statistical comparisons, the differences were considered significant at p<0.05. The 
correlation between Jagged1/Notch1/Notch3 expressions and tumor stages was analyzed by 
Chi square test. 
 
Results 
 
Jagged1 and Notch3, but not Notch1, are highly expressed in lung cancer tumors 
To determine expression of Notch signaling components in lung cancer, we compared their 
expression levels in adjacent normal lung tissue to that in the involved lung tumor tissue 
from our microarray dataset of Vanderbilt patients.  We have identified that Notch3 is the 
only receptor among all four Notch receptors to be upregulated at the mRNA level in lung 
tumors compared with normal lung tissues (Fig. 4.1A).  In contrast, several Notch ligands 
(Jagged1, 2, DLL1, and 3), except DLL4, are overexpressed in 49 lung cancer patient 
samples compared with 9 adjacent normal lung tissues (Fig. 4.1B).  Notch1, Notch3 and 
Jagged1 have been extensively documented to function as oncogenes in human solid 
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tumors (135, 164, 210).  To further investigate the frequency of Notch1, Notch3 receptors 
and Jagged1 protein expression in lung cancer patients, we performed an 
immunohistochemistry analysis using a tissue microarray consisting of 101 NSCLC tissues 
and 20 normal lung tissues. Indeed, Notch3 and Jagged1, but not Notch1 are frequently 
highly expressed in NSCLC tumors  (Fig. 4.2A).  We also classified their expression level 
based on tumor stages. Both Jagged1 and Notch3 expressions are elevated in more 
advanced stage tumors, but low in normal tissue with a statistical significance (Fig. 4.2B 
and C). Notch1 does not appear to correlate with tumor stage, as the levels of Notch1 
protein do not increase with advanced stages of tumor progression (Fig. 4.2D).  
 
Abrogation of Jagged1 suppresses NSCLC tumor growth both in vitro and in vivo 
Due to the fact that Jagged1 is overexpressed in NSCLC and literatures indicate that 
Jagged1 plays an oncogenic role in many cancers (136, 290-292), we hypothesized that 
Jagged1 is oncogenic in lung cancer and inhibition of Jagged1 will suppress lung cancer 
tumorigenesis.  To define whether the Notch1 and 3 receptors and Jagged1 and 2 ligands 
are expressed in lung cancer cell lines as in NSCLC tumors, we examined Calu-6, H358, 
Calu-1, H1993, H2122, H23, H1299 and an immortalized lung epithelial cell line 16HBE.  
Jagged1 ligand is highly expressed in these lung cancer cell lines, but not in immortalized 
lung epithelial cell line 16HBE (Fig. 4.3A).  Jagged2 ligand is also expressed in these cell 
lines, but the expression level and frequency is much lower than Jagged1.  As expected, 
Notch1 and Notch3 are expressed in both lung cancer cell lines and 16HBE (Fig. 4.3A). 
DLL1, DLL3 and DLL4 protein expression was not detected in these cell lines using 
multiple commercially available antibodies (data not shown).  These data suggest that 
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Jagged1 is the dominant Notch ligand expressed in lung cancer cell lines.  To test our 
hypothesis, we used shRNAs against Jagged1 to stably knockdown Jagged1 in lung cancer 
cell lines Calu-6 and H358 (Fig. 4.3B). Abrogation of Jagged1 in these cell lines 
significantly decreased cell growth (Fig. 4.3C, Fig. 4.8A). Importantly, inhibition of 
Jagged1 in Calu-6 and Calu-1 cell lines also suppressed their ability to form colonies in 
soft agar (Fig. 4.3D). In vivo, we observed a statistically significant reduction of tumor 
growth with Jag1 KD in both Calu-6 and H358 cell lines compared with non-targeted 
control Calu-6 and H358 cells (Fig. 4.3E). 
 
Jagged1 promotes NSCLC growth mainly through a CBF-1-independent mechanism 
To investigate if Jagged1 promotes lung cancer growth through CBF-1-dependent 
canonical Notch signaling, we generated Calu-6 and H358 cell lines stably expressing 
dominant-negative Mastermind like-1, which encodes the N-terminal Notch-binding 
domain of  
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Figure 4.1. Notch3 receptor, Jagged1, Jagged2, DLL1 and DLL3 ligands are upregulated in 
lung tumors compared with normal lung tissues from microarray analysis.  A. Relative 
expression of Notch 1-4 receptors,  B. Notch ligands Jagged1, 2 and Dll 1,3 ,4 in clinical samples of 
lung cancer, by Affymetrix chip, Human genome U133.  Data in log 2 scale and normalized with the 
average from a pooled normal lung control (BD Clontech) and nine normal lung tissues (10 total 
samples).  The numbers and types of samples are as follows: 19 squamous cell carcinoma, 23 
adenocarcinoma, and 7 large cell carcinoma. 
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Figure 4.2. Tissue microarray analysis of Jagged1, Notch1 and Notch3 in normal lung and 
NSCLC samples. A. Representative images of immunohistochemistry.  B. Percentage of samples with 
different Jagged1, C. Notch1, D. Notch3 expression levels in normal tissue and NSCLC classified by 
different stages. Blue bar: percentage of negative staining; red bar: percentage of weak staining; yellow 
bar: percentage of moderate staining; green bar: percentage of strong staining. The significant p values 
indicate significant association between stages and protein expression. 
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Figure 4.3. Jagged1 regulates lung cancer cell growth both in vitro and in vivo.  A. Western blot 
showing Jagged1, Jagged2, Notch1 and Notch3 protein expression levels in lung cancer cell lines and 
immortalized lung epithelial cell 16HBE.  B. Western blot showing Jagged1 expression in Calu-6 and 
H358 cells with non-target control shRNA and shRNA against Jagged1.  C. Cell growth curve of Calu-6 
and H358 cells with non-target control shRNA and Jagged1 shRNA for 3 days measured by MTT cell 
proliferation assay.  D. Colonies numbers of Calu1 and Calu-6 cells with non-target control shRNA and 
Jagged1 shRNA using soft agarose colony formation assay.  Quantification of colonies numbers is the 
average colony numbers of 3 respective experiments.  E. Tumor growth curve of Calu-6 and H358 cells 
with non-target control shRNA and Jagged1 shRNA of in vivo mouse xenograft tumor model.  p values is 
from Welch’s t-test. * indicated p<0.05, statistically significant. 
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MAML1 fused with GFP protein (DNMAML) to suppress Notch-CBF-1-MAML mediated 
gene transcription (117).  Expression of DNMAML in Calu-6 and H358 cells significantly 
decreased N1ICD activated CBF-1 luciferase reporter (Fig. 4.4A), and reduced canonical 
Notch target gene Hey1 mRNA expression (Fig. 4.4B) indicating that expression of 
DNMAML protein in lung cancer cell lines inhibits CBF-1-dependent canonical Notch 
activity.  We observed that inhibition of canonical Notch signaling does not affect Calu-6 
cell growth with 10% serum, while cell growth is reduced in media without serum.  In 
H358 cells, grown under conditions with or without serum, there is a slight but statistically 
significant reduction of cell growth when canonical Notch signaling is inhibited (Fig. 
4.4C).  Nevertheless, the reduction rates in both cell lines are minimal compared to the 
effects caused by abrogation of Jagged1.  We do not observe any increase of apoptotic cells 
in DNMAML expressing cells compared with control when grown in either 10% serum or 
serum free medium (data not shown).  In vivo, the xenograft tumor models generated with 
Calu-6 cells demonstrated no difference in tumor growth by expression of DNMAML 
protein. While there is a statistically significant reduction of tumor volume by DNMAML 
expression compared to control in xenograft tumors generated with H358 cells examined 
before the tumor reached the size of 0.3 cm3.  However, as tumors progressed, they reached 
the same size independent of DNMAML expression (Fig. 4.4D).  
 
Jagged1 signaling activates AKT in lung cancer via IGF and/or EGF signaling 
Given our observations that Jagged1 promotes lung cancer cell growth mainly via CBF-1-
independent non-canonical Notch signaling, we set out to investigate the possible  
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Figure 4.4. Inhibition of canonical Notch signaling by DNMAML slightly inhibits lung cancer 
progression in vitro and in vivo.  A. Luciferase reporter activities of CBF‐1 response element for Calu‐6 and H358 cells with migR1 vector control and DNMAML expression induced by N1ICD.  B. Relative expression of Hey1 mRNA measured by real‐time quantitative RT‐PCR for Calu‐6 and H358 cells with migR1 vector control and DNMAML expression vectors.  C. Cell growth curve of Calu‐6 and H358 cells with migR1 vector control and DNMAML expression vectors for 3 days under serum free and 10% FBS medium measured by MTT cell proliferation assay.  D. Tumor growth curve of Calu‐6 and H358 cells Calu‐6 and H358 cells with migR1 vector control and DNMAML expression vectors in mouse xenograft tumor model. p values is from Welch’s t‐test. * indicated p<0.05, statistically significant.   
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Figure 4.5. Jagged1 signaling regulates AKT pathway through crosstalk to EGF and/or IGF 
signaling. Western blot showing phospho-AKT, total-AKT, phospho-ERK, and total-ERK 
expression in Calu-6 and H358 with stable expression of non-target control shRNA, Jagged1 
shRNA, migR1 control vector and DNMAML after stimulation of A. 50ng/ml EGF for 0min, 5min 
and 30min,  B. 10ng/ml IGF for 0min, 5min and 30min.   
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Figure 4.6. Figure 5. Abrogation of Jagged1 promotes lung cancer cell migration.  A. Cell 
migration of H358, Calu-6, Calu-1, and H1993 with non-target control shRNA and Jagged1 shRNA 
measured by transwell migration assay.  B. Ability of H358 cells with non-target shRNA and Jagged1 
shRNA to close wound within 48 hours. C. Western blot showing that rat Jagged1 with HA tag is stably 
expressed in Calu-6 cells.  And Cell migration of Calu-6 cells with pCDNA3.1 vector+non-target 
control shRNA, rat Jagged1 expression vector+non-target shRNA, pCDNA3.1+hJagged1 shRNA, and 
rat Jagged1 expression vector+hJagged1 shRNA.  
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mechanism.  Based on the report of AKT activation being a key mediator of Notch1 pro-
survival effects under hypoxia through IGF1R signaling in lung cancer (293), and of 
crosstalk between Notch receptor intracellular domain and EGF signaling during cancer 
progression (225, 226, 294), we tested if Jagged1 can activate AKT and/or ERK signaling 
by crosstalk with these pathways.  We observed that in Calu-6, abrogation of Jagged1 
attenuates IGF but not EGF mediated phosphorylation of AKT.  However, in H358, 
abrogation of Jagged1 attenuates both EGF and, to a lesser extent, IGF mediated 
phosphorylation of AKT. DNMAML expression has no effect on phosphorylation of AKT 
in either cell line (Fig. 4.5A, B), suggesting that Jagged1 regulates lung cancer growth by 
activation of AKT through crosstalk with EGF and/or IGF signaling. Phosphorylation of 
ERK is not affected in either Jag1 KD or DNMAML expressing cell lines (Fig. 4.5A, B), 
which may be due to the fact that both Calu-6 and H358 cell lines have a KRAS mutation, 
such that phosphorylation of ERK is constitutively activated.  
 
Abrogation of Jagged1 promotes lung cancer cell migration 
To test if Jagged1 signaling affects tumor migration, we performed a transwell migration 
assay in H358, Calu-6, Calu-1 and H1993 cells.  Surprisingly, we observed a statistically 
significant increase of cell migration when Jagged1 signaling is attenuated (Fig. 4.6A). 
With an additional independent shRNA against in Calu-6 cells, we were able to 
demonstrate a consistent stimulation of lung cancer cell migration (Fig. 4.8C).  Moreover, 
using a wound-healing assay, we also observed that H358 cells with Jag1 KD shRNA 
closed the wound faster than control within 48 hours (Fig. 4.6B). To rule out off-target  
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Figure 4.7. Jagged1 regulates lung cancer cell migration is mediated by Integrin β1 signaling.  A. 
Western blot showing that expression of Integrin β1 protein level and its downstream cascade 
phosphorylation of FAK, and phosphorylation of Src protein in Calu-6 and H358 cells with non-target 
control shRNA and Jagged1 shRNA.  B. Immunofluorescent staining of F-actin in Calu-6 and H358 cells 
with non-target control shRNA and Jagged1 shRNA on fibronectin coated chambers.  C. Cell adhesion 
and spreading of H358 cells with non-target control shRNA and Jagged1 shRNA on collagen I and 
fibronectin coated plates.  D. Immunofluorescent staining of F-actin and phospho-FAK in H358 cells with 
non-target control shRNA and Jagged1 shRNA on Fibronecton coated glasses chambers.  E. Cell 
migration of Calu-6 cells with non-target control shRNA and Jagged1 shRNA treated with control IgG 
and Integrin β1 blocking antibody.    
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Figure 4.8. Abrogation of Jagged1 by different shRNA showed the same effect in cell growth and 
migration. A. Cell growth of Calu-6 with non-target control shRNA, Jagged1 shRNA #1 and #2  for 2 
days measured by MTT cell proliferation assay. B. Western blot showing that expression of Jagged1 and 
Integrin β1 protein levels in Calu-6 and H358 cells infected with non-target control shRNA, Jagged1 
shRNA #1 and #2. C. Cell migration of Calu-6 cells with non-target control shRNA, Jagged1 shRNA#1 
and #2 treated with control IgG and Integrin β1 blocking antibody.  Migrating cells were counted and 
expressed as the mean values (+- S.D) of triplicate wells (bar graphs), with p values from Welch’s t-test. 
* indicates statistically significant p<0.05.  Jagged1 shRNA #1 is an additional  shRNA.  #2 is the same 
shRNA used in all the studies. 
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Figure 4.9. Inhibition of canonical Notch signaling does not affect lung cancer cell migration.  A. Cell 
migration of Calu-6 cells with migR1 control vector and DNMAML expression. Migrated cells were counted 
and expressed as the mean values (+- S.D) of triplicate wells (bar graphs).  B. Western blot showing Integrin 
β1 protein expression level in Calu-6 cells with migR1 vector control and DNMAML expression.  C. 
Relative expression of Integrin β1 mRNA level in Calu-6 cell and H358 cell with non-target control shRNA, 
shRNA against Jagged1, migR1 control vector and DNMAML expression.  Relative Integrin β1 mRNA 
expression value was normalized by GAPDH mRNA expression.   
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effects of shRNA, as a cause of the increased migration, we re-expressed rat Jagged1 
protein stably in Calu-6 cell with abrogation of human Jagged1, as there is no consensus 
sequence for this shRNA in rat Jagged1.  Stable re-expression of rat Jagged1 protein in 
Calu-6 cells with human Jagged1 shRNA significantly decreased cell migration compared 
with Jag1 KD cells (Fig. 4.6C). Stable re-expression of rat Jagged1 protein in Calu-6 cell 
with non-target control shRNA does not affect cell migration, likely due to the high 
endogenous level of Jagged1 in Calu-6 cells.  Inhibition of CBF-1-dependent canonical 
Notch signaling by stable expression of DNMAML protein does not affect cell migration in 
either Calu-6 (Fig. 4.9A) or H358 cell lines (data not shown), suggesting that Jagged1 
regulation of lung cancer cell migration is not through CBF-1-dependent canonical Notch 
signaling. 
 
Jagged1 regulates lung cancer cell migration through integrin β1 signaling 
Integrins contribute to cell movement by providing traction to migratory cells through the 
signals from extracellular matrix (295).  Expression of the intracellular domain of Notch1 
has been linked to the activation of β1 integrin independent of CBF-1 transcriptional 
activity, and without affecting integrin expression (296).  Indeed, integrin β1 protein level 
was increased upon Jagged1 knockdown in both cell lines (Fig. 4.7A, Fig. 4.8B), whereas 
integrin α5 and α1 expression levels are not altered by attenuation of Jagged1 (data not 
shown). Additionally, downstream integrin signaling cascades including phospho-FAK and 
phospho-Src are also upregulated (Fig 4.7A). A prominent function of integrins is to 
mediate the adhesion of cells to their substrate providing a physical link between ECM and 
cytoskeleton (297). Decreasing expression levels of Jagged1 increased actin stress fibers 
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and caused a disorganized actin cytoskeleton when cells were cultured on fibronectin-
coated chambers (Fig. 4.7B). Increase of adhesion spreading of H358 Jag1 KD cells is 
observed as well when cells were cultured on collagen I or fibronectin coated plates for 4 
hours (Fig. 4.7C).  Focal adhesion sites are increased in Jag1 KD H358 cells when cells 
cultured on fibronectin-coated chambers (Fig. 4.7D).  Furthermore, inhibition of integrin 
β1 by a blocking antibody in Jag1 KD Calu-6 decreased the number of migrating cells to 
the same level as control (Fig. 4.7E, Fig. 4.8C), indicating that integrin β1 is the essential 
factor regulated by Jagged1 to induce cell migration. In contrast, stable expression of 
DNMAML protein did not affect integrin β1 protein levels in either Calu-6 or H358 (Fig. 
4.9B). In addition, neither Jag1 KD nor DNMAML expression affected integrin β1 mRNA 
expression levels (Fig. 4.9C), indicating that the effect of Jag1 KD on integrin β1 protein 
expression is post-transcriptional. 
 
Discussion 
Altered expression level of oncoproteins in tumors compared with normal tissue is often an 
indication of relative biological importance in tumorigenesis and may help define 
therapeutic targets in human cancer.  Even more strongly, lack of target expression 
suggests lack of efficacy.  Expression of Notch components in human cancer including 
lung cancer has been previously described, and the Notch ligand Jagged1 has been shown 
to correlate with poor overall survival in breast cancer (136, 290).  Notch3 has been shown 
to be upregulated in colorectal cancer (298), NSCLC (225), ovarian cancer (153), and 
cervical cancer (299).  Our data further strengthen the finding in lung cancer that Jagged1 
and Notch3 are overexpressed, and their expression is correlated with advanced tumor 
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stages, indicating their oncogenic function in lung cancer.  In contrast, Notch1 protein is 
not upregulated in NSCLC tumors compared with normal lung tissue using clinical 
samples, suggesting that Notch1 may not be an important target in NSCLC.  
 
Inhibition of Notch3 signaling has been shown previously to suppress growth of lung 
cancer cells (225, 226, 285). However, in two assayed KRAS mutant cell lines, H356 and 
Calu-6, knockdown of either Notch1 or Notch3 did not lead to remarkable growth 
suppression as observed upon knockdown of Jagged1 (data not shown). Lack of an obvious 
change in growth may be explained by redundant roles of Notch1 and Notch3 on the 
regulation of lung cancer cell growth in genetic subclasses. Notch3, Notch1, Jagged1 and 
Jagged2 have been shown to play roles in various lung cancer models with different 
genetic background (219, 226, 229). Notably, these studies did not investigate the 
importance of CBF-1-dependent canonical Notch signaling in lung cancer. In this study, 
we have used DNMAML to suppress canonical Notch signaling. The DNMAML approach 
is more specific for Notch signaling than knocking down levels of CBF-1, as the 
DNMAML protein can still bind to NICD, but lacks the C-terminal portion to initiate gene 
transcription. Our study demonstrates that in particular lung cancer contexts, inhibition of 
CBF-1-dependent canonical Notch signaling had minimal effects on tumor cell growth in 
vitro and in vivo, implying that the pro-tumor effects of Notch signaling in these tumors 
may not be primarily through CBF-1-dependent canonical Notch signaling. Besides 
targeting Notch receptors and ligands, stapled peptides preventing formation of Notch-
CBF-1-MAML transcriptional complex have emerged as a potential therapy to target CBF-
1-dependent Notch signaling, such as T-ALL (269).  Our study indicates that strategies to 
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target Notch-CBF-1-MAML transcriptional machinery may not work for inhibition of lung 
tumor growth. Notch signaling has been found to crosstalk with other signaling pathways 
independent of CBF-1 (284).  We found that Jagged1-mediated Notch signaling is able to 
activate the AKT signaling pathway through crosstalk with EGF and/or IGF signaling, also 
independent of CBF-1.  Other signaling pathways may also cooperate with Notch signaling 
as well in a CBF-1-independent manner during lung cancer tumorigenesis. Further 
investigations will be needed to address this further. 
 
For patients with NSCLC, the biggest threat to survival is metastasis. Several studies 
indicate Notch signaling promotes EMT and tumor metastasis via regulation of EMT 
regulators Slug, ZEB and miR200 (181, 190, 288).  However, in our study, inhibition of 
Jagged1 does not affect the process of EMT in lung cancer cells (data not shown). 
Surprisingly, we found that abrogation of Jagged1 increased motility of lung cancer cells 
through upregulation of integrin β1 protein expression, which then activates the FAK-SRC 
signaling cascade.  Indeed, integerin α5β1 has been link to NSCLC metastasis by the 
observation that increased expression of integrins α5β1 is significantly correlated with 
lymph node metastasis of human NSCLC patients (300).  The finding that Jagged1 is 
responsible for growth promotion but migration suppression appears counter-intuitive. The 
reasons why Jagged1 has such paradoxical function in tumor progression is unknown, but 
it is possible that tumor cells surviving from the inhibition of Jagged1 become more 
aggressive/metastatic via upregulation of the integrin signaling pathway.  This result 
clearly raises the possibility that chronic blockade of Jagged1 in lung cancer could be a 
double-edged sword. Inhibition of integrin β1 by a blocking antibody reverses the 
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migration phenotype upon Jagged1 abrogation, indicating that the combination of a 
Jagged1 inhibiting reagent with an integrin β1 inhibitor could be a good strategy to target 
lung cancer.   
 
Recently, Yang et al reported that Jagged2 promotes metastasis of transgenic mutant 
KRAS-driven adenocarcinoma cells through downregulation of miR-200, while Jagged1 
does not affect metastasis in this model (181).  The fact that we observed a different 
migration effect of Jagged1 in human lung cancer cell lines may due to the complicated 
genetic landscape of lung cancer cell lines compared to genetically defined tumor models.  
Moreover, we performed an analysis of microRNA expression with control and Jag1 KD in 
Calu-6 cells, but did not see any significant expression changes of the microRNAs 
observed in the murine study upon Jagged1 inhibition (data not shown). This suggests that 
in the human lung cancer cell line Calu-6, Jagged1 is not regulating cell migration through 
miR-200 expression.   
 
Ectopic expression of N1ICD caused down-regulation of multiple matrix-adhesion genes, 
including integrin β1 in immortalized mammary epithelial cells in MCF-10A (301).  It is 
not clear from our study if Jagged1 regulates cell motility and integrin β1 expression in 
lung cancer in a Notch receptor-dependent manner.  We have tried to assess this aspect 
using the immortalized lung epithelial cell line 16HBE overexpressing constitutive active 
N1ICD.  However, neither cells migration nor integrin β1 protein expression is altered 
upon constitutively activation of Notch1 (Fig 4.10A).  In addition, by blocking S3 cleavage 
of Notch receptors using a γ-secretase inhibitor MRK003, we did not observe an increase 
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of integrin β1 or phospho-FAK protein expression (Fig. 4.10B).  These data suggest the 
possibility that Jagged1 regulates lung cancer migration and integrin β1 protein expression 
through Jagged1 signaling independent of Notch receptors.  Yet, we have not ruled out 
whether full-length or membrane tethered Notch receptors suppress cell migration and 
integrin β1 expression.  Also, whether the process is regulated through multiple activated 
Notch receptors is not clear.  This question can be addressed when the blocking antibodies 
for individual Notch receptors become available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Neither overexpression of N1ICD nor treatment with a γ -secretase inhibitor 
affects Integrin β1 protein expression.  A. Western blot showing Integrin β1 expression in 
16HBE cells with control pBabe vector and N1ICD expression vector.  B. Western blot showing 
Integrin β1 expression and phospho-FAK expression in Calu6, H358, Calu1 and H1993 cells 
before and after 10uM gamma-secretase inhibitor treatment for 24 hours.   
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CHAPTER V  
 
SUMMARY AND DISCUSSION 
 
Summary 
Notch signaling is important in the regulation of human physiological and pathological 
processes including various human cancers such as T-ALL, ovarian cancer, breast cancer, 
pancreatic cancer and lung cancer, which makes Notch signaling as an attractive target for 
the treatment of human cancers.  In lung cancer, it has been reported by our group that the 
existence of chromosome translocation and overexpression of Notch3 in patient tumor 
specimens occurs, further inhibition of Notch3 signaling by RNA interference or with a 
pharmacological γ-secretase inhibitor results in suppression of tumor progression in vitro 
and in vivo.  Due to the contradictory roles of Notch1 in lung cancer and nonspecificity and 
gut toxicity of GSIs, specific inhibitors against Notch3 signaling may have more 
advantages for lung cancer patients over pan-Notch inhibitors.  The goal of the work 
described in this thesis was the development of therapeutic reagents targeting Notch3 
signaling in lung cancer.   
 
We used a high-throughput strategy to screen a peptide library spanning all 34 EGF-like 
repeats of Notch3 extracellular domain for their ability to induce apoptosis of the lung 
cancer cell line HCC2429. We also generated neutralizing mAbs against putative ligand 
binding regions of Notch3 receptor.  Moreover, we tested the hypothesis that targeting 
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Jagged1 or the Notch-CBF-1-MAML transcriptional complex are potentially alternative 
approaches to block Notch3 signaling in lung cancer.  
 
The work presented here has demonstrated that 1) a rationale for developing anti-Notch3 
therapeutic reagents by interfering with receptor-ligand interactions in lung cancer, such as 
by decoy receptor peptides or neutralizing antibodies; 2) Notch3 EGF-like repeats 7-10 and 
21-22 are putative ligand binding regions which differ from that of Notch1; 3) Fc-fusion 
proteins with peptides representing Notch3 ligand binding regions are able to inhibit 
Notch3 signaling and suppress lung cancer progression in vitro and in vivo; 4) mAbs 
targeting Notch3 EGF-like repeats 7-10 or 21-22 are able to bind to full-length Notch3 and 
suppress production of the activated form of Notch3 in lung cancer cells; 5) the roles of the 
Notch ligand Jagged1 in lung cancer cell growth and migration are paradoxical; 6) 
abrogation of Jagged1 results in promotion of lung cancer cell migration through 
upregulation of integrin β1 protein level; 7) blocking the CBF-1 dependent canonical 
Notch pathway has minimal effects on lung cancer growth and migration.  
 
The Fc-fusion proteins and neutralizing mAbs developed in this thesis project have the 
potential to be further developed and used in lung cancer patients to target Notch3 
signaling.  Furthermore we provide a rationale for targeting the receptor-ligand interaction 
of Notch3 signaling in lung cancer.  It is noteworthy that inhibition of Notch-CBF-1-
MAML in two lung cancer cells has very minimum effects on lung tumor growth. This 
suggests that the alternative mechanisms of Notch signaling are important in lung cancer.  
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Lastly, the unexpected pro-migratory effect of chronic inhibition of Notch ligand Jagged1 
in lung cancer cells may help guide a strategy for how anti-Jagged1 therapies are used. 
 
Discussion 
Our work has raised as many questions as it has answered.  Given that Notch is involved in 
a series of fundamental processes during embryonic development and in adult tissues, the 
emerging reports of Notch signaling in human cancers highlights the intriguing dual role of 
a single signaling and complexity of Notch signaling in human cancers of different context.   
Even in the same context as lung cancer, the roles of different components of Notch 
signaling are not the same.  The divergent roles of Notch signaling raise several following 
unsolved questions that need to be solved in order to understand Notch signaling in human 
cancers.  
 
What are the roles of Notch3 versus Notch1 in lung cancer, and why do they behave 
differently? 
The third mammalian Notch, the Notch3 gene was initially described as being expressed in 
proliferating neuroepithelium (302).  Targeted deletion of Notch3 does not result in 
embryonic lethality as is observed with deletion of Notch1 and Notch2, possibly due to 
different tissue distribution.  The biological functions of Notch3 and Notch1 in human 
cancers, such as lung cancer are different.  In the lung cancer cell line HCC2429, which 
expresses both Notch1 and Notch3 receptors, deletion of Notch3 by siRNA abrogated the 
response to GSI treatment, suggesting that Notch3 but not Notch1 contributes to 
tumorigenesis of HCC2429 cells.  Moreover, in HCC2429 cells, Notch3 seems to 
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preferentially activate Hey1 gene transcription instead of Hes1, as cells retaining Notch3 
expression show higher expression of Hey1, whereas no difference in Hes1 is observed 
between the control and Notch3 knockdown (226).  The variation in their downstream 
targets may explain the biological difference between Notch3 and Notch1 in lung cancer 
progression. 
 
In lung cancer cells with different genetic backgrounds, such as those harboring a KRAS 
mutation, the situation is quite different.  We showed in chapter IV that attenuation of 
Jagged1 in H358 and Calu-6 cells suppressed their growth in vitro and in vivo.  Originally, 
we have knocked down Notch1 and Notch3 in both cell lines by two independent shRNAs.  
However, we did not observe any growth defects upon inhibition of either Notch1 or 
Notch3 (data not shown).  After measuring Notch receptor levels in each knockdown line, 
we observed that in the Notch1 knockdown cells, Notch3 level is slightly increased 
compared with control, whereas in the Notch3 knockdown cells, Notch1 level is also 
increased compared with control, indicating that both Notch1 and Notch3 are potentially 
important in regulating lung cancer cell growth, and their function in lung cancer 
progression is redundant.  More insights into differential functions of Notch3 versus 
Notch1 in lung cancer could be assessed when specific inhibitors against individual Notch 
receptors become available.   
 
Although Notch3 shares a similar basic structure with Notch1 and Notch2, Notch3 displays 
several structural differences, which would explain the functional difference between 
Notch3 and Notch1 in cancers.  Firstly, Notch3 has a shorter C-terminal region including 
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the TAD domain, which may explain the weaker transactivation activity of N3ICD when 
compared to that of N1ICD and N2ICD (303).  Secondly, the amino acid identity between 
Notch3 and Notch1 in the RAM domain is low, which mediates the interaction with CBF-
1, is low (272).  Both of these differences could possibly explain the altered N3ICD in the 
regulation of gene transcriptions.  Thirdly, there are subtle differences in the 
transmembrane domain of Notch3 compared to that of other Notch proteins (304), which 
may mediate differential Notch3 intramembranous cleavage as well as its recruitment to 
the membrane.  Finally, there is a slight differences with respect to its EGF-like repeats as 
Notch3 lacks EGF-like repeats 2, 3 and 21 in Notch1 and Notch2 (302), which may lead to 
a change in specificity and affinity with Notch ligands.  In the thesis study, we found that 
Notch3 EGF-like repeat 7-10 and 21-22 are essential to mediate ligand interaction, which 
is different from that of Notch1, EGF-like repeat 11-12 from published works, which 
would add a novel difference between Notch3 and Notch1.  
 
How do two regions of Notch3 ECD mediate receptor-ligand interaction? 
In the work described in chapter II, we found two ligand binding regions of Notch3 
receptor, while in Notch1 only one ligand-binding region was reported.  However, it is 
highly possible that Notch1 also has an additional ligand-binding region in the similar 
region.  Ligand-binding domains of Drosophila Notch were identified by a cell aggregation 
assay, in which cells expressing a series of deletion mutants of Notch lacking different 
EGF-like repeat were assayed for their abilities to aggregate Serrate/Delte expressing cells.  
In our study, we used a functional assay to evaluate signaling transduction activities of 
Notch3 mutants and showed that deletion of EGF-like 7-10 or 21-22 of Notch3 receptor 
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significantly suppressed production of N3ICD and expression of Notch target genes Hes1 
and Hey1.  Therefore, it is possible that the aggregation assay only identified minimum 
regions for ligand binding but not minimum regions for ligand-mediated activation of 
Notch signaling.  It is possible that EGF-like repeats 21-22 of Notch3 or its equivalent 
EGF-like repeat 25-26 of Notch1 may contribute to secondary ligand-binding site in order 
to generate a pulling force on both sides of the ligand after the primary binding of EGF-like 
repeat 7-10 of Notch3 or 11-12 of Notch1.  Indeed, deletion of EGF-like repeat 24-26 of 
Drosophila Notch, also defined as Abruptex region, has been shown to reduce Notch 
signaling activated by Serrate but not Delta (274), suggesting an additional region of EGF-
like repeat is important for Serrate-mediated Notch signaling.  Jagged1 ligands have around 
8 more EGF-like repeats than DLL ligands. Thus, it is possible that Jagged ligands bind to 
two regions of Notch receptors, whereas DLL ligands only bind to one region of Notch 
receptors.  In our study, we used HCC2429 cells that highly express Jagged1 ligands 
instead of DLL ligands, to screen the peptide library.  Thus that secondary binding site 
identified from this study could just mediate Notch3-Jagged1 interaction, but not that with 
DLL ligands.  More studies need to be done to address the following questions for better 
understanding of receptor-ligand interaction in Notch signaling: 1). Whether EGF-like 
repeats 25-26 of Notch1 are important for Notch1-mediated signaling transduction. 2). 
Whether EGF-like repeats 21-22 of Notch3 only binds to Jagged ligands, but not DLL 
ligands. 3). Which domain in Jagged ligands are responsible for binding to Notch3 EGF-
like repeat 21-22?  
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It is not clear if individual Notch receptors have a preference for binding to Jagged ligands 
versus DLL ligands.  In vitro solid- phase binding assay showed that mouse Jagged1 bound 
to various soluble Notch receptors including their N-terminal and EGF-like repeats 1-15 
with differing affinity as Notch3>Notch2>Notch1 (25), suggesting that there is there is 
some preferential relationship between Notch3 and Jagged1.  Indeed, preferential 
interaction between Jagged1 and Notch3 are indicated in the context of cancer cell survival 
and growth (155, 173, 226).  Moreover, It has bee showed that different DSL proteins bind 
to soluble Notch3 or Notch1 proteins including their N-terminal and EGF-like repeat 1-15 
with different affinity as DLL1>Jagged2>Jagged1 (305).  In fact, binding affinities 
between receptors and different ligands identified by in vitro solid-phase binding assay 
may not be representative of the in vivo situation as there is a possibility that affinities are 
modulated by other factors such as Fringe proteins. Fringe modified Notch receptors prefer 
to bind to DLL ligands instead of Jagged ligands (35).  More studies to investigate the 
existence of preferential interactions between different receptors and ligands using 
mammalian cell systems would aid the design of therapeutic agents against individual 
Notch receptors/ligands pairs.  
 
 Are Notch mutations drivers or passengers in cancer? 
Notch1 mutations were first identified in T-ALL, and mutagenesis studies indicated that 
these mutations are activating and drive T-ALL (110).  Later, mutations in FBXW7 
ubiquitin ligase, which regulates levels of Notch, cyclinE and other proteins, were found in 
human colorectal, ovarian, endometrial tumors and T-ALL and B-ALL (306).  Notch genes 
are very large genes consisting of up to 34 coding exons and about 30 EGF-like repeats, 
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which hampers classical DNA sequencing.  Thanks to the accelerating technologies for 
deep sequencing of the cancer genome and cancer transcriptome, more and more unknown 
mutations have being identified in human cancers including in the Notch gene family.  
Inactivating mutations of Notch1 were found as a potentially important tumor suppressors 
in head and neck cancer by two independent groups. This was done by sequencing the 
exons of all known human genes in tumor DNA and comparing it to the sequence to that of 
the corresponding normal DNA of the same patient.  In both studies, inactivating mutations 
of Notch1 were found in 10 to 15% of the head and neck squamous cell carcinomas 
(HNSCCs), and Notch1 was the second most frequently mutated gene after TP53 in 
HNSCC.  Mutations in Notch2 and Notch3 genes are found as well with less frequency.  In 
the study conducted by Stransky et al. the authors showed showed that several Notch1 
nonsense mutations are predicted to generate truncated proteins lacking the C-terminal 
ankyrin repeat domain, and that several mutations cluster in highly conserved residues 
situated within or nearby the putative ligand-binding regions.  Agrawal et al. found several 
mutations in the intracellular domain in addition to truncations and mutations in the ECD.  
However, those mutations show little overlap.  Unlike Notch3 mutations in CADASIL 
(cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) that mutations altered the number of cysteine residues in the 
extracellular domain leading to its abnormal accumulation in the vessels of patients, most 
of the nonsynonymous mutations identified in Notch1 ECD in these two studies are not in 
cysteine residue, and the consequences of these mutations are hard to predict.  While the 
finding of numerous inactivation mutations in Notch1 in HNSCCs combined with the 
observation that Notch1 null mice developed a skin cancer provide strong evidence that 
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Notch1 is an important tumor suppressor in HNSCCs, this does not necessarily indicate 
that they are all “ driver mutations” causally associated with the malignant transformation 
process.  Tumor cells are genetically unstable and acquired many mutations including 
“passenger mutations”, which are probably a consequence of malignant transformation but 
not the cause.  Conversely, Agrawal et al. also found inactivating mutation of FBXW7 in 
tumors that lack inactivating mutation of Notch1.  The primary function of Fbxw7 in 
cancer is to mediate degradation of Notch receptor so as to inactivate Notch signaling.  We 
would expect to see activating mutation of negative regulators of a tumor suppressor gene.  
Therefore, it is still not well defined that Notch1 is a tumor suppressor in HNSCC.  More 
mechanistic studies in cell lines and animal models are required to demonstrate the exact 
roles of the mutated Notch1 receptor in HNSCC.  It is possible that more and more Notch 
mutations and other unknown mutations will be found crossing multiple human cancers 
including lung cancer, by next generation sequencing or RNAseq.  Development of 
bioinformatic approaches and more efficient functional assays to assess newly identified 
mutations will be essential to determine their exact functions as driver mutations or 
passenger mutations, which would further facilitate designs of targeted therapies against 
driver mutations in human cancers. 
 
Do Notch inhibitors in cancer function only as anti-angiogenic agents? 
Multipe evidences suggest the oncogenic roles of Notch signaling in the tumorigenesis of 
multiple human cancers.  Thus, targeting Notch signaling became an attractive approach, 
and various pharmaceutical and biotech companies are generating Notch inhibitors, 
including Roche/Genentech, Roche, Regeneron, Merck, Pfizer and Eli Lilly etc.  Most 
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development has focused on small molecule inhibitors targeting γ-secretase, while more 
and more companies are switching to more specific inhibitors against individual Notch 
receptors or ligands.  However, individual Notch receptors/ligands inhibitors have been 
more appreciated by their anti-angiogenic effects in solid tumors, as Notch signaling is 
highly activated in vasculature and is upstream of VEGF signaling in the regulation of 
angiogenesis.  Wu et al. have screened a panel of nearly 45 cell lines for anti-Notch1 mAb 
against NRR region, and identified a human colon cancer line MT-3 as a sensitive line in a 
dose-dependent but ligand-independent manner.  It turned out that this cell line has an 
activating point mutation in the NRR region, which activates Notch1 signaling independent 
of ligand.  They also demonstrate the anti-Notch1 antibody treatment decreased tumor 
angiogenesis in the xenograft model generated from Calu-6 and HM7 cells which were 
previously reported to be sensitive to anti-angiogenic therapy. However, growth of these 
cell lines is not affected by anti-Notch1 mAbs treatment in cell culture.  Their data suggest 
that except for the tumor cells harboring activating mutations of Notch1 receptor, anti-
Notch1 mAbs basically inhibited tumor growth through anti-angiogenesis.   
 
Are anti-Notch therapies only anti-angiogenic agents in tumors without Notch mutations? 
Our data would suggest that this is not the case.  In chapter IV of the thesis, using the same 
cell line Calu-6, we showed that abrogation of Notch ligand Jagged1 suppressed cell 
growth both in vitro and in vivo.  Indeed treatment with the GSI, MRK003, in the same cell 
line attenuated cell growth in vitro as well (data not shown), suggesting that Notch 
signaling does play a role in the cell growth of Calu-6 cells.  The redundant functions of 
Notch signaling mediated by different Notch receptors could explain why this cell line can 
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respond to GSIs and ligand inhibition but not anti-Notch1 mAbs. Blocking Jagged1 or 
using γ-secretase shuts down all four Notch receptors mediated signaling, while anti-
Notch1 mAbs only works to inhibit Notch1 mediated signaling.  Since Notch1 is the major 
player in tumor blood vessel, inhibition of Notch1 is sufficient to attenuate angiogenesis 
driven by Notch signaling.  However, there are many examples in the literature of cancer 
cell lines responding to pan-Notch inhibitors, such as GSIs, which attenuate tumor 
progression in vitro and in vivo, suggesting that anti-Notch treatment would work directly 
on tumor growth as well.  
 
In terms of inhibitors that target specifically each of the Notch receptors, one needs to 
know which Notch receptor is important in certain human cancers.  For example, in lung 
cancer, Notch3 is a better target than Notch1.  We showed in chapter IV that Notch3, but 
not Notch1 is highly expressed in lung cancer tissues, and that its expression being 
correlated with advanced stage disease.  If multiple Notch receptors are present and 
functionally redundant in certain cancers, GSIs would be a better choice than inhibitors for 
individual Notch receptors if side effects of GSIs could be overcome.  More studies need to 
be done to determine which Notch receptors or if all-Notch receptors are important in 
certain cancers so as to determine which Notch inhibitors should be used.  
 
Can Notch inhibitors be used as single agents for cancer therapy? 
Based on the published data regarding the use of Notch inhibitors to treat cancer cells in 
vitro and in vivo, cancer cells harboring mutations in genes involved with Notch signaling 
are sensitive to anti-Notch treatment.  Examples of these include T-ALL cells harboring 
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activating mutations of Notch1, primary lung cancer cells with activating mutations of 
Notch1 or loss of Numb expression, and HCC2429 cells with Notch3 translocation (220, 
226, 254).  Plentz et al. have screened around 400 human cancer cell lines derived from 
different solid tumors for their responsiveness to a selective GSI, MRK003, and found that 
50% of their cohort of 26 PDAC cell lines was sensitive to the inhibitor.  Moreover, the 
GSI completely inhibited tumor development in the genetically engineered model of 
invasive PDAC (148).  These studies suggest that some subtypes of cancer without a 
genetic alternation of Notch would respond to anti-Notch therapy.  However, even tumors 
addicted to EGFR signaling would not respond completely to EGFR tyrosine kinase 
inhibitor (TKI) or eventually developed resistance via different mechanisms. Moreover 
responsiveness of inhibitors in real patients is not predictable based on the responsiveness 
in genetic tumor model or xenograft tumors model due to the genetic complexity of 
individual patients.  The phase I clinical trial analyzing the effects of a GSI in relapsed and 
refractory T-ALL showed that none of the patients enrolled in this study showed any 
significant clinical response (307), which correlates with the weak antileukemic effects of 
GSIs against human T-ALL cells in vitro, consistent with existence of some other signaling 
pathways in synergy with Notch1 signaling in human T-ALL patients.  Nevertheless, given 
the fact that inhibition of Notch1 signaling has a profound effect on the homeostasis of T-
ALL (308-310), it has been reported that GSIs are able to reverse glucocorticoid resistance 
in T-ALL (267).  In lung cancer, HCC2429 cells with high Notch3 expression are sensitive 
to Notch inhibition, whereas other lung cancer cell lines, such as A549 are not sensitive to 
anti-Notch treatment.  At this point, there is no other existing genetic alternation in 
HCC2429.  By comparison, most of lung cancer cells lines harbor various genetic 
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alternations that are important for cancer cell survivals. Therefore, for the majority of lung 
cancer patients, Notch inhibitors would not work as a single agent for treatment.  Recently, 
based on the notion that Notch signaling plays important roles in the maintenance of cancer 
stem cells in many cancers including lung cancer and glioma, anti-Notch therapies open a 
new window to treat cancer stem cells, which are resistance to conventional chemo- and 
radiation treatment.  Even though the cancer stem cell hypothesis is still under debate, the 
efficacy of Notch inhibitors to suppress progression of cancer cells with different clonal 
and tumorigenic capacities provides the rationale that anti-Notch therapy could increase the 
efficacy of conventional therapies for cancer patients.  In addition, in lung cancer, it had 
been demonstrated that Notch3 and EGFR signaling cooperate together to modulate 
apoptosis through induction of proapoptotic protein Bim expression.  Using a GSI and 
erlotinib in a xenograft model, tumor inhibition was observed to be enhanced compared 
with each agent alone, suggesting that anti-Notch therapy could be useful to increase 
responsiveness of lung cancer patients to EGFR TKI.  Thereby, in my opinion, although 
Notch signaling is very important in multiple cancers, anti-Notch agents might produce 
little benefit as a single agent in treatment regimen of a majority of cancer patients.  
Instead, anti-Notch thereby may provide optimal benefit when treating patients using a 
combination of anti-Notch inhibitors with conventional drugs or other targeted agents.  
 
What are the biomarkers to predict sensitivity to Notch inhibition? 
Predictive biomarkers are used to assess the probability that a patient will benefit from a 
particular treatment (311).  Mutations in the genetic region encoding the kinase domain of 
EGFR predict the sensitivity of lung tumors to the EGFR TKI erotinib (312).  Conversely, 
  126 
distinct mutations in KRAS predict that patients with lung cancer will fail to respond to 
erlotinib (313). In T-ALL, activating mutations of Notch1 could predict the possibility of 
the patient responding to Notch inhibitors.  However, in solid tumors, such as lung cancer, 
very few mutations of components in Notch signaling are present.  Thus, it becomes 
important to define the biomarkers that can determine if tumors would be sensitive to 
Notch inhibitors or not.  Nowadays, most studies to determine which cells would be 
sensitive to Notch inhibitors are based on expression levels of Notch components in tumor 
cells.  For example, high expression levels of Notch receptors, ligands or downstream 
targets Hes1 or Hey1 are often used as indicators for responsiveness to anti-Notch therapy, 
such as GSIs.  However, due to the complexity of Notch signaling and its roles in the 
maintenance of cancer stem cells, using expression levels of Notch related proteins as 
predictive biomarkers for anti-Notch therapy would be very limited to guide personalized 
cancer therapies.  AVEO Pharmaceutical Inc had reported at the AACR annual meeting 
that active Notch signaling alone did not predict dependence of Notch, but expression of a 
single Notch target gene HeyL was highly correlated with sensitivity of human cancer cell 
lines to inhibition of ligand-dependent Notch signaling.  Moreover, they showed that 
pancreatic cancer cell lines harboring a KRAS mutation are more sensitive to Notch 
pathway inhibition.  Recently, Sage’s group reported that Notch signaling was activated in 
HCC tumors derived from Rb depletion mice.  However, the treatment of a GSI increased 
the tumor incidence and size (314).  One would expect that signaling pathways activated in 
tumors are most likely to be oncogenic rather than tumor suppressive.  However, this study 
indicates that in liver cancer, Notch signaling is in fact tumor suppressive and high 
expression of Notch associated proteins in tumors is not sufficient to predict outcomes of 
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Notch inhibition.  Due to the context dependent roles of Notch signaling in human cancers, 
it will be important to identify predictive biomarkers for responsiveness to Notch inhibitors 
for each cancer type.  In lung cancer, more studies need to be done to firstly, elucidate if 
high expression of Notch receptors or ligands is enough to indicate importance of Notch 
signaling among multiple lung cancer cell lines; secondly, to determine the genetic 
alternations of certain cancer cells that would / would not be inhibited by anti-Notch 
agents; thirdly, to figure out a way to assess the presence of Notch-associated cancer stem 
cells from patient biopsy; fourthly, to investigate characteristics or gene signatures of 
tumors from patients that respond to GSI treatment from clinical trials.  Overall, cancer is a 
complicated disease of genetic complexity and heterogeneity.  So it is always important to 
develop clinical biomarkers to determine which patients are most likely to benefit from 
specific targeted therapies. 
 
What are the difficulties in developing Notch blocking agents? 
We generated neutralizing monoclonal antibodies against Notch3 putative ligand binding 
regions, EGF-like repeat 7-10 and 21-22, respectively, and we have identified a handful of 
mAbs that are able to bind to Notch3 receptor.  These mAbs have been able to reduce 
production of N3ICD in HCC2429 cells.  However, once we expanded the hybridoma 
clones to produce large amount of mAbs in a bioreactor, the mAbs lost their abilities to 
reduce production of N3ICD in the HCC2429 cells.  The myeloma cell line SP2/0 used for 
making the hybridoma expresses the Notch1, Notch2 and Notch3 receptors (data not 
shown).  Indeed, it had been reported that inhibition of Notch signaling by a GSI induces 
apoptosis of myeloma (315).  Thus, it is possible that the mAbs produced by the hybridoma 
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inhibits its own growth so as to influence the ability to produce antibodies with the correct 
conformation.  There are two approaches used by published studies to generate Notch 
inhibitory antibodies: making mAbs by hybridomas (253) or screening a phage display 
library (254, 255).  The only blocking antibodies to significantly suppress tumor growth are 
antibodies generated by Siebel’s group at Genentech.  They screened a phage display 
library for phages binding to NRR regions of Notch1 and Notch2 respectively, and 
generated antibodies to express full-length IgGs by cloning the light chain (VL) and heavy 
chain (VH) regions into LPG3 and LPG4 vectors, respectively, then transiently expressed 
antibodies in mammalian cells and purified using protein A.  Using this method, they 
avoided the possibility that Notch neutralizing antibodies affects production and 
conformation of antibodies themselves.  Li et al. used whole Notch3 extracellular domain 
as an antigen to generate Notch3 blocking antibodies from the hybridomas, and showed 
that antibodies recognizing both the NRR region and ligand-binding regions are able to 
block Notch3 signaling. However, they only showed their abilities in blocking ligand-
mediated signaling transduction and inhibition of cell proliferation and migration in 
HEK293T-Notch3 cells, but not their anti-tumor abilities in tumor cells.  It has been three 
years since they reported these anti-Notch3 blocking antibodies, but to our knowledge, no 
anti-tumor activities of those antibodies were ever reported.  Originally, in the 
collaboration with Dr. Ray Mernaugh we tried to screen the phage display library for 
antibodies against all the Notch3 EGF-like repeats.  The peptides used in the apoptosis 
screening described in chapter II were originally designed for screening of the phage 
display library.  We found several phage display antibodies that bind to Notch3 peptides.  
However, these antibodies failed to either immunoprecipitate full-length Notch3 or inhibit 
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Notch3 signal transduction.  It is possible that we took a wrong approach in screening the 
phage display library using small peptides of Notch3 ECD.  Notch3 EGF-like repeat 7-10 
and 21-22 proteins should be used for screening of phage display library if our antibodies 
from hybridomas fail to block Notch3 signaling or suppress tumor growth in lung cancer.  
Studies published during the thesis research suggested that the NRR region is the better 
target than the ligand binding regions of Notch1/3 receptors.  Therefore, it is also a good 
strategy to target Notch3 NRR regions by screening a phage display library or making 
mAbs from hybridomas.  
 
Small molecule inhibitors may interfere with receptor-ligand interaction as well, albeit 
small molecule inhibitors are rarely used for blocking extracellular protein-protein 
interaction.  In fact, we have tried to screen small molecule inhibitors by fluorescent 
depolarization assay and Corning EPIC label free technology.  However, we could not 
prove the concept of these assays for further screening.  Cell-based assay would be more 
feasible for screening of small molecule inhibitors against Notch signaling but the readout 
of the screening would be very critical.  CBF-1 reporter activity could be used to screen the 
inhibitors against canonical Notch signaling.  Unfortunately the hits from screening may 
not only target Notch signaling due to unspecific roles of CBF-1.  A FRET assay to assess 
NICD-CBF-1 interaction is more specific for screening inhibitors against canonical Notch 
signaling.  However, none of these approaches is able to identify specific inhibitors for 
individual Notch receptor mediated signaling as all the Notch receptors share similar 
intracellular mechanisms to activate downstream targets.  Due to gut toxicity caused by 
inhibition of both Notch1 and Notch2 signaling, specific inhibitors against individual 
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Notch receptor mediated signaling would be more useful in the clinic.  Fragment-based 
approaches and structure-based design are prominent steps in cancer drug discovery, such 
as the discovery of the Bcl-2 inhibitor ABT-737 (316).  Indeed, structures of both putative 
Notch1 ligand binding region and Jagged1 ligand binding region were solved separately, 
and a computational models of the structures of their complexes were also generated.  
Therefore, it is possible to design inhibitors to interfere with an individual Notch receptor-
ligand interaction based on their structures.  More structural studies of ligand binding 
regions of each Notch receptor, such as Notch3 EGF-like repeat 7-10 and 21-22, and 
individual ligands as well as their interaction complexes would be very useful for the 
design of small molecule inhibitors.  
 
What are the mechanisms for non-canonical Notch signaling in cancer? 
Our study described in chapter IV demonstrated that CBF-1 dependent canonical Notch 
signaling is not important in lung cancer cell growth in vitro and in vivo determined in lung 
cancer cell lines Calu-6 and H358.  In other words, the CBF-1 independent non-canonical 
Notch signaling has a greater impact in lung cancer (Fig 5.1).  We also tried to assess the 
importance of CBF-1 dependent canonical Notch signaling in a Notch3-dependent cell line 
HCC2429 by expressing DNMAML protein.  In cell culture, cell growth was not 
attenuated in cell culture, yet an increase in tumor growth was observed in a xenograft 
tumor model (data not shown).  We do not understand why inhibition of canonical Notch 
signaling in a cell line dependent on Notch3 in fact promotes tumor growth in vivo.  One 
possibility may be due to different functions between canonical and non-canonical Notch 
signalingn in HCC2429 cells.  Nonetheless, this result further confirmed that Notch3 
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mediated tumor progression of another cell line, HCC2429, is primarily through a CBF-1 
independent mechanism.  Nowadays, there are two accepted methods to shut down CBF-1 
dependent canonical Notch signaling: the one is to knock down CBF-1 and the other is to 
express a dominant negative version of MAML protein.  I have tried both strategies to shut 
down canonical Notch signaling.  Knockdown of CBF-1 in these cell lines did not result in 
a decrease of CBF-1 luciferase reporter activity in the presence or absence of NICD (data 
not shown).  Therefore, we have focused on the method using DNMAML protein, which is 
actually more specific as it is still able to bind to NICD but fails to initiate NICD-mediated 
genes transcription mediated by NICD.  However, none of these methods is specific for 
canonical Notch signaling, since both CBF-1 and MAML protein have biological functions 
besides activation of canonical Notch signaling and SAHM1 may have off-target activity.  
For example, MAML1 is emerging as a co-activator of other pathways such as NF-κB to 
regulate cellular survival (317).  More experimental tools for specifically attenuating CBF-
1-dependent canonical Notch signaling will be meaningful to the Notch field, such as small 
molecule inhibitors/peptides to specifically saturate the binding domain of individual 
NICD to CBF-1, or small molecule inhibitors to prevent specific NICD localization to the 
nucleus.   
 
There are multiple ways of how Notch signaling functions independent of CBF-1.  We 
believe that there would be various unknown mechanisms of how Notch signaling 
functions independent of CBF-1 to regulate lung cancer tumorigenesis within different 
genetic backgrounds.  NICD could interact with other transcriptional factors in addition to 
CBF-1, and initiates transcription of non-canonical Notch target genes as NICD lacking its 
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RAM domain that mediates its binding to CBF-1 is able to translocate into the nucleus and 
induce neoplastic transformation (237, 238).  Alternatively, NICD, membrane-tethered 
receptor or full-length receptor could crosstalk with other signaling pathways to activate 
non-canonical Notch targets (Fig 5.1).  Further studies to identify the interactome of 
membrane tethered Notch receptors and the activated form of Notch receptors in both the 
cytoplasm and nucleus would help reveal the potential mechanisms of how non-canonical 
Notch signaling impacts lung cancer tumorigenesis.   
 
Are Notch ligands pro-migratory or anti-migratory?  
Previous reports indicate the pro-migratory roles of Notch signaling in cancer progression 
by activating migratory signaling pathways or providing migratory microenvironments.  
However, the functions of Notch ligands in cell migration are controversial.  Lindner et al, 
elucidated that secreted forms of the extracellular domain of Jagged1, which suppresses 
Notch signaling, decreases extracellular matrix adhesion and migration of NIH3T3 cells 
(318).  In contrast, a DLL1 ligand has been reported to reduce the motility of 3T3 cells, 
which is independent of its activity as a Notch ligand (319).  Our findings show that 
knockdown of Jagged1 protein in lung cancer cell lines actually increases cell motility.  It 
is possible that the extracellular regions of Notch ligands, lacking the intracellular domain, 
are different compared with full-length Notch ligands in the regulation of cell motility.  
Indeed, evidence indicates that DSL proteins can also undergo proteolytic cleavage, which 
may elicit an intracellular signaling activity within the ligand expressing cells (246, 247, 
320-322).  Ectopic expression of Jagged1 can transform rat kidney epithelial cells 
independent of Notch signaling, which is mediated by the PDZ motif in Jagged1 
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intracellular domain (245).  Additionally, Jagged1 intracellular domain can activate AP-1 
mediated transcription as well (246).  Therefore, in our study, we could not rule out the 
possibility that Jagged1 ICD or full-length Jagged1 directly contributes to lung cancer cell 
growth and migration independent of Notch signaling (Fig 5.1).  Further studies are needed 
to address: firstly, if inhibition of individual or all Notch receptors or together promotes 
lung cancer migration; secondly, if Jagged1 has its own functions in lung cancer 
independent of Notch; thirdly, if Jagged1 ICD has any biological functions in lung cancer 
growth and migration.   
 
What are potential mechanisms for how Jagged1 regulates integrin in cancer? 
In chaper V, we found that abrogation of Jagged1 in lung cancer cell lines increased 
integrin β1 protein expression independent of CBF-1.  However, we do not know the 
mechanism of how Jagged1 regulates integrin β1 protein expression.  Since Jagged1 does 
not regulate integrin β1 mRNA transcription, we tried to identify the intermediates to link 
expression of integrin β1 with Jagged1 by comparing with the gene expression signatures 
between control and Jag1 KD Calu-6 cells via microarray analysis.  We found several 
candidate molecules, such as Urokinase-type plasminogen activator (uPA) that is 
upregulated in Jag1 KD cells compared with control.  It had been reported that EGFR 
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Figure 5.1.  Schema of how Jagged1 mediated Notch signaling regulates lung 
cancer cell growth and migration.  CSL‐dependent canonical Notch signaling does not regulate lung cancer cell growth and migration.  Instead, CSL‐independent non‐canonical Notch signaling or Jagged1 itself could contribute to promote lung cancer growth and suppress migration by regulating non‐canonical Notch target genes.  
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siganling, integrin β1 and uPA-uPAR signaling can cross talk to promote cell invasion and 
metastasis (323).  Thus, we originally hypothesized that integrin β1protein level is 
upregulated autonomously by activation of integrin β1 signaling via crosstalk with uPA-
uPAR signaling.  However, when we inhibited uPA-uPAR signaling by an uPA blocking 
antibody in control and JAG1 KD Calu-6 cells, neither integrin β1 protein level nor cell 
migration was altered, suggesting that uPA is not the intermediate factor regulated by 
Jagged1 to regulate integrin β1 level and cell migration.  There are plenty of genes 
regulated by Jagged1 in Calu-6 cells, which potentially contribute to cell growth, migration 
and metastasis based on the published literature (Figure 5.2).  It is possible that some or 
one of these genes is responsible to regulate integrin β1 protein expression, or some of 
these genes cooperatively contribute to the migration phenotypes driven by abrogation of 
Jagged1. Further studies will be needed to test these possibilities.  Moreover, it is also 
possible that Jagged1 promotes degradation of integrin β1 by directly / indirectly 
interacting with integrin β1. Identification of Jagged1 interacting proteins would be helpful 
to test this hypothesis.  
 
Integrins are heterodimeric transmembrane glycoproteins, which mediate cell-cell and cell-
matrix interaction (297).  Integrin signaling is crucial for embryogenesis, and contributes to 
the neurogenesis, myogenesis and angiogenesis processes (324, 325) which are also tightly 
regulated by Notch signaling.  Genetic studies have demonstrated that Notch and integrin 
mutations have related phenotypes in key developmental processes such as vascular 
development and somitogenesis.  In neural stem cells, expression of Notch4 in endothelial 
cells increased cell adhesion to collagen (326).  Hodkinson et al. demonstrated that NICD 
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could activate integrin-ligand binding activity without affecting the integrin expression 
level in a CHO cell system (296).  Previous reports had also linked Notch signaling and 
integrin expression in the epidermis.  For example, in vivo α4β6 integrin expression is 
decreased in N1ICD transgenic skins, but not altered in RBPj κ (i.e CBF-1) knockout mice 
(327).  Moreover, in mouse epidermal development, integrin expression is decreased in 
DLL1-null keratinocytes but increased in Jagged1-null cells (328).  Our finding in chapter 
IV showed that abrogation of Jagged1-mediated Notch signaling resulted in an increase of 
integrin β1 protein level independent of CBF-1, which is consistent with the Jagged1-null 
phenomena in the epidermis. Therefore, it is possible that Notch may affect integrin 
expression and activation, modulating important developmental processes by alternating 
cell-matrix interactions (329).  In addition, Notch signaling in cancer cells uses the same 
mechanism to regulate cell adhesion, migration, and metastasis.  We do not quite 
understand why “smart” tumor cells activated integrin signaling when Jagged1 is 
attenuated.  Jagged ligands have a von Willebrand factor (vWF) type C domain in its 
extracellular domain, which also exists in the majority of integrin and extracellular matrix 
proteins.  Thus, on the one hand, it is possible that Jagged1 also mediates cell adhesion 
through its vWF domain.  When Jagged1 is abrogated, cancer cells activate integrin 
signaling to compensate for the lack of Jagged1 as an adhesion molecule.  On the other 
hand, Jagged1-Notch signaling mediates a cell-cell interaction through ligand-receptor 
interaction. Based on the aggregation assay performed in Drosophila cells, loss of Jagged1 
on the cell surface results in a decrease of cell-cell adhesion/ interaction.  Therefore, it is 
also possible that when less Jagged1 protein is presented on the cell surface, cancer cells 
lose cell-cell adhesion so as to activate cell-matrix adhesion via upregulation of integrin β1 
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protein.  Further studies to investigate the roles of Jagged1 in cell adhesion would be useful 
to address why and how abrogation of Jagged1 leads to upregulation of integrin β1, and 
possibly identify new functions of Jagged1 and Notch signaling in cancers.  
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Figure 5.2. Heat-map image for the differentially expressed genes 
between control and JAG1 KD Calu-6 cells. The selected genes are genes 
potentially contribute to cell migration and metastasis. Red indicates higher 
expression level, and green indicates lower expression level.    
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 Concluding remark 
Notch3 signaling is important in the regulation of lung cancer growth and maintenance of 
lung cancer stem cells.  Therefore, this thesis has focused on targeting Notch3 signaling in 
lung cancer.  We discovered EGF-like repeat 7-10 and 21-22 as ligand binding regions of 
Notch3.  Based on this discovery, we generated Fc-fusion proteins and monoclonal 
antibodies to interfere with receptor-ligand interaction.  Our studies demonstrate that it is 
possible to develop potent inhibitors that interfere with receptor-ligand interaction of an 
individual mammalian Notch receptor, Notch3.  This “proof-of-principle” demonstration 
has significant mechanistic and applied implications.  Further development and characterization of these Fc‐fusion proteins and mAbs targeting Notch3 is thus likely to have a broad experimental and therapeutic impact.  Owing to the complexity of 
Notch signaling and the complicated genetic landscape of lung cancer, additional studies 
applying these Fc-fusion proteins and antibodies to more lung cancer cell lines and tumor 
models or other cancer types such as ovarian cancer would help to further evaluate the 
efficacy of these agents.  
 
Our studies also demonstrated a CBF-1 independent mechanism of Jagged1 in lung cancer 
cell growth and migration, which differs from the conventional thought about how Notch 
signaling regulates lung cancer progression.  Our studies reveal a new angle for studying 
Notch signaling and lung cancer.  Further studies investigating the detailed mechanisms of 
how Jagged1/Notch signaling contributes to lung cancer progression non-canonically 
would insight into the world of Notch biology, as well as lung cancer physiopathology.  
With the contribution of the emerging new technologies, experimental tools, and 
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accumulating knowledge of Notch signaling, it is possible to better understand the biology 
of Notch signaling in lung cancer, and direct lung cancer therapies using novel Notch 
inhibitors.                         
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